
<html lang="en"     class="pb-page"  data-request-id="dbfd4ace-9e2c-4869-87f6-f2dc06a427b3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b01169;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors" /></meta><meta name="dc.Creator" content="Harald  Engelhardt" /></meta><meta name="dc.Creator" content="Dietrich  Böse" /></meta><meta name="dc.Creator" content="Mark  Petronczki" /></meta><meta name="dc.Creator" content="Dirk  Scharn" /></meta><meta name="dc.Creator" content="Gerd  Bader" /></meta><meta name="dc.Creator" content="Anke  Baum" /></meta><meta name="dc.Creator" content="Andreas  Bergner" /></meta><meta name="dc.Creator" content="Eugene  Chong" /></meta><meta name="dc.Creator" content="Sandra  Döbel" /></meta><meta name="dc.Creator" content="Georg  Egger" /></meta><meta name="dc.Creator" content="Christian  Engelhardt" /></meta><meta name="dc.Creator" content="Peter  Ettmayer" /></meta><meta name="dc.Creator" content="Julian E.  Fuchs" /></meta><meta name="dc.Creator" content="Thomas  Gerstberger" /></meta><meta name="dc.Creator" content="Nina  Gonnella" /></meta><meta name="dc.Creator" content="Andreas  Grimm" /></meta><meta name="dc.Creator" content="Elisabeth  Grondal" /></meta><meta name="dc.Creator" content="Nizar  Haddad" /></meta><meta name="dc.Creator" content="Barbara  Hopfgartner" /></meta><meta name="dc.Creator" content="Roland  Kousek" /></meta><meta name="dc.Creator" content="Mariusz  Krawiec" /></meta><meta name="dc.Creator" content="Monika  Kriz" /></meta><meta name="dc.Creator" content="Lyne  Lamarre" /></meta><meta name="dc.Creator" content="Joyce  Leung" /></meta><meta name="dc.Creator" content="Moriz  Mayer" /></meta><meta name="dc.Creator" content="Nitinchandra D.  Patel" /></meta><meta name="dc.Creator" content="Biljana Peric  Simov" /></meta><meta name="dc.Creator" content="Jonathan T.  Reeves" /></meta><meta name="dc.Creator" content="Renate  Schnitzer" /></meta><meta name="dc.Creator" content="Andreas  Schrenk" /></meta><meta name="dc.Creator" content="Bernadette  Sharps" /></meta><meta name="dc.Creator" content="Flavio  Solca" /></meta><meta name="dc.Creator" content="Heinz  Stadtmüller" /></meta><meta name="dc.Creator" content="Zhulin  Tan" /></meta><meta name="dc.Creator" content="Tobias  Wunberg" /></meta><meta name="dc.Creator" content="Andreas  Zoephel" /></meta><meta name="dc.Creator" content="Darryl B.  McConnell" /></meta><meta name="dc.Description" content="The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kina..." /></meta><meta name="Description" content="The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kina..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 5, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01169" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01169" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01169" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01169" /></link>
        
    
    

<title>Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01169" /></meta><meta property="og:title" content="Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0023.jpeg" /></meta><meta property="og:description" content="The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable. Most patients relapse within two years of therapy often due to acquisition of an additional mutation in EGFR kinase domain that confers resistance to TKIs. Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs. Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI. BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model. Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the molecule through macrocyclization." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01169"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01169">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01169&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01169&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01169&amp;href=/doi/10.1021/acs.jmedchem.9b01169" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10272-10293</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01310" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01344" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Harald Engelhardt</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harald Engelhardt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#5f373e2d3e333b713a31383a33373e2d3b2b1f3d303a372d3631383a2d723631383a33373a3632713c3032"><span class="__cf_email__" data-cfemail="6f070e1d0e030b410a01080a03070e1d0b1b2f0d000a071d0601080a1d420601080a03070a0602410c0002">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harald++Engelhardt">Harald Engelhardt</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8170-1893" title="Orcid link">http://orcid.org/0000-0001-8170-1893</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dietrich Böse</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dietrich Böse</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dietrich++B%C3%B6se">Dietrich Böse</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Petronczki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Petronczki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Petronczki">Mark Petronczki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dirk Scharn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dirk Scharn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dirk++Scharn">Dirk Scharn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gerd Bader</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gerd Bader</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gerd++Bader">Gerd Bader</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anke Baum</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anke Baum</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anke++Baum">Anke Baum</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Bergner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Bergner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Bergner">Andreas Bergner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eugene Chong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eugene Chong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eugene++Chong">Eugene Chong</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5038-0131" title="Orcid link">http://orcid.org/0000-0002-5038-0131</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandra Döbel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandra Döbel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++D%C3%B6bel">Sandra Döbel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Georg Egger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Georg Egger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Georg++Egger">Georg Egger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Engelhardt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Engelhardt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Engelhardt">Christian Engelhardt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Ettmayer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Ettmayer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Ettmayer">Peter Ettmayer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8422-2625" title="Orcid link">http://orcid.org/0000-0002-8422-2625</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julian E. Fuchs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julian E. Fuchs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julian+E.++Fuchs">Julian E. Fuchs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Gerstberger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Gerstberger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Gerstberger">Thomas Gerstberger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nina Gonnella</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nina Gonnella</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nina++Gonnella">Nina Gonnella</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8944-7180" title="Orcid link">http://orcid.org/0000-0001-8944-7180</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Grimm</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Grimm</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Grimm">Andreas Grimm</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elisabeth Grondal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elisabeth Grondal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elisabeth++Grondal">Elisabeth Grondal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nizar Haddad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nizar Haddad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nizar++Haddad">Nizar Haddad</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara Hopfgartner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara Hopfgartner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Hopfgartner">Barbara Hopfgartner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roland Kousek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roland Kousek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roland++Kousek">Roland Kousek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mariusz Krawiec</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mariusz Krawiec</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mariusz++Krawiec">Mariusz Krawiec</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Monika Kriz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Monika Kriz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Monika++Kriz">Monika Kriz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lyne Lamarre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lyne Lamarre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lyne++Lamarre">Lyne Lamarre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joyce Leung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joyce Leung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joyce++Leung">Joyce Leung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Moriz Mayer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Moriz Mayer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Moriz++Mayer">Moriz Mayer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nitinchandra D. Patel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nitinchandra D. Patel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nitinchandra+D.++Patel">Nitinchandra D. Patel</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9571-6658" title="Orcid link">http://orcid.org/0000-0001-9571-6658</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Biljana Peric Simov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Biljana Peric Simov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Biljana+Peric++Simov">Biljana Peric Simov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan T. Reeves</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan T. Reeves</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+T.++Reeves">Jonathan T. Reeves</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3051-3304" title="Orcid link">http://orcid.org/0000-0002-3051-3304</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Renate Schnitzer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Renate Schnitzer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Renate++Schnitzer">Renate Schnitzer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Schrenk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Schrenk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Schrenk">Andreas Schrenk</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bernadette Sharps</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bernadette Sharps</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bernadette++Sharps">Bernadette Sharps</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Flavio Solca</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Flavio Solca</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Flavio++Solca">Flavio Solca</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Heinz Stadtmüller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Heinz Stadtmüller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Heinz++Stadtm%C3%BCller">Heinz Stadtmüller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhulin Tan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhulin Tan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhulin++Tan">Zhulin Tan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tobias Wunberg</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tobias Wunberg</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tobias++Wunberg">Tobias Wunberg</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andreas Zoephel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andreas Zoephel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andreas++Zoephel">Andreas Zoephel</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Darryl B. McConnell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darryl B. McConnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Boehringer Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darryl+B.++McConnell">Darryl B. McConnell</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01169&amp;href=/doi/10.1021%2Facs.jmedchem.9b01169" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10272–10293</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 5, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 August 2019</li><li><span class="item_label"><b>Published</b> online</span>5 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 November 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01169" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01169</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01169"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8089</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01169" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Harald&quot;,&quot;last_name&quot;:&quot;Engelhardt&quot;},{&quot;first_name&quot;:&quot;Dietrich&quot;,&quot;last_name&quot;:&quot;Böse&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Petronczki&quot;},{&quot;first_name&quot;:&quot;Dirk&quot;,&quot;last_name&quot;:&quot;Scharn&quot;},{&quot;first_name&quot;:&quot;Gerd&quot;,&quot;last_name&quot;:&quot;Bader&quot;},{&quot;first_name&quot;:&quot;Anke&quot;,&quot;last_name&quot;:&quot;Baum&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Bergner&quot;},{&quot;first_name&quot;:&quot;Eugene&quot;,&quot;last_name&quot;:&quot;Chong&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Döbel&quot;},{&quot;first_name&quot;:&quot;Georg&quot;,&quot;last_name&quot;:&quot;Egger&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Engelhardt&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Ettmayer&quot;},{&quot;first_name&quot;:&quot;Julian&quot;,&quot;last_name&quot;:&quot;E. Fuchs&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Gerstberger&quot;},{&quot;first_name&quot;:&quot;Nina&quot;,&quot;last_name&quot;:&quot;Gonnella&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Grimm&quot;},{&quot;first_name&quot;:&quot;Elisabeth&quot;,&quot;last_name&quot;:&quot;Grondal&quot;},{&quot;first_name&quot;:&quot;Nizar&quot;,&quot;last_name&quot;:&quot;Haddad&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Hopfgartner&quot;},{&quot;first_name&quot;:&quot;Roland&quot;,&quot;last_name&quot;:&quot;Kousek&quot;},{&quot;first_name&quot;:&quot;Mariusz&quot;,&quot;last_name&quot;:&quot;Krawiec&quot;},{&quot;first_name&quot;:&quot;Monika&quot;,&quot;last_name&quot;:&quot;Kriz&quot;},{&quot;first_name&quot;:&quot;Lyne&quot;,&quot;last_name&quot;:&quot;Lamarre&quot;},{&quot;first_name&quot;:&quot;Joyce&quot;,&quot;last_name&quot;:&quot;Leung&quot;},{&quot;first_name&quot;:&quot;Moriz&quot;,&quot;last_name&quot;:&quot;Mayer&quot;},{&quot;first_name&quot;:&quot;Nitinchandra&quot;,&quot;last_name&quot;:&quot;D. Patel&quot;},{&quot;first_name&quot;:&quot;Biljana&quot;,&quot;last_name&quot;:&quot;Peric Simov&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;T. Reeves&quot;},{&quot;first_name&quot;:&quot;Renate&quot;,&quot;last_name&quot;:&quot;Schnitzer&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Schrenk&quot;},{&quot;first_name&quot;:&quot;Bernadette&quot;,&quot;last_name&quot;:&quot;Sharps&quot;},{&quot;first_name&quot;:&quot;Flavio&quot;,&quot;last_name&quot;:&quot;Solca&quot;},{&quot;first_name&quot;:&quot;Heinz&quot;,&quot;last_name&quot;:&quot;Stadtmüller&quot;},{&quot;first_name&quot;:&quot;Zhulin&quot;,&quot;last_name&quot;:&quot;Tan&quot;},{&quot;first_name&quot;:&quot;Tobias&quot;,&quot;last_name&quot;:&quot;Wunberg&quot;},{&quot;first_name&quot;:&quot;Andreas&quot;,&quot;last_name&quot;:&quot;Zoephel&quot;},{&quot;first_name&quot;:&quot;Darryl&quot;,&quot;last_name&quot;:&quot;B. McConnell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10272-10293&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01169&quot;},&quot;abstract&quot;:&quot;The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable. Most patients relapse within two years of therapy often due to acquisition of an additional mutation in EGFR kinase domain that confers resistance to TKIs. Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs. Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI. BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model. Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the molecule through macrocyclization.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01169&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01169" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01169&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01169" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01169&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01169" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01169&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01169&amp;href=/doi/10.1021/acs.jmedchem.9b01169" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01169" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01169" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26pmid%3D31689114%26genre%3Darticle%26aulast%3DEngelhardt%26date%3D2019%26atitle%3DStart%2BSelective%2Band%2BRigidify%253A%2BThe%2BDiscovery%2BPath%2Btoward%2Ba%2BNext%2BGeneration%2Bof%2BEGFR%2BTyrosine%2BKinase%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291163" title="Macrocycles">Macrocycles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/jmcmar.2019.62.issue-22/20191127/jmcmar.2019.62.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable. Most patients relapse within two years of therapy often due to acquisition of an additional mutation in EGFR kinase domain that confers resistance to TKIs. Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs. Here, we describe the discovery of <b>BI-4020</b>, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI. <b>BI-4020</b> potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFR<sup>del19 T790M C797S</sup> xenograft model. Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the molecule through macrocyclization.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases are one of the most successfully pursued drug target families with more than 50 kinase inhibitors approved by the FDA to date.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Despite this success, discovering kinase inhibitors with a sufficiently high degree of kinome selectivity and hence tolerability remains a significant challenge to medicinal chemists.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> This challenge is exacerbated in oncology by the emergence of drug resistance, which requires next generation inhibitors that are able to inhibit both primary and resistant oncogenic clones while maintaining kinome selectivity.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> New approaches for the discovery of highly selective kinase inhibitors have emerged such as the screening of libraries of kinase inhibitors with intrinsic selectivity profiles<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> and macrocyclization of kinase inhibitors.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a></div><div class="NLM_p">The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that transduces mitogenic signals. Mutations in the EGFR gene are found in approximately 12–47% of nonsmall cell lung cancer (NSCLC) tumors with adenocarcinoma histology.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The two most frequent EGFR alterations found in NSCLC tumors are short in-frame deletions in exon 19 (del19) of the EGFR gene and L858R, a single missense mutation in exon 21.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> These two mutations cause ligand-independent EGFR activation and are collectively referred to as EGFR<sup>M+</sup>. Del19 and L858R mutations in EGFR sensitize NSCLC tumors to the treatment with EGFR tyrosine kinase inhibitors (TKIs). Clinical experience shows that the objective response rate in lung cancer patients carrying tumors with EGFR<sup>M+</sup> is approximately 60–85% in first line with the first, second, and third generation EGFR TKIs erlotinib, gefitinib, afatinib, and osimertinib (see structures in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17">(14−17)</a> These responses demonstrate that EGFR<sup>M+</sup> NSCLC cells and tumors depend on oncogenic EGFR activity for survival and proliferation, establishing del19 or L858R mutated EGFR variants as a validated drug targets and predictive biomarkers for the treatment of NSCLC.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of selected approved first, second, and third generation EGFR TKIs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While tumor responses are accompanied by marked tumor shrinkage in patients, the response is usually not durable, and most patients relapse within 9.2–14.7 months of treatment with first and second generation EGFR TKIs.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14−18)</a> The most prominent molecular resistance mechanism associated with disease progression in 50–70% of patients treated with first and second generation EGFR inhibitors is the acquisition of a secondary mutation in EGFR, the gatekeeper mutation T790M.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> This mutation attenuates the inhibitory activity of first and second generation TKIs in cellular assays. EGFR wild-type sparing covalent third generation EGFR TKIs, such as osimertinib, have been developed that effectively inhibit the primary EGFR mutations del19 and L858R independent of the presence or absence of the secondary T790M resistance mutation.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a></div><div class="NLM_p">While osimertinib in second line treatment of EGFR M<sup>+</sup> T790M-positive NSCLC patients demonstrates clear clinical efficacy,<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> disease progression occurs after an average duration of 10 months.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Recent data suggest that 20–40% of second line patients relapsing on osimertinib TKI<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29">(25−29)</a> acquire a tertiary EGFR mutation at the cysteine residue (C797S) required for covalent inhibitor binding.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Crucially, the EGFR del19/L858R T790M C797S cis mutant kinase variant that emerges in second line patients progressing on osimertinib<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29">(25−29)</a> can no longer be inhibited by any of the approved first, second, or third generation EGFR TKIs.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> While the EGFR resistance mutation spectrum after first line osimertinib treatment has not been extensively studied, first available data also suggest the emergence of the C797S mutation.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Hence, the next generation of EGFR TKIs should (a) be highly active against most common EGFR activation mutation del19, (b) not be susceptible to the most common resistance mutations T790M and/or C797S, (c) have low inhibition of EGFR<sup>wt</sup> to avoid on-target toxicities such as rash and diarrhea, and (d) be highly selective across the human kinome.</div><div class="NLM_p">Recently, a number of potent EGFR inhibitors able to overcome EGFR T790M and C797S resistance mutations were reported,<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41 ref42 ref43 ref44">(31−44)</a> but these compounds are equipotent or more active on EGFR<sup>wt</sup> (see <b>R1</b>–<b>3</b> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38">(31−38)</a> Conversely, some cases of good selectivity for mutated versus wild-type EGFR have been reported but with low overall in vitro potency (see <b>R4</b> and <b>R6</b> in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> The noncovalent inhibitor <b>R5</b><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> has demonstrated acceptable p-EGFR biomarker modulation in vivo in a NCI-H1975 xenograft model (EGFR<sup>L858R T790M</sup>) after high oral dose administration, but the compound displays an insufficient EGFR wt-sparing ratio. Allosteric EGFR inhibitors, which overcome T790M and C797S resistance and display EGFR wt-sparing behavior, have been reported,<a onclick="showRef(event, 'ref45 ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47 ref48 ref49">(45−49)</a> but these compounds are only active on the L858R mutant but not on the most prevalent del19 mutant.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overview of selected published EGFR inhibitors with inhibition data (<b>R1</b> = <b>31b</b>;<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a><b>R2</b> = <b>JND3229</b>;<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><b>R3</b> = <b>B30</b>;<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><b>R4</b> = <b>42</b>;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a><b>R5</b> = <b>21</b>;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and <b>R6</b> = <b>19</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>). Compound <b>1</b> serves as a starting point for this work, and <b>BI-4020</b> demonstrates the superiority of the compounds reported by this work as compared to state of the art.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this Article, we describe the discovery of <b>BI-4020</b>, the first compound to exhibit a next generation EGFR TKI profile, wt-sparing, capable of inhibiting complex EGFR mutations containing T790M and/or C797S modifications, including a triple cis mutation in the EGFR<sup>del19</sup> background. Key to the discovery was the identification of a highly selective but moderately potent benzimidazole by screening our corporate selective kinase inhibitor library followed by complete rigidification of the molecule through macrocyclization. <b>BI-4020</b> is a noncovalent, macrocyclic TKI, which inhibits not only the triple mutant EGFR<sup>del19 T790M C797S</sup> variant but also the double mutant EGFR<sup>del19 T790M</sup> and primary mutant EGFR<sup>del19</sup> while sparing activity against EGFR<sup>wt</sup> (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). <b>BI-4020</b> shows high potency on EGFR mutant cells, high kinome selectivity, and good DMPK properties, which led to tumor regressions in the human PC-9 (EGFR<sup>del19 T790M C797S</sup>) triple mutant NSCLC xenograft model in mice.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Selectivity First: Screening for a Highly Selective Rather than a Highly Active Starting Point</h3><div class="NLM_p">At the outset of the project, we decided to start a screening campaign to find chemical starting points, which provided selectivity for the mutated EGFR proteins over EGFR<sup>wt</sup> protein rather than a high activity. We hypothesized that it would be easier to improve upon the activity of an EGFR<sup>wt</sup> selective molecule than it would be to rationally design EGFR<sup>wt</sup> selectivity of a potent but unselective inhibitor. A structure-based design approach to generate selectivity for the EGFR primary activation mutation L858R and del19 over EGFR<sup>wt</sup> was further ruled out as no structural differences between the binding pockets from the publicly available X-ray structures of the EGFR<sup>L858R</sup> and EGFR<sup>wt</sup> proteins were observable.</div><div class="NLM_p">Instead, we resolved to design a focused in-house library based on Boehringer Ingelheim kinase selectivity panel data obtained with previous research compounds from various projects. Focusing on selective kinase inhibitors where more than 10 mg of solid was in stock and that fulfilled minimal drug-like properties (heavy atoms ≤34 or soluble at pH 6.8), we compiled a list of 1826 kinase inhibitors from 40 past kinase and 47 nonkinase projects. A compound, which qualifies as a selective kinase inhibitor, needs to be tested against at least 30 kinases and should be active in at least 2 assays (single concentration measurement using a biochemical kinase assay; compound needs to display a value below 50% of control), but should not hit more than 10% of all tested kinases. Interestingly, this Selective Kinase Inhibitor (SKIny) Screening Library covered 269 kinases.</div><div class="NLM_p">Despite the fact that we were most interested in the more frequent appearing EGFR<sup>del19 T790M C797S</sup> mutation, the triple mutant EGFR<sup>L858R T790M C979S</sup> protein was used for the biochemical screening assay, because we were not able to obtain sufficient high quality amounts of the EGFR<sup>del19 T790M C797S</sup> protein. In parallel to an activity screening, we conducted a selectivity screening using the EGFR<sup>wt</sup> protein to directly assess the WT-sparing effect of the hits found in the screen. The aminobenzimidazole <b>1</b> was identified as a promising hit from the screen as it showed reasonable affinity to mutated EGFR (IC<sub>50</sub> EGFR<sup>L858R T790M C797S</sup> = 2100 nM; IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 250 nM) and had no measurable affinity to EGFR<sup>wt</sup> (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). To assess the overall kinase selectivity of <b>1</b>, we performed a kinase selectivity assay<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> with 238 kinases and found that only 5% of the screened kinases were inhibited above 70%. To determine the overall kinase selectivity for further compounds more quickly, we have defined a diverse set of 30 kinases representing the kinome. For key compounds <b>1</b>, <b>3</b>, and <b>BI-4020</b>, we have confirmed the results of the small panel with a larger set of kinases (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <b>2</b>). Gratifyingly, we were also already able to measure biomarker modulation in an EGFR<sup>del19 T790M C797S</sup>-dependent BaF3 cell line with an IC<sub>50</sub> = 790 nM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR for the Open-Chain Aminobenzimidazoles <b>1</b>–<b>5</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0019.gif" alt="" id="GRAPHIC-d7e896-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0020.gif" alt="" id="gr19" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn2"><div class="footnote" id="t1fn2"><sup><sup>a</sup></sup><p class="last">Data are reported as geometric mean of at least three independent measurements, and in brackets is the geometric standard deviation as multiplicative factor given. Biochemical kinase assay using different EGFR variants, which measures the inhibitory effect of compounds on the phosphorylation activity of EGFR enzyme forms on poly-GT substrate in the presence of ATP. *: EGFR<sup>d19 TM CS</sup> means EGFR<sup>del19 T790M C797S</sup>. **: EGFR<sup>LR TM CS</sup> means EGFR<sup>L858R T790M C797S</sup>. #: Activity of compound at or below assay wall (assay wall around 3 nM due to enzyme concentration/activity and substrate concentration).</p></div><div class="footnote" id="t1fn3"><sup><sup>b</sup></sup><p class="last">Kinase selectivity was determined using the “SelectScreen Kinase Profiling Services” from ThermoFisher.</p></div><div class="footnote" id="t1fn4"><sup><sup>c</sup></sup><p class="last">Measurement of inhibition of the p-EGFR<sup>del19 T790M C797S</sup> signal in BaF3 cells after 4 h compound treatment.</p></div><div class="footnote" id="t1fn5"><sup><sup>d</sup></sup><p class="last">BaF3 cells bearing EGFR<sup>del19 T790M C797S</sup> protein were treated for 3 days with compound, the effect on proliferation was measured; nd means not determined.</p></div></div><div></div></div><div class="NLM_p">EGFR<sup>L858R</sup> protein was used for protein crystallography as EGFR<sup>del19</sup> protein has proven particularly recalcitrant to X-ray crystallography with no structures published. Compound <b>1</b> was successfully crystallized with EGFR<sup>L858R</sup> with the gatekeeper mutation T790M (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). From the X-ray structure, a two-point hinge binding motive can be seen, with the benzimidazole N–H and carbonyl group binding to Met793. The isobutyl hydroxy group fills the sugar pocket<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> of the kinase, while the pyridine substituent in the R<sub>2</sub>-position (nomenclature see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) binds to the Lys745 in the phosphate region of the pocket. No clash between the bulky Met790 gatekeeper residue and the benzimidazole is observed. Important for our further optimization was the observation that the torsion angle between the two aromatic rings of <b>1</b> is ∼40°, which was found to be a low-energy conformation based on a QM-torsion angle scan (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Therefore, the dihedral angle was scanned in 10° steps while optimizing all other degrees of freedom within the ligand on the ωB97XD/cc-pVDZ level of theory.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of ligand <b>1</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a>) bound to the ATP pocket of the EGFR<sup>L858R T790M</sup> protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. QM-torsion angle scans for compounds <b>1</b>, <b>3</b>, <b>3a</b>, <b>4</b>, and <b>5</b>. The baseline energy is set for each compound individually (to zero), and not deducted from the lowest energy of all compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A close analogue (<b>2</b>) missing the fluorine atom in the R<sub>1</sub> position (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was found to show similar activities in the biochemical and biomarker assays (IC<sub>50</sub> EGFR<sup>L858R T790M C797S</sup> = 2700 nM; IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 173 nM). Because of synthetic accessibility, we decided to move on with our further optimization program without a substituent in the R<sub>1</sub> position.</div><div class="NLM_p">In the next step, we decided to address the hydroxyl group of the side chain of Thr854 via a nitrogen acceptor from the X-position of the central aromatic ring system (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In addition, the newly designed ligands should still have a torsion angle of 30–40° at a low-energy conformation to enable a proper interaction with Lys754. To access both requirements, we performed a QM-torsion angle scan for the bis aryl system of the newly designed compounds <b>3</b>, <b>3a</b>, and <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><div class="NLM_p">The pyridyl nitrogen of the R<sub>2</sub> moiety of compound <b>3</b> desymmetrizes the bis aryl system further, and therefore a larger energy difference between the minima (30° and 160°) in comparison to compound <b>1</b> is observed (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In case of the minimum at 30°, both pyridyl nitrogens of compound <b>3</b> are located at the same side, which leads to an unfavorable dipole–dipole interaction (overall dipole: 3.87 D) as compared to the minimum at 160° for which the pyridyl nitrogens are located at the opposite side leading to partial dipole cancellation (overall dipole: 2.35 D).</div><div class="NLM_p">The local minimum at 30° of compound <b>3</b> would allow the ligand to interact via the pyridyl nitrogen of the R<sub>2</sub> moiety with Lys745. However, this local minimum is approximately 1 kcal/mol higher than the absolute minimum, which is located at 160°. Therefore, an energy penalty has to be paid for the nonoptimal dihedral angle, but a gain in binding affinity was expected due to the interaction with Thr854. Interestingly, the benzimidazole <b>3</b> showed a factor of 3–8 improved activity in the biochemical assays (IC<sub>50</sub> EGFR<sup>L858R T790M C797S</sup> = 353 nM; IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 57 nM) and demonstrated an even more pronounced gain in potency in the cellular biomarker modulation assay, while at the same time maintaining the low affinity for wild-type EGFR.</div><div class="NLM_p">For compound <b>4</b>, a similar situation was observed. A local minimum was found at a torsion angle of 0°, while the absolute minimum is approximately 1 kcal/mol lower and is located at 180°. Again, an energy penalty must be paid for the nonoptimal dihedral angle, but on the other hand a gain in binding affinity could be expected due to the interaction with Thr854. Also, for compound <b>4</b>, a slight improvement of activity was observed in biochemical and an even more pronounced gain in the cellular biomarker modulation assay.</div><div class="NLM_p">We investigated several different aromatic ring systems for the R<sub>2</sub> position with the goal to identify motifs, which would bind with the absolute minimum conformation regarding the dihedral angle of the bis aryl system to EGFR. One possible solution is shown by compound <b>3a</b>, which bears a 4-methoxy-pyrid-3-yl moiety at the R<sub>2</sub> position. The QM-torsion angle scan (see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) for the bis aryl system showed high energy for dihedral angle 160–180° due to unfavorable interactions of the methoxy group and the facing pyridyl nitrogen, but an absolute minimum at 30°. The unfavorable dipole–dipole interaction between the two ring nitrogen atoms at 30° is also given for compound <b>3a</b>, but the energy penalty is compensated by the favorable electrostatic interactions of the methoxy group with the facing proton (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Figure S1</a>). Therefore, the energy at 30° of ligand <b>3a</b> is lower than that for compound <b>3</b>. This optimized binding conformation of ligand <b>3a</b> translates into a 30-fold improved biochemical activity based on the EGFR<sup>L858R T790M C797S</sup> protein as compared to ligands <b>3</b> and <b>4</b>. The same trend can be seen comparing the biochemical EGFR<sup>del19 T790M C797S</sup> data. This improved biochemical activity led to a 35-fold improved p-EGFR<sup>del19 T790M C797S</sup> biomarker modulation and to a 5-fold improved antiproliferative effect in BaF3 cells as compared to ligands <b>3</b> and <b>4</b>. However, the compound displayed a clearly lower general kinase selectivity as compared to compounds <b>3</b> and <b>4</b> (36% hits; see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These data show that activity can be massively gained by optimal interaction with Lys745, but at the expense of reduced kinase selectivity.</div><div class="NLM_p">We hypothesized that better kinase selectivity could be achieved, if the pocket around Lys745 (phosphate region) is addressed by an aromatic system, which bears no acceptor. Prerequisite for this strategy was that the envisioned R<sub>2</sub> moiety does not clash with Lys745, which could be achieved with a dihedral angle of <20°.</div><div class="NLM_p">To probe the hypothesis, we synthesized benzimidazole <b>5</b>, which does not contain a hydrogen-bond acceptor atom in the second aromatic ring and carries only a symmetric phenyl ring in the R<sub>2</sub>-position. Therefore, almost no energy difference is seen between the minima (20° and 160°; see <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). To our delight, we found that, while the biochemical and cellular potency against EGFR mutated cells was basically unchanged as compared to compound <b>3</b>, the selectivity was significantly improved, as it is evident from the not observable cytotoxic activity against EGFR independent cells. At the same time, the kinase selectivity was found to be very high, as only mutant EGFR was hit among a panel of 30 kinases. Furthermore, benzimidazole <b>5</b> also showed an excellent wt-sparing effect based on the comparison of the antiproliferative effect on EGFR<sup>del19 T790M C797S</sup> versus EGFR<sup>wt</sup> in BaF3 cell lines (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">The X-ray structure of compound <b>5</b> with EGFR<sup>L858R T790M</sup> shows (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) that the compound binds to the protein with the expected dihedral angle of the bis aryl system of approximately 20°. In addition, the distance to the Lys745 and Glu762 is sufficiently large (3.5 Å) to avoid a clash.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray structure of compound <b>5</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9C">6S9C</a>) in complex with EGFR<sup>L858R T790M</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Entropy-Driven Optimization: Rigidification through Macrocyclization</h3><div class="NLM_p">Compound <b>5</b> represented a selective but not yet sufficiently potent compound (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entry 6). In analogy to the discovery of lorlatinib,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> we chose reduction of ligand entropy through macrocyclization as the strategy to improve potency.<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a> We pursued both theoretical and experimental methods to assist the design of cyclized compounds. Initially, as for the computational conformation analysis of ligand <b>5</b>, the MOE module LowModeMD,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> followed by semi empirical (MOPAC, AM1) energy minimization of all of the conformers in vacuo, was employed for the analysis and selection of low-energy conformers. In the course of the project, we then complemented this approach with enhanced sampling molecular dynamics methods in explicit solvation.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> These findings were supported by a detailed 2D NMR analysis of compound <b>5</b>, which showed ROE correlations between protons, as indicated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The ROEs support the presence of both active and inactive conformational states in the population observed in solution. This was further corroborated by QM-DFT <sup>13</sup>C, <sup>1</sup>H, and partial <sup>15</sup>N chemical shift predictions, which support a Boltzmann-weighted energy distribution, with significant population of active and inactive conformers.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> We therefore expected a significant improvement of binding affinity to EGFR<sup>del19 T790M C979S</sup> if the molecule could be constrained in its “active” binding conformation.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Two-Dimensional Representation of the Most Prevalent Conformations of Ligand <b>5</b> As Computationally Predicted and Detected in Solution by 2D-NMR<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Important ROE-correlations are displayed as arrows.</p></p></figure><div class="NLM_p">Starting from ligand <b>5</b> as a template for the active conformation, several different macrocyclic variants with varying linker lengths and attachment points were designed. The macrocycles were then virtually subjected to conformational searches (MOE LowModeMD),<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> followed by AM1 energy minimization of all conformers. Low-energy conformations were compared to the binding conformation of amino benzimidazole <b>5</b> and macrocyclic ligand <b>6</b>, with a C<sub>5</sub>H<sub>10</sub>O linker found to display a good overlap with the desired “active” conformation (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Overlay of X-ray-based structure of compound <b>5</b> (orange) and calculated minimum conformation structure of macrocyclic ligand <b>6</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first macrocyclic ligand <b>6</b> displayed a biochemical activity in the EGFR<sup>del19 T790M C797S</sup> assay at the assay wall,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> which hampers the evaluation of the activity improvement. Fortunately, the biochemical activity of macrocycle <b>6</b> in the EGFR<sup>L858R T790M C797S</sup> assay is still above the assay wall (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Table S8</a>, entry 1), and therefore a 17-fold improved biochemical activity over the open chain ligand <b>5</b> can be determined. The gain in biochemical activity translates into a 5-fold improvement of cellular potency over the open chain ligand <b>5</b> as is evident from the inhibition of the p-EGFR signal and antiproliferative effect on EGFR<sup>del19 T790M C979S</sup>-dependent BaF3 cells (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, entry 1). Noteworthy for compound <b>6</b> was the favorable EGFR<sup>wt</sup> and general kinase selectivity (0/30 kinases were hit at 1 μM)<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> observed.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR for the Macrocyclic Benzimidazoles <b>6</b>–<b>9</b> and <b>BI-4020</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0021.gif" alt="" id="GRAPHIC-d7e1401-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0022.gif" alt="" id="gr20" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data are reported as geometric mean of at least three independent measurements, and in brackets is the geometric standard deviation as multiplicative factor given. *: EGFR<sup>d19 TM CS</sup> means EGFR<sup>del19 T790M C797S</sup>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Kinase selectivity was determined using the “SelectScreen Kinase Profiling Services” from ThermoFisher.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Measurement of inhibition of the p-EGFR<sup>del19 T790M C797S</sup> signal in BaF3 cells after 4 h compound treatment.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">BaF3 cells bearing EGFR<sup>del19 T790M C797S</sup> protein were treated for 3 days with compound, and the effect on proliferation was measured.</p></div></div><div></div></div><div class="NLM_p">From the protein X-ray structure (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), it is evident that the observed potency improvement resulted mostly from the conformational restrictions as no new or changed interactions with the EGFR protein are visible. Also, the observed binding conformation of ligand <b>6</b> is in excellent agreement with the computationally predicted minimum conformation.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. X-ray structure of compound <b>6</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D">6S9D</a>) in complex with EGFR<sup>L85R T790M</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the predicted minimum energy conformation of ligand <b>6</b>, it was expected that the bis aryl torsion angle in the macrocyclic ligand should be constrained to approx ∼40°, a value that is very close to the observed angle in the X-ray structure (39°) (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). This indicated that a reinstallment of a hydrogen-bond acceptor in the second aromatic ring should lead to a favorable hydrogen-bond formation to Lys745. Therefore, we decided to further improve the potency of the molecule by implementing a polar interaction with Lys745, as was seen in ligands <b>1</b>–<b>4</b>. We chose the <i>N</i>-methylpyrazole from ligand <b>4</b> rather than the pyridine moiety of compound <b>3</b>, because the metabolic stability predicted from human hepatocytes was superior for ligand <b>4</b> (%QH: 12%) over ligand <b>3</b> (%QH: 34%). Additionally, a fluorine atom was reinstalled in the α-position (R<sub>1</sub>) of the pyridine nitrogen to fill the observed small subpocket in the protein X-ray structure of <b>6</b> with the EGFR protein (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). We hypothesized that this substituent might be in part responsible for the excellent general kinase selectivity of ligand <b>1</b>. These structural changes resulted in ligand <b>7</b>, which showed at least an additional 5-fold improved biochemical activity in the EGFR<sup>L858R T790M C797S</sup> assay. It is noteworthy that macrocycle <b>7</b> also shows activity around the assay wall in this biochemical assay (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Table S8</a>, entry 2). This prevents the use of biochemical EGFR assays to determine further potency improvements. Also, a 5-fold improved antiproliferative effect against EGFR<sup>del19 T790M C797S</sup>-dependent cells of ligand <b>7</b> versus <b>6</b> can be seen. At the same time, we observed a submicromolar antiproliferative effect against EGFR<sup>wt</sup> and EGFR independent cells for the first time. However, the ratio of the IC<sub>50</sub> values remained unchanged between ligand <b>6</b> (IC<sub>50</sub> EGFR<sup>wt</sup>/IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 48) and ligand <b>7</b> (IC<sub>50</sub> EGFR<sup>wt</sup>/IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 45), suggesting a generally improved kinase activity instead of a specific improvement for mutant EGFR. The size of the substituent at the R<sub>1</sub>-position was increased from fluorine to methyl, which gave rise to compound <b>8</b>. While the cellular potency of aminobenzimidazole <b>8</b> (IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 5 nM) was found to be unchanged as compared to ligand <b>7</b> (IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 6 nM), the selectivity for EGFR mutant-dependent cells over EGFR<sup>wt</sup>-dependent cell or EGFR independent cells was significantly improved for ligand <b>8</b> (IC<sub>50</sub> EGFR<sup>wt</sup>/IC<sub>50</sub> EGFR<sup>del19 T790M C797S</sup> = 460). The enhanced selectivity for EGFR mutant-dependent cells over EGFR independent cells was also reflected by the improved overall kinase selectivity profile (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). For all further studies, we kept the methyl group in the R<sub>1</sub>-position as a “selectivity trigger”, which allowed us to further improve the potency while maintaining excellent kinase selectivity.</div><div class="NLM_p">In the next step, we reinvestigated the three-dimensional shape of our molecule by means of computational conformation analysis. From our previous computations and from the protein X-ray structures with ligand <b>6</b>, we knew that the conformation of the macrocyclic ligands was not flat but rather bowl shaped. From the lack of a stereo center in ligands <b>6</b>–<b>8</b>, these bowl-shaped molecules could adopt two enantiotopic minimum energy conformations (see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>: green and magenta ligands). We hypothesized that the interconversion between these two enantiotopic conformers would go through a low-energy transition state and would be fast at room temperature. From the protein X-ray structures with ligand <b>6</b>, the desired enantiomer was already known (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>; green ligand), and we envisioned a further improvement of the cellular potency by an additional restriction of the ligand to only one enantiotopic minimum conformer. To do so, we decided to install a stereo center in the linker and therefore to desymmetrize the molecule, so that the conformation at the newly installed stereo center would determine the conformational outcome of the entire ligand. Furthermore, we speculated that a correctly placed alkyl substituent in the linker would help to fill the “sugar-pocket” of the EGFR protein, which was previously filled by the bulky isobutyl-hydroxy group in ligands <b>1</b>–<b>5</b>.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Two calculated enantiotopic minimum energy conformations of compound <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Again, we compared the calculated minimum conformations of the newly designed ligands to the desired “active” conformation of ligand <b>6</b>, this time focusing our attention toward the optimal conformation of the linker and the absolute configuration of the minimum conformers. After investigating numerous possible macrocyclic ligands, we decided to synthesize ligand <b>9</b> with an additional methyl group in 2-position of the linker. On the basis of our calculations, the newly installed stereogenic center needed to be (<i>R</i>)-configured to give the ligand in the desired shape. Satisfyingly, we found that ligand <b>9</b> shows an additional improvement in cellular potency against mutant EGFR-dependent cells (IC<sub>50</sub> EGFR<sup>del19 T790M C979S</sup> = 1 nM) without losing the favorable selectivity window against EGFR<sup>wt</sup>-dependent cell lines (IC<sub>50</sub> EGFR<sup>wt</sup>/IC<sub>50</sub> EGFR<sup>del19 T790M C979S</sup> > 1000) and EGFR independent cell lines, and as before the overall kinase selectivity was maintained. While we were unsuccessful in obtaining an X-ray crystal structure of this molecule with the EGFR protein, we were able to solve a small-molecule X-ray structure of a very close analogue of <b>9</b> bearing a bromine substituent at the R<sub>3</sub> position <b>9-Br</b> (see <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure of <b>9Br</b> and comparison of small compound X-ray structure of <b>9Br</b> (brown, CCDC 1941612) with the calculated minimum energy conformation of <b>9</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The small-molecule X-ray structure of <b>9Br</b> with the heavy atom in 6-position of the benzimidazole allowed not only for the unambiguous determination of the absolute configuration at the newly created stereo center (<i>R</i>-configuration), but also confirmed the predicted minimum energy conformation of <b>9</b> (see <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><div class="NLM_p">At this point in the project, we felt that no further optimization of the cellular potency of the benzimidazole ligands was necessary. Instead, we focused any further optimization toward improving the DMPK parameters of the molecules. Particularly, the high plasma protein binding and the low aqueous solubility of ligand <b>9</b> were of concern (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). We believed that the high lipophilicity at the phenyl core caused the observed low solubility. Therefore, we decided to investigate several different solubilizing groups attached to the phenyl core. From the X-ray structure of ligand <b>6</b> (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) with the EGFR protein, an exit vector toward the solvent from positions 5 and 6 of the benzimidazole core became apparent.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. DMPK Properties of Macrocycle <b>9</b> and <b>BI-4020</b> in Comparison to <b>Osimertinib</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="×" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">metabolic stability hepatocytes<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> [%QH]</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">PPB free fraction<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="rowsep1 colsep0" align="center" char="×">permeability pampa assay<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center" char=".">solubility<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> at pH 6.8 [μg/mL]</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char="×">Papp A-B [cm/s] at pH 7.4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="."><0.1</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char="."><0.3</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char="×">0.2 × 10<sup>–6</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>BI-4020</b></td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char="×">5.3 × 10<sup>–6</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>osimertinib</b></td><td class="colsep0 rowsep0" align="char" char=".">86</td><td class="colsep0 rowsep0" align="char" char=".">83</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char="."><0.1</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char="×">2.7 × 10<sup>–6</sup></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Aqueous solubility was determined from 1 mg/mL solid compound dispensed into aqueous McIlvaine buffer (pH 6.8).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">In vivo hepatic clearance (CL) was predicted by in vitro incubations of 1 μM EGFR TKI with cryopreserved hepatocytes (Celsis IVT) and measured depletion over 240 min by quantitation of EGFR TKI by LC/MS/MS.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Plasma protein binding (PPB) was determined by equilibrium dialysis. Plasma was spiked with EGFR TKI and dialyzed against Soerensen buffer (pH 7.4) for 3 h at 37 °C.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Permeability was accessed by using a chamber separated by a microfilter disc (coated with structured layers of immobilized artificial phospholipid membranes) into a donor and an acceptor area.</p></div></div></div><div class="NLM_p">During our studies, we found that only very few substituents at the 5-position were accepted without dramatic loss in cellular activity (data not shown). Therefore, we decided to focus on solubilizing groups at the 6-position of the molecule and synthesized several ligands with varying solubilizing groups. From this collection of molecules, ligand <b>BI-4020</b> was identified as the most promising ligand with optimally balanced properties. The human clearance predicted by hepatocytes of compound <b>BI-4020</b> was higher than that for ligand <b>9</b>, but still in an acceptable range. Solubility, fraction unbound in plasma, and permeability of ligand <b>BI-4020</b> were clearly improved as compared to ligand <b>9</b>.</div><div class="NLM_p">Surprisingly, an additional boost in cellular activity was observed with ligand <b>BI-4020</b> (IC<sub>50</sub> EGFR<sup>del19 T790M C979S</sup> = 0.2 nM) showing for the first time subnanomolar activity. Pampa data indicate that the cellular potency gain could be explained by the improved permeability of BI-4020 (Papp A-B at pH 7.4:5.3 × 10<sup>–6</sup> cm/s) as compared to ligand <b>9</b> (Papp A-B at pH 7.4:0.2 × 10<sup>–6</sup> cm/s). While the absolute activity on EGFR<sup>wt</sup> was also significantly increased (IC<sub>50</sub> EGFR<sup>wt</sup> = 190 nM), the ratio between EGFR<sup>wt</sup> and EGFR mutant-dependent cells remained high (IC<sub>50</sub> EGFR<sup>wt</sup>/IC<sub>50</sub> EGFR<sup>del19 T790M C979S</sup> > 950). Furthermore, the ratio between EGFR independent and EGFR mutant-dependent cells was even increased. The kinase selectivity, now measured on three different panels (30 kinases, 238 kinases, and 394 kinases), remained also unchanged.</div><div class="NLM_p">Aqueous solubility was determined from 1 mg/mL solid compound dispensed into aqueous McIlvaine buffer (pH 4.5 or 6.8), or dissolved in acetonitrile/water (1:1) as reference. Dissolved concentrations were determined with an Agilent 1200 HPLC/DAD-UV system.</div><div class="NLM_p">Plasma protein binding (PPB) was determined by equilibrium dialysis. Plasma was spiked with EGFR TKI and dialyzed against Soerensen buffer (pH 7.4) for 3 h at 37 °C. PPB was calculated by quantifying EGFR TKI concentrations in plasma and buffer by HPLC/MS-MS. In vivo hepatic clearance (CL) was predicted by in vitro incubations of EGFR TKI with cryopreserved hepatocytes (Celsis IVT) and measured depletion over 240 min by quantitation of EGFR TKI by LC/MS/MS and using the well-stirred model. PAMPA parameters were determined as described previously.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">Next, we benchmarked the antiproliferative effects of <b>BI-4020</b> with osimertinib in a series of relevant EGFR mutant cell lines (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Comparison between Ligand <b>BI-4020</b> and <b>Osimertinib</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cellular potency<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">unit</th><th class="colsep0 rowsep0" align="center"><b>BI-4020</b></th><th class="colsep0 rowsep0" align="center"><b>osimertinib</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> p-EGFR BaF3 (EGFR<sup>del19TMCS</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">[nM]</td><td class="colsep0 rowsep0" align="left">0.6 (1.07)</td><td class="colsep0 rowsep0" align="left">3100 (1.22)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> BaF3 (EGFR<sup>del19TMCS</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">[nM]</td><td class="colsep0 rowsep0" align="left">0.2 (1.15)</td><td class="colsep0 rowsep0" align="left">780 (1.06)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> BaF3 (EGFR<sup>del19</sup>)</td><td class="colsep0 rowsep0" align="left">[nM]</td><td class="colsep0 rowsep0" align="left">1 (1.09)</td><td class="colsep0 rowsep0" align="left">1 (1.11)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> BaF3 (EGFR<sup>wt</sup>)</td><td class="colsep0 rowsep0" align="left">[nM]</td><td class="colsep0 rowsep0" align="left">190 (1.19)</td><td class="colsep0 rowsep0" align="left">81 (1.16)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> BaF3 (EGFR indep.)</td><td class="colsep0 rowsep0" align="left">[nM]</td><td class="colsep0 rowsep0" align="left">1100 (1.15)</td><td class="colsep0 rowsep0" align="left">1100 (1.23)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> PC-9 (EGFR<sup>del19TMCS</sup><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a>)</td><td class="colsep0 rowsep0" align="left">[nM]</td><td class="colsep0 rowsep0" align="left">1.3 (1.10)</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> A431 (EGFR<sup>wt</sup>)</td><td class="colsep0 rowsep0" align="left">[nM]</td><td class="colsep0 rowsep0" align="left">200 (1.12)</td><td class="colsep0 rowsep0" align="left">84 (1.05)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">kinase selectivity</td><td class="colsep0 rowsep0" align="left">% hit (no. total)</td><td class="colsep0 rowsep0" align="left">8% (238)</td><td class="colsep0 rowsep0" align="left">7% (238)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Data are reported as geometric mean of at least three independent measurements, and in brackets is given the geometric standard deviation as multiplicative factor.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">BaF3 cells bearing different EGFR variants were treated for 3 days with compound, and the effect on proliferation was measured.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">EGFR<sup>del19 TM CS</sup> means EGFR<sup>del19 T790M C797S</sup>.</p></div></div></div><div class="NLM_p last">While the covalent inhibitor osimertinib showed only weak in vitro biomarker modulation of the triple mutant EGFR due to the Cys797 to Ser797 resistance mutation, noncovalent inhibitor <b>BI-4020</b> showed strong subnanomolar potency (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The strong biomarker modulation of ligand <b>BI-4020</b> translates into subnanomolar antiproliferative effects against EGFR<sup>del19 T790M C979S</sup>-dependent BaF3 cells, whereas osimertinib was approximately 4000-fold less active. Osimertinib and <b>BI-4020</b> display equivalent activity on EGFR<sup>del19</sup> BaF3 cells as well as comparable selectivity for EGFR mutant over EGFR<sup>wt</sup> (see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). As expected already from the BaF3 cell profile, also an excellent potency of 1.3 nM was observed for <b>BI-4020</b> in the NSCLC cell line PC-9<sup>del19 T790M C797S</sup>, whereas osimertinib shows no anti proliferative effect up to 1 μM. The great EGFR wt-sparing effect of <b>BI-4020</b> (150 fold; see <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) could be also demonstrated using the NSCLC cell pair A431 (EGFR<sup>wt</sup>) and PC-9<sup>del19 T790M C797S</sup>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vitro and In Vivo Characterization of Macrocycle <b>BI-4020</b>: First EGFR TKI Showing Regression in an EGFR<sup>del19 T790M C797S</sup> Model</h3><div class="NLM_p">On the basis of the high potency and favorable in vitro DMPK parameters (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), the macrocycle <b>BI-4020</b> was chosen for in vivo studies. The measured clearance of 56% QH nicely matches the predicted clearance from hepatocytes. A volume of distribution of 4.2 l/kg indicates good distribution into tissue. After oral dosing of 10 mg/kg, a medium bioavailability is observed, and the unbound IC<sub>50</sub> is covered for more than 6 h, enabling further biomarker studies (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Figure S4</a>).</div><div class="NLM_p">To test the ability of the macrocycle <b>BI-4020</b> to inhibit EGFR in vivo, mice bearing subcutaneous PC-9<sup>del19 T790M C797S</sup> xenotransplants were treated orally with the vehicle (natrosol) or 10 mg/kg of compound <b>BI-4020</b>. Tumors were subsequently harvested 6, 18, and 24 h after treatment with <b>BI-4020</b>. Analysis and quantification of Tyr1068 phosphorylated EGFR (p-EGFR) from tumor lysates revealed that single oral administration of 10 mg/kg of <b>BI-4020</b> suppressed EGFR<sup>del19 T790M C797S</sup> phosphorylation 5–10-fold at all three time points as compared to the 6 h vehicle control (see <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). These results demonstrate pharmacodynamic biomarker modulation of double resistance mutation-positive EGFR in vivo by oral administration of compound <b>BI-4020</b> across a 24 h period and prompted us to conduct tumor growth efficacy experiments.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. In vivo biomarker modulation by macrocycle <b>BI-4020</b>; <i>x</i>-axis, time point of biomarker analysis after treatment with vehicle (control) or with 10 mg/kg <b>BI-4020</b> p.o.; <i>y</i>-axis, ratio of p-EGFR signal versus EGFR total signal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Daily oral treatment with 10 mg/kg <b>BI-4020</b> was tested for in vivo efficacy in the <i>EGFR</i><sup><i>del19 T790M C797S</i></sup> mutant human nonsmall cell lung cancer model PC-9<sup><i>del19 T790M C797S</i></sup>. At treatment start, the tumors display a size between 53 and 153 mm<sup>3</sup>. All groups were treated for 19 days. <b>BI-4020</b> induced strong regressions in 10 out of 10 tumors leading to a TGI of 121% (<i>P</i> = 0.0005) (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), while daily treatment with 25 mg/kg osimertinib showed no effect of tumor growth with a TGI of 6% in the same model (<i>p</i> > 0.05). Both treatments were well tolerated in all mice.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Xenograft model with PC-9 cells bearing a EGFR<sup>del19 T790M C797S</sup> protein; control group, 10 animals; treatment groups, 8 animals; animal type and strain, 6–8 week old, female BomTac:NMRI-Foxn1<sup>nu</sup> mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Synthesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a>–<a class="ref internalNav" href="#sch7" aria-label="7">7</a> illustrate the routes that were used to synthesize the compounds described herein.</div><figure id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>1</b>–<b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd dppf, Cs<sub>2</sub>CO<sub>3</sub>, DME, water, 90 °C; 16 h; (ii) LiOH, THF, MeOH, 20 °C, 2 h; (iii) HATU, DIPEA, dioxane, 60 °C, 12 h.</p></p></figure><div class="NLM_p">Carboxylic acids <b>13a</b>–<b>f</b> were synthesized applying a Suzuki reaction of the commercially available bromides <b>11a</b>–<b>d</b> and boronic acids <b>12a</b>–<b>d</b> followed by an ester cleavage. Amide coupling of aminobenzimidazole <b>14</b> and carboxylic acids <b>13a</b>–<b>f</b> led to the final compounds <b>1</b>–<b>5</b> (see <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><div class="NLM_p">Key intermediates <b>22a</b>–<b>c</b> were synthesized from starting material <b>15</b> applying an alkylation reaction followed by the reduction of the nitro group in intermediate <b>17</b> and a ring closure reaction of diamine <b>18</b>. Alternatively, key intermediates <b>22a</b>–<b>c</b> were synthesized by alkylating phenols <b>16b</b>,<b>c</b> with 1,5-dibromo-pentane <b>19</b> followed by a substitution reaction of <b>20a</b>,<b>b</b> with aminobenzimidazole <b>21</b>. Final compounds <b>6</b>, <b>7</b>, and <b>9Br</b> were synthesized from <b>22a</b>–<b>c</b> by cleaving the ester followed by an amide coupling. Key intermediate <b>26</b> was synthesized from aminobenzimidazole <b>21</b> applying an alkylation reaction with bromide <b>23</b> followed by an amide coupling with carboxylic acid <b>25</b>. Final compound <b>8</b> was synthesized via a Mitsunobu reaction starting from intermediate <b>26</b> (see <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>6</b>–<b>9Br</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) DMF, K<sub>2</sub>CO<sub>3</sub>, 60°C, 16 h; (ii) Pt and V/C, 3 bar H<sub>2</sub>, MeOH, 20°C, 16 h; (iii) CN–Br, CH<sub>2</sub>Cl<sub>2</sub>, <i>t</i>-BuOH, 20°C, 18 h; (iv) ACN, K<sub>2</sub>CO<sub>3</sub>, reflux, 16 h; (v) ACN, K<sub>2</sub>CO<sub>3</sub>, 110 °C (MW), 16 h; (vi) NaOH, THF, water, 20 °C, 1 h; (vii) TBTU, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 20°C, 30 min; (viii) ACN, K<sub>2</sub>CO<sub>3</sub>, reflux, 16 h; (ix) HATU, EtNi–Pr<sub>2</sub>, dioxane, 20°C, 16 h; (x) HCl in dioxane, EtOH, 20 °C, 16 h; (xi) PPh<sub>3</sub>, DIAD, THF, 20 °C, 30 min.</p></p></figure><div class="NLM_p">Catalytic hydrogenation of <b>9Br</b> with palladium on carbon led to macrocycle <b>9</b>. Benzimidazol <b>BI-4020</b> was synthesized from key intermediate <b>9Br</b> applying a reductive carbonylation reaction, which led to aldehyde <b>27</b>, followed by a reductive amination reaction (see <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>.)</div><figure id="sch4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>9</b> and <b>BI-4020</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd/C, H<sub>2</sub>, MeOH, 20 °C, 4 h; (ii) Pd(OAc)<sub>2</sub>, di(1-adamantyl)-<i>n</i>-butylphosphine, TMEDA, H<sub>2</sub>/CO, dioxane, 100 °C, 24 h; (iii) NaBH(OAc)<sub>3</sub>, HOAc, CH<sub>2</sub>Cl<sub>2</sub>, 20 °C, 6 h.</p></p></figure><div class="NLM_p">Phenols <b>16a</b> and <b>16b</b> were synthesized via a palladium-catalyzed cross-coupling reaction from chloropyridines <b>28</b> and <b>30</b>. Biaryl <b>36</b> was synthesized via Suzuki coupling of iodide <b>35</b> with boronic ester <b>34</b>, which was prepared by a CH activation of pyridine derivate <b>32</b>. Deprotection of phenolether <b>36</b> applying a palladium-catalyzed debenzylation reaction led to phenol <b>16c</b> (see <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>16a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) PdCl<sub>2</sub>DPPF, anisole, Na<sub>2</sub>CO<sub>3</sub>, 130 °C, 16 h; (ii) PdCl<sub>2</sub>DPPF, dioxane, K<sub>2</sub>CO<sub>3</sub>, 90 °C, 16 h; (iii) (1,5-cyclooctadiene)(methoxy)iridium(I) dimer, 4,4′-di-<i>tert</i>-butyl-2,2′-bipyridyl, 20 °C, 90 h; (iv) PdCl<sub>2</sub>DPPF, dioxane, K<sub>2</sub>CO<sub>3</sub>, 90 °C, 1 h; (v) Pd/C, 5 bar H<sub>2</sub>, MeOH, 20 °C, 16 h.</p></p></figure><div class="NLM_p">Key intermediate <b>25</b> was synthesized from 2-chloro-isonicotinic acid methyl ester <b>38</b> applying a CH activation reaction followed by a Suzuki coupling and ester cleavage. SEM protection of pyrazole <b>29</b> was followed by an electrophilic aromatic substitution reaction leading to iodo-pyrazole <b>44</b> (see <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compound <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) SEM-Cl, K<sub>2</sub>CO<sub>3</sub>, ACN, 20 °C, 14 h; (ii) NIS, ACN, 0–20 °C, 2 h; (iii) (1,5-cyclooctadiene)(methoxy)iridium(I) dimer, 4,4′-di-<i>tert</i>-butyl-2,2′-bipyridyl, 20 °C, 66 h; (iv) tris(dibenzylideneacetone)dipalladium, di(1-adamantyl)-<i>n</i>-butylphosphine, Cs<sub>2</sub>CO<sub>3</sub>, toluene, water, 50 °C, 2 h; (v) trimethylboroxine, tris(dibenzylideneacetone)dipalladium, di(1-adamantyl)-<i>n</i>-butylphosphine, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C, 18 h; (vi) NaOH, THF, 20 °C, 1 h.</p></p></figure><div class="NLM_p">Nucleophilic aromatic substitution reaction of amine <b>43</b> with electrophile <b>41</b> followed by an esterification with methanesulfonyl chloride led to nitroaniline <b>15</b> (see <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>).</div><figure id="sch7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, DMF, 20 °C, 24 h; (ii) MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 1 h.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48067" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48067" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The highly selective aminobenzimidazole <b>1</b> with 250 nM inhibition constant for EGFR<sup>del19 T790M C797S</sup> was identified by screening our corporate selective kinase inhibitor library. Structure-based design and macrocyclization led to the discovery of <b>BI-4020</b>, a highly active, noncovalent EGFR inhibitor. The strategy to increase the potency of a given ligand by restricting its conformational space to the “active” conformation by means of macrocyclization was shown to be a key contributor to success. <b>BI-4020</b> displays a single digit-nanomolar antiproliferative activity against EGFR mutant-dependent cells, including cells that are dependent on EGFR bearing the two most clinically prevalent resistance mutations T790M and C797S. At the same time, <b>BI-4020</b> shows a sufficient EGFR<sup>wt</sup> sparing window and high kinome selectivity that is comparable to that observed with osimertinib. Furthermore, <b>BI-4020</b> induces tumor regressions in the osimertinib resistant PC-9 (EGFR<sup>del19 T790M C797S</sup>) triple mutant mouse xenograft model.</div><div class="NLM_p last">Altogether, for the first time, a highly active, EGFR<sup>wt</sup> sparing next generation EGFR TKI with an excellent in vitro and in vivo activity was presented. Representatives from this promising compound class will be further profiled to be developed toward a clinical candidate, which will be active in a clinical setting where osimertinib resistance has occurred and no targeted treatment option with a TKI is available at the moment.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Remarks</h3><div class="NLM_p">Chemicals and reagents were obtained from commercial suppliers and were used without further purification. All moisture-sensitive reactions were carried out under a nitrogen atmosphere in commercially available anhydrous solvents. Starting materials and intermediates are commercially available unless specified otherwise. NMR experiments were acquired as described in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div class="NLM_p">High-resolution mass spectrometry data were obtained on a LTQ Orbitrap XL (Thermo Scientific) coupled with a Triversa Nanomate Nanospray ion source (ADVION Bioscience Inc.).</div><div class="NLM_p">Analytical HPLC–MS analyses were conducted using an Agilent 1100 series LC/MSD system. The analytic methods A1 and A2 are defined in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Table S1</a>. Compound purities were calculated as the percentage peak area of the analyzed compound by UV detection at 254 nm. If purity data are not explicitly mentioned, the compound displays a purity >95%. Flash column chromatography was carried out using hand packed silica gel 60 (230–400 mesh) or prepacked silica gel columns from Biotage, and product was eluted under medium pressure liquid chromatography. Preparative high performance chromatography was carried out on a Gilson system (pump system, 333 and 334 prep-scale HPLC pump; fraction collector, 215 liquid handler; detector, Gilson UV/vis 155) using prepacked reversed phase silica gel columns from waters. The methods for preparative high performance chromatography P1–P3 are defined in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Table S1</a>.</div><div class="NLM_p">The in vitro biological data shown in this publication are the geometric mean of at least three independent measurements.</div><div class="NLM_p">All compounds for which biology data were shown were screened for PAINS, and none of them was classified as pan assay interference compound.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 3-Fluoro-<i>N</i>-[1-(2-hydroxy-2-methyl-propyl)-1<i>H</i>-benzoimidazol-2-yl]-5-pyridin-3-yl-enzamide (<b>1</b>)</h4><div class="NLM_p">Compound <b>1</b> was synthesized according to the procedure of compound <b>2</b>.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.27 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 405 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>21</sub>FN<sub>4</sub>O<sub>2</sub>, 405.17213; found, 405.17126; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.85 (br s, 1H), 8.97 (d, <i>J</i> = 2.21 Hz, 1H), 8.64 (dd, <i>J</i> = 1.42, 4.89 Hz, 1H), 8.36 (s, 1H), 8.17 (td, <i>J</i> = 1.73, 8.20 Hz, 1H), 7.95 (dd, <i>J</i> = 1.10, 9.30 Hz, 1H), 7.78–7.83 (m, 1H), 7.63 (dd, <i>J</i> = 1.73, 6.78 Hz, 1H), 7.52–7.58 (m, 2H), 7.24 (ddd, <i>J</i> = 1.42, 5.52, 7.25 Hz, 2H), 5.05 (s, 1H), 4.25 (s, 2H), 1.25 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.3, 162.6 (d, <i>J</i>(CF) = 243.4 Hz), 152.9, 149.2, 147.7, 141.6 (d, <i>J</i>(CF) = 6.4 Hz), 139.2 (d, <i>J</i>(CF) = 8.2 Hz), 134.4, 134.3, 130.7, 128.8, 124.0, 122.9, 122.6, 122.6, 116.2 (d, <i>J</i>(CF) = 22.7 Hz), 114.5 (d, <i>J</i>(CF) = 21.8 Hz), 111.9, 111.7, 71.0, 52.8, 27.9.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-[1-(2-Hydroxy-2-methyl-propyl)-1<i>H</i>-benzoimidazol-2-yl]-5-pyridin-3-yl-enzamide (<b>2</b>)</h4><div class="NLM_p last">3-(Pyridin-3-yl)benzoic acid <b>13b</b> (65 mg, 0.33 mmol) and 1-(2-amino-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-2-methylpropan-2-ol <b>14</b> (65 mg, 0.32 mmol) were dissolved in 2 mL of DMF, and HATU (137 mg, 0.36 mmol) and ethyldiisopropylamine (163 μL, 0.95 mmol) were added. The reaction mixture was stirred for 3 h at room temperature. The volatile components have been evaporated under reduced pressure, and the crude product was purified applying preparative high performance chromatography method P1, yielding 94 mg (75%, 0.24 mmol) of the title compound. Purity by method A1, >95%; RT = 1.21 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 387 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>, 387.18155; found, 387.18221; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.87 (br s, 1H), 8.94 (d, <i>J</i> = 1.58 Hz, 1H), 8.62 (dd, <i>J</i> = 1.58, 4.73 Hz, 1H), 8.51 (s, 1H), 8.23–8.30 (m, 1H), 8.12–8.16 (m, 1H), 7.85–7.92 (m, 1H), 7.61–7.66 (m, 2H), 7.53–7.59 (m, 1H), 7.55 (dd, <i>J</i> = 1.58, 6.31 Hz, 1H), 7.23 (s, 2H), 5.11 (br s, 1H), 4.25 (s, 2H), 1.25 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.6, 152.9, 148.6, 147.5, 139.0, 136.8, 135.6, 134.3, 130.7, 129.6, 129.0, 129.0, 128.3, 126.9, 124.1, 122.5, 111.9, 111.5, 71.0, 52.9, 27.8. Compounds <b>1</b> and <b>3</b>–<b>5</b> were synthesized accordingly.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> [2,3′]Bipyridinyl-4-carboxylic Acid [1-(2-Hydroxy-2-methyl-propyl)-1<i>H</i>-benzoimidazol-2-yl]-amide (<b>3</b>)</h4><div class="NLM_p">Compound <b>3</b> was synthesized according to the procedure of compound <b>2</b>.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.10 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 388 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>, 388.17680; found, 388.1771; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.94 (br s, 1H), 9.28 (d, <i>J</i> = 1.89 Hz, 1H), 8.87 (d, <i>J</i> = 5.04 Hz, 1H), 8.68 (dd, <i>J</i> = 1.26, 4.73 Hz, 1H), 8.59 (s, 1H), 8.45–8.49 (m, 1H), 8.09 (dd, <i>J</i> = 1.10, 4.89 Hz, 1H), 7.64–7.68 (m, 1H), 7.55–7.61 (m, 2H), 7.22–7.30 (m, 2H), 4.97–5.04 (m, 1H), 4.22–4.32 (m, 2H), 1.26 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.1, 154.4, 152.8, 150.5, 150.0, 147.7, 146.7, 134.1, 134.0, 130.7, 128.8, 123.9, 122.7, 122.7, 121.9, 119.0, 112.0, 111.9, 71.0, 52.9, 27.9.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 4′-Methoxy-[2,3′]bipyridinyl-4-carboxylic Acid [1-(2-Hydroxy-2-methyl-propyl)-1<i>H</i>-benzoimidazol-2-yl]-amide (<b>3a</b>)</h4><div class="NLM_p">Compound <b>3a</b> was synthesized according to the procedure of compound <b>2</b>.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.08 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 418 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>, 418.18737; found, 418.18740; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.68–13.22 (m, 1H), 8.80 (br d, <i>J</i> = 4.73 Hz, 1H), 8.61 (s, 1H), 8.52 (br s, 1H), 8.05 (dd, <i>J</i> = 1.26, 5.04 Hz, 1H), 7.83 (d, <i>J</i> = 8.20 Hz, 1H), 7.63 (d, <i>J</i> = 8.20 Hz, 1H), 7.24–7.29 (m, 1H), 7.22 (d, <i>J</i> = 5.67 Hz, 1H), 7.15 (t, <i>J</i> = 7.57 Hz, 1H), 7.03 (t, <i>J</i> = 7.57 Hz, 1H), 5.01 (s, 1H), 4.31–4.41 (m, 2H), 3.79 (s, 3H), 1.26 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.8, 162.6, 156.5, 153.0, 151.4, 150.9, 150.0, 146.0, 138.0, 132.9, 124.0, 123.8, 121.6, 121.5, 121.2, 116.4, 111.3, 107.6, 71.1, 55.8, 52.9, 27.9.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-[1-(2-Hydroxy-2-methyl-propyl)-1<i>H</i>-benzoimidazol-2-yl]-2-(1-methyl-1<i>H</i>-pyrazol-4-yl)-isonicotinamide (<b>4</b>)</h4><div class="NLM_p">Compound <b>4</b> was synthesized according to the procedure of compound <b>2</b>.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.06 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 391 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>21</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>, 391.18770; found, 391.18765; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.88 (br s, 1H), 8.64 (dd, <i>J</i> = 0.63, 5.04 Hz, 1H), 8.33 (s, 1H), 8.21 (s, 1H), 8.01 (s, 1H), 7.84 (dd, <i>J</i> = 1.26, 4.73 Hz, 1H), 7.63–7.68 (m, 1H), 7.57 (dd, <i>J</i> = 1.42, 7.41 Hz, 1H), 7.21–7.29 (m, 2H), 5.00 (s, 1H), 4.26 (s, 2H), 3.92 (s, 3H), 1.26 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.5, 152.8, 152.1, 149.9, 146.1, 136.9, 130.7, 129.6, 128.8, 122.8, 122.7, 122.6, 119.7, 117.7, 112.0, 111.9, 71.0, 52.8, 38.8, 27.8.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-[1-(2-Hydroxy-2-methyl-propyl)-1<i>H</i>-benzoimidazol-2-yl]-2-phenyl-isonicotinamide (<b>5</b>)</h4><div class="NLM_p">Compound <b>5</b> was synthesized according to the procedure of compound <b>2</b>.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.31 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 387 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>, 387.18155; found, 387.18197; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.93 (br s, 1H), 8.82 (d, <i>J</i> = 5.04 Hz, 1H), 8.55 (s, 1H), 8.11 (d, <i>J</i> = 7.57 Hz, 2H), 8.03 (d, <i>J</i> = 5.04 Hz, 1H), 7.66 (br d, <i>J</i> = 7.25 Hz, 1H), 7.52–7.59 (m, 3H), 7.45–7.51 (m, 1H), 7.21–7.29 (m, 2H), 5.02 (s, 1H), 4.27 (s, 2H), 1.27 (s, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.3, 156.6, 152.8, 150.2, 146.5, 138.7, 130.7, 129.2, 128.9, 128.8, 126.5, 122.7, 122.7, 121.2, 118.6, 112.0, 111.9, 71.0, 52.9, 27.9.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 5<sup>1</sup><i>H</i>-11-Oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(1,2)-benzenacycloundecaphan-3-one (<b>6</b>)</h4><div class="NLM_p">2-{2-[5-(2-Imino-2,3-dihydro-benzimidazol-1-yl)-pentyloxy]-phenyl}-isonicotinic acid <i>tert</i>-butyl ester <b>22b</b> (186 mg, 0.39 mmol) was dissolved in dichloromethane, and trifluoroacetic acid (0.45 mL, 5.60 mmol) was added at room temperature. The reaction mixture was stirred for 20 h at room temperature. After complete conversion to product, the mixture was concentrated under reduced pressure. The residue was resolved in dichloromethane neutralized with 5 mL of Et<sub>3</sub>N, and the mixture was concentrated under reduced pressure again. The crude product was used in the next step without further purification, and yield was estimated as quantitative.</div><div class="NLM_p">2-{2-[5-(2-Imino-2,3-dihydro-benzoimidazol-1-yl)-pentyloxy]-phenyl}-isonicotonic acid as a crude product (160 mg, 0.38 mmol) was dissolved in dichloromethane, and 0.17 mL Et<sub>3</sub>N (1.15 mmol) was added at room temperature. The solution was stirred for 30 min at room temperature, and HATU (164 mg, 0.42 mmol) was added. The reaction mixture was stirred for 16 h at room temperature. After complete conversion, to the reaction mixture was added water, and it was extracted with dichloromethane. Collected organic layers were dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified applying preparative high performance chromatography method P3 yielding 23 mg (15%, 0.058 mmol) of the title compound.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.48 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 399 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>, 399.18155; found, 399.18060; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (s, 1H), 9.25 (s, 1H), 8.80 (dd, <i>J</i> = 0.63, 5.04 Hz, 1H), 8.24 (dd, <i>J</i> = 1.73, 7.72 Hz, 1H), 7.80 (dd, <i>J</i> = 1.42, 4.89 Hz, 1H), 7.51–7.58 (m, 2H), 7.42 (ddd, <i>J</i> = 1.89, 7.01, 8.43 Hz, 1H), 7.28 (dtd, <i>J</i> = 0.95, 7.65, 19.39 Hz, 2H), 7.19 (d, <i>J</i> = 7.88 Hz, 1H), 7.09 (t, <i>J</i> = 7.30 Hz, 1H), 4.23 (td, <i>J</i> = 5.00, 17.10 Hz, 4H), 1.86–2.11 (m, 6H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.4, 157.0, 154.4, 152.2, 149.6, 145.8, 130.5, 130.5, 129.3, 128.9, 126.4, 124.2, 122.9, 122.8, 120.5, 120.1, 112.6, 112.1, 109.5, 67.9, 41.2, 28.7, 28.7, 24.9.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>E</i>)-2<sup>6</sup>-Fluoro-1<sup>1</sup>-methyl-5<sup>2</sup>,5<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>,5<sup>1</sup><i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (<b>7</b>)</h4><div class="NLM_p">2-(5-{[5-(2-Amino-1<i>H</i>-1,3-benzodiazol-1-yl]pentyloxy}-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-fluoropyridine-4-carboxylic acid <b>22c</b> (30 mg, 0.068 mmol) and HATU (29 mg, 0.075 mmol) were suspended in 2 mL of dichloromethane, and 40 μL of <i><sup>i</sup></i>Pr<sub>2</sub>EtN (0.21 mmol) was added at room temperature. The reaction mixture was stirred for 16 h at room temperature. After complete conversion time, volatile components have been evaporated under reduced pressure.</div><div class="NLM_p">The crude product was purified by applying preparative high performance chromatography method P3 yielding 20 mg (70%) of the title compound.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.34 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 421 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>21</sub>FN<sub>6</sub>O<sub>2</sub>, 421.17828; found, 421.17800; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.78 (s, 1H), 8.49 (s, 1H), 7.88 (s, 1H), 7.62 (d, <i>J</i> = 7.88 Hz, 1H), 7.55 (d, <i>J</i> = 7.57 Hz, 1H), 7.20–7.34 (m, 3H), 4.11–4.30 (m, 4H), 3.74 (s, 3H), 2.05 (br d, <i>J</i> = 6.62 Hz, 4H), 1.73–1.88 (m, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.2 (d, <i>J</i>(CF) = 3.6 Hz), 163.9 (d, <i>J</i>(CF) = 234.3 Hz), 152.9 (d, <i>J</i>(CF) = 7.3 Hz), 152.0, 151.7, 150.1 (d, <i>J</i>(CF) = 14.5 Hz), 137.5, 129.8, 129.3, 123.5, 123.3, 116.7 (d, <i>J</i>(CF) = 2.7 Hz), 112.8, 110.1, 107.0, 104.4 (d, <i>J</i>(CF) = 39.1 Hz), 72.3, 42.9, 34.7, 28.0, 25.4, 21.9.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>E</i>)-1<sup>1</sup>,2<sup>6</sup>-Dimethyl-5<sup>2</sup>,5<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>,5<sup>1</sup><i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (<b>8</b>)</h4><div class="NLM_p">(E)-2-(5-Hydroxy-1-methyl-1<i>H</i>-pyrazol-4-yl)-<i>N</i>-(1-(5-hydroxypentyl)-1,3-dihydro-2<i>H</i>-benzo[<i>d</i>]imidazol-2-ylidene)-6-methylisonicotinamide <b>26</b> (50 mg, 0.12 mmol) was dissolved in 5 mL of anhydrous tetrahydrofuran. Diisopropyl azodicarboxylate (100 μL, 0.48 mmol) was added, and the reaction vessel was purged with argon. Triphenylphosphine (130 mg, 0.47 mmol) was added, and the reaction mixture was stirred at room temperature. After completion of the reaction, water was added and the reaction mixture was extracted with dichloromethane. The combined organic layers were dried over magnesium sulfate and concentrated. The residue was purified applying preparative high performance chromatography (method P1), yielding 31 mg (65%, 0.07 mmol) of the title compound.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.30 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 417 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub>, 417.20335; found, 417.20338; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.67 (br s, 1H), 8.41 (s, 1H), 7.92 (s, 1H), 7.59 (d, <i>J</i> = 7.57 Hz, 1H), 7.57 (d, <i>J</i> = 0.63 Hz, 1H), 7.54 (d, <i>J</i> = 7.50 Hz, 1H), 7.28 (ddd, <i>J</i> = 1.50, 7.00, 8.10 Hz, 1H), 7.23 (ddd, <i>J</i> = 1.00, 7.00, 8.10 Hz, 1H), 4.17–4.24 (m, 4H), 3.73 (s, 3H), 2.56 (s, 3H), 1.99–2.12 (m, 4H), 1.75–1.84 (m, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.6, 158.0, 151.7, 150.7, 150.4, 146.3, 136.9, 129.4, 128.9, 122.8, 122.6, 118.2, 115.7, 112.2, 109.4, 107.8, 71.6, 42.3, 34.1, 27.5, 24.8, 24.5, 21.3.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>R</i>,<i>E</i>)-1<sup>1</sup>,2<sup>6</sup>,7-Trimethyl-5<sup>2</sup>,5<sup>3</sup>-dihydro-1<sup>1</sup><i>H</i>,5<sup>1</sup><i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (<b>9</b>)</h4><div class="NLM_p">(<i>R</i>,<i>E</i>)-5<sup>6</sup>-Bromo-1<sup>1</sup>,2<sup>6</sup>,7-trimethyl-5<sup>2</sup>,5<sup>3</sup>-dihydro-11<i>H</i>,51<i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one <b>9Br</b> (100 mg, 0.20 mmol) was dissolved in 3 mL of DMF, and then triethysilane (0.32 mL, 1.91 mmol), sodium carbonate (72 mg, 0.68 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (4 mg, 0,005 mmol) were added at 25 °C. The reaction mixture was stirred at 90 °C for 16 h, and afterward it was filtered over Celite and the solvents were removed under reduced pressure. The residue was purified applying preparative high performance chromatography (method P1), yielding 21 mg (25%, 0.05 mmol) of the title compound.</div><div class="NLM_p last">Purity by method A1, >95%; RT = 1.36 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 431 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.74 (br s, 1H), 8.43 (s, 1H), 7.92 (s, 1H), 7.60 (d, <i>J</i> = 7.88 Hz, 1H), 7.57 (s, 1H), 7.55 (d, <i>J</i> = 7.57 Hz, 1H), 7.28 (t, <i>J</i> = 7.70 Hz, 1H), 7.23 (t, <i>J</i> = 7.70 Hz, 1H), 4.35 (td, <i>J</i> = 4.49, 9.30 Hz, 1H), 4.20 (dd, <i>J</i> = 2.84, 13.56 Hz, 1H), 3.97–4.04 (m, 1H), 3.93 (dd, <i>J</i> = 10.40, 13.56 Hz, 1H), 3.73 (s, 3H), 2.80 (br d, <i>J</i> = 3.47 Hz, 1H), 2.56 (s, 3H), 2.15–2.27 (m, 1H), 1.85–2.04 (m, 2H), 1.39–1.51 (m, 1H), 0.81 (d, <i>J</i> = 6.62 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.3, 158.0, 151.6, 150.8, 150.4, 146.2, 136.9, 130.4, 128.8, 122.9, 122.5, 118.2, 115.7, 112.2, 109.7, 107.8, 71.3, 49.4, 34.1, 28.8, 28.7, 25.5, 24.5, 16.8.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>,<i>E</i>)-5<sup>6</sup>-Bromo-1<sup>1</sup>,2<sup>6</sup>,7-trimethyl-5<sup>2</sup>,5<sup>3</sup>-dihydro-11<i>H</i>,51<i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (<b>9Br</b>)</h4><div class="NLM_p last">(<i>R</i>)-2-(5-((5-(2-Amino-6-bromo-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinic acid <b>22a′</b> (9.70 g, 18.4 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (200 mL), and Et<sub>3</sub>N (10.3 mL, 73.6 mmol) was added. To the resultant solution was added TBTU (7.09 g, 22.1 mmol), and the reaction mixture was stirred at room temperature for 15 min. The reaction mixture was washed with water (3 × 100 mL), and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude product was purified by chromatography on SiO<sub>2</sub> using CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) as eluent. The resultant material was further purified by recrystallization from hot toluene to give the title compound (5.24 g, 10.3 mmol, 56%) as a white solid. Purity by method A1, >95%; RT = 1.46 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 509/511 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>25</sub>BrN<sub>6</sub>O<sub>2</sub>, 509.12948; found, 509.12799; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.84 (br s, 1H), 8.41 (s, 1H), 7.92 (s, 2H), 7.56 (s, 1H), 7.47 (d, <i>J</i> = 8.40 Hz, 1H), 7.39 (dd, <i>J</i> = 1.80, 8.40 Hz, 1H), 4.28–4.41 (m, 1H), 4.11–4.20 (m, 1H), 3.93–4.05 (m, 2H), 3.73 (s, 3H), 2.72–2.87 (m, 1H), 2.56 (s, 3H), 2.14–2.28 (m, 1H), 1.84–2.05 (m, 2H), 1.37–1.51 (m, 1H), 0.81 (d, <i>J</i> = 6.59 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.1, 158.5, 152.4, 151.2, 150.9, 146.4, 137.4, 132.4, 128.6, 125.7, 118.6, 116.2, 115.5, 114.3, 113.0, 108.2, 71.7, 50.0, 34.6, 29.1, 29.0, 26.0, 24.9, 17.1.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>,<i>E</i>)-11,26,7-Trimethyl-56-((4-methylpiperazin-1-yl)methyl)-52,53-dihydro-11<i>H</i>,51<i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one (<b>BI-4020</b>)</h4><div class="NLM_p last">(<i>R</i>,<i>E</i>)-11,26,7-Trimethyl-3-oxo-52,53-dihydro-11<i>H</i>,51<i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-56-carbaldehyde <b>27</b> (2.00 g, 3.82 mmol, 87% purity) and 1-methylpiperazine (2.83 g, 28.25 mmol) were dissolved in 40 mL of DCM, and AcOH (1.99 g, 19.86 mmol) and sodium triacetoxyborohydride (2.26 g, 10.7 mmol) were added sequentially. The reaction mixture was stirred for 6 h at room temperature. The reaction was quenched with satd NaHCO<sub>3</sub> (15 mL), and the volatile components were evaporated under reduced pressure. The crude residue was partitioned between 2-methyltetrahydrofuran (25 mL) and satd NH<sub>4</sub>Cl (20 mL), and the resulting organic layer was washed with 5% brine (25 mL). The final organic layer was dried over magnesium sulfate and concentrated under reduced pressure to dryness, and the crude product was purified by Combiflash using 10% MeOH in DCM (<i>R</i><sub><i>f</i></sub> 0.18 in 10% MeOH in DCM) yielding 1.5 g of off-white foam (72.4%, 2.76 mmol) of the desired product <b>BI-4020</b>. Purity by method A1, >95%; RT = 1.26 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 543 (M + H)<sup>+</sup>; HRMS (<i>m</i>/<i>z</i>), [M + H]<sup>+</sup> calculated for C<sub>30</sub>H<sub>38</sub>N<sub>8</sub>O<sub>2</sub>, 543.31905; found, 543.31976; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.67 (br s, 1H), 8.42 (s, 1H), 7.92 (s, 1H), 7.56 (s, 1H), 7.49 (s, 1H), 7.47 (d, <i>J</i> = 8.20 Hz, 1H), 7.43–7.48 (m, 1H), 7.16 (dd, <i>J</i> = 0.95, 8.20 Hz, 1H), 4.35 (td, <i>J</i> = 4.57, 9.14 Hz, 1H), 4.19 (dd, <i>J</i> = 2.99, 13.71 Hz, 1H), 3.96–4.03 (m, 1H), 3.92 (dd, <i>J</i> = 10.09, 13.56 Hz, 1H), 3.71–3.75 (m, 1H), 3.73 (s, 2H), 3.55 (d, <i>J</i> = 3.15 Hz, 2H), 2.72–2.85 (m, 1H), 2.55 (s, 3H), 2.17–2.47 (m, 8H), 2.14 (s, 3H), 1.86–2.03 (m, 2H), 1.40–1.52 (m, 1H), 0.80 (d, <i>J</i> = 6.62 Hz, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.3, 157.9, 151.7, 150.8, 150.4, 146.2, 136.9, 133.4, 130.4, 127.8, 123.5, 118.2, 115.7, 111.8, 109.8, 107.8, 71.3, 62.2, 54.7, 52.5, 49.3, 45.7, 34.1, 28.7, 28.7, 25.5, 24.5, 16.8.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Carboxy-4′-methoxy-[2,3′-bipyridin]-1′-ium Chloride (<b>13d</b>)</h4><div class="NLM_p"><i>tert</i>-Butyl-2-bromoisonicotinate (6.50 g; 25.18 mmol), monolithium 4-methoxypyridine-3-boronate (8.17 g; 50.37 mmol), tri-<i>tert</i>-butylphosphonium tetrafluoroborate (731 mg; 2.52 mmol), and palladium(II) acetate (565 mg; 2.52 mmol) were dissolved in 195 mL of 1,2-dimethoxyethane and 65 mL of water. The mixture was flushed with argon and stirred at room temperature for 5 min. Cesium carbonate (13.95 g; 42.81 mmol) then was added, and stirring was continued at 80 °C for 16 h. The reaction mixture was poured on water and extracted with DCM once. The organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified applying preparative high performance chromatography (method P3). The resulting <i>tert</i>-butyl 2-(4-methoxypyridin-3-yl)pyridine-4-carboxylate (4.86 g; 16.12 mmol) was dissolved in 276 mL of acetonitrile, and 11 mL of concentrated hydrochloric acid (131.08 mmol) was added. The mixture was stirred at 55 °C for 16 h. The precipitate was filtered off, washed with cold acetonitrile, and dried in a vacuum to give 4.18 g (62%, 15.69 mmol) of the title compound.</div><div class="NLM_p last">Purity by method A2, 96%; RT = 0.21 min; MS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 231 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>R</i>)-5-((5-Bromo-2-nitrophenyl)amino)-4-methylpentyl Methanesulfonate (<b>15</b>)</h4><div class="NLM_p last">(<i>R</i>)-5-((5-Bromo-2-nitrophenyl)amino)-4-methylpentan-1-ol <b>42</b> (20.0 g, 63.2 mmol) and Et<sub>3</sub>N (13.2 mL, 94.8 mmol) were mixed with CH<sub>2</sub>Cl<sub>2</sub> (85 mL), and the resultant solution was cooled to 0 °C. MsCl (5.87 mL, 75.8 mmol) was added dropwise at 0 °C, and upon completion of the addition the cooling bath was removed and the reaction mixture was allowed to stir at room temperature for 1 h. The mixture was then washed sequentially with saturated aqueous NaHCO<sub>3</sub> solution and water, and the organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield the title compound (24.7 g, 62.5 mmol, 99%) as an orange oil. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>13</sub>H<sub>20</sub>BrN<sub>2</sub>O<sub>5</sub>S, 395.02708; found, 395.02683; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.09 (br, 1H), 7.97 (d, <i>J</i> = 9.07 Hz, 1H), 6.96 (d, <i>J</i> = 1.98 Hz, 1H), 6.71 (dd, <i>J</i> = 1.98, 9.08 Hz, 1H), 4.22 (t, <i>J</i> = 6.31 Hz, 2H), 3.21–3.15 (m, 1H), 3.11–3.05 (m, 1H), 2.99 (s, 3H), 1.93–1.70 (m, 3H), 1.64–1.55 (m, 1H), 1.41–1.30 (m, 1H), 1.04 (d, <i>J</i> = 6.69 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 145.9, 131.8, 130.8, 128.2, 118.6, 116.4, 69.8, 49.1, 37.4, 32.3, 30.3, 26.6, 17.8.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Methyl 2-(5-Hydroxy-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate Hydrochloride (<b>16a</b>)</h4><div class="NLM_p last">Methyl 2-chloro-6-methylisonicotinate <b>28</b> (50.0 g, 269.4 mmol), 1-methyl-1<i>H</i>-pyrazol-5-ol <b>29</b> (52.9 g, 538.8 mmol), PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (6.60 g, 8.08 mmol), powdered Na<sub>2</sub>CO<sub>3</sub> (62.8 g, 592.7 mmol), and anisole (1000 mL) were heated at 130 °C under nitrogen for 16 h. The reaction mixture was then cooled to room temperature and was filtered through a 2 cm pad of Celite. The Celite pad was washed with toluene (200 mL). The dark filtrate was treated with MeOH (150 mL), followed by dropwise addition of 4 M HCl in dioxane (100 mL, 400 mmol). The resultant slurry was stirred at room temperature for 1 h and then was filtered. The filter cake was washed with toluene and heptane, and was then dried under vacuum at 50 °C to yield the title compound (47.5 g, 98.4 wt %, 164.7 mmol, 61%) as a yellow solid. HRMS (<i>m</i>/<i>z</i>): [M + H – HCl]<sup>+</sup> calculated for C<sub>12</sub>H<sub>14</sub>N<sub>3</sub>O<sub>3</sub>, 248.10297; found, 248.10291; <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ 8.17 (s, 1H), 8.03 (m, 1H), 7.65 (m, 1H), 3.91 (s, 3H), 3.42 (s, 3H), 2.63 (s, 3H); <sup>13</sup>C NMR (100 MHz, D<sub>2</sub>O) δ 164.3, 160.3, 151.9, 147.9, 143.8, 132.5, 120.1, 117.9, 95.5, 53.9, 30.2, 19.3.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Methyl (<i>R</i>)-2-(5-((5-((5-Bromo-2-nitrophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate (<b>17</b>)</h4><div class="NLM_p last">(<i>R</i>)-5-((5-Bromo-2-nitrophenyl)amino)-4-methylpentyl methanesulfonate <b>15</b> (13.8 g, 95% purity, 33.1 mmol) and methyl 2-(5-hydroxy-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate hydrochloride <b>16a</b> (9.63 g, 33.9 mmol) were dissolved in DMF (50 mL). K<sub>2</sub>CO<sub>3</sub> (11.4 g, 82.8 mmol) then was added, and the mixture was stirred at 60 °C for 18 h. The reaction mixture was then cooled to room temperature, diluted with methyl <i>tert</i>-butyl ether, and washed twice with water. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield the title compound (15.4 g, 28.2 mmol, 85%) as an orange oil. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>29</sub>BrN<sub>5</sub>O<sub>5</sub>, 546.13466; found, 546.13479; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.16 (br m, 1H), 8.01 (d, <i>J</i> = 9.12 Hz, 1H), 7.88 (s, 1H), 7.87–7.86 (m, 1H), 7.48–7.47 (m, 1H), 7.00 (d, <i>J</i> = 1.94 Hz, 1H), 6.73 (dd, <i>J</i> = 1.98, 9.09 Hz, 1H), 4.16 (t, <i>J</i> = 6.39 Hz, 2H), 3.94 (s, 3H), 3.75 (s, 3H), 3.28–3.22 (m, 1H), 3.16–3.10 (m, 1H), 2.61 (s, 3H), 2.02–1.81 (m, 3H), 1.77–1.69 (m, 1H), 1.53–1.43 (m, 1H), 1.10 (d, <i>J</i> = 6.67 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 166.1, 159.1, 152.2, 151.4, 145.9, 138.0, 137.9, 131.7, 130.8, 128.2, 118.9, 118.6, 116.3, 107.3, 74.8, 52.6, 49.2, 34.3, 32.6, 30.8, 27.3, 24.7, 17.8.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Methyl (<i>R</i>)-2-(5-((5-((2-Amino-5-bromophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate (<b>18</b>)</h4><div class="NLM_p last">Methyl (<i>R</i>)-2-(5-((5-((5-bromo-2-nitrophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate <b>17</b> (2.75 g, 5.03 mmol) and 50% wet catalyst 1%Pt/2%V/C (2.4 g, 0.015 mmol Pt) were added to a 100 mL hydrogenation autoclave, followed by addition of MeOH (40 mL). The reaction mixture was purged with nitrogen three times and then with hydrogen once, followed by hydrogenation under 100 psi H<sub>2</sub> at 20 °C for 16 h. The reaction mixture was filtered through Celite to remove the catalyst, and then the solvent was removed under reduced pressure to yield the title compound (2.54 g, 4.92 mmol, 98%) as a dark oil. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>31</sub>BrN<sub>5</sub>O<sub>3</sub>, 516.16048; found, 526.16075; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81 (s, 2H), 7.80 (m, 1H), 7.41 (br s, 1H), 6.66 (dd, <i>J</i> = 2.1, 8.1 Hz, 1H), 6.49 (d, <i>J</i> = 2.1 Hz, 1H), 4.06 (t, <i>J</i> = 6.4 Hz, 1H), 3.88 (s, 3H), 3.67 (s, 3H), 3.05 (br s, 3H), 2.95 (dd, <i>J</i> = 6.4, 12.2 Hz, 1H), 2.85 (dd, <i>J</i> = 6.4, 12.0 Hz, 1H), 2.54 (s, 3H), 1.76 (m, 4H), 1.34 (m, 1H), 0.97 (d, <i>J</i> = 6.5 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 166.2, 159.2, 152.2, 151.6, 139.6, 138.1, 138.0, 132.7, 120.5, 119.0, 117.8, 116.4, 114.0, 113.3, 107.3, 75.1, 52.6, 50.2, 34.3, 32.8, 30.9, 27.4, 24.7, 18.0.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Methyl (<i>R</i>)-2-(5-((5-(2-Amino-6-bromo-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate (<b>22a</b>)</h4><div class="NLM_p last">Methyl (<i>R</i>)-2-(5-((5-((2-amino-5-bromophenyl)amino)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate <b>18</b> (2.60 g, 5.03 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) and <i>tert</i>-butanol (5 mL). The resultant solution was treated with cyanogen bromide (0.64 g, 6.04 mmol), and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was treated with saturated aqueous NaHCO<sub>3</sub> solution and stirred for 10 min. The layers were separated, and the organic phase was washed again with saturated aqueous NaHCO<sub>3</sub> solution. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield the title compound (2.26 g, 4.17 mmol, 83%) as a dark foamy solid. This compound was difficult to purify by chromatography or crystallization and was taken into the next steps directly. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>30</sub>BrN<sub>6</sub>O<sub>3</sub>, 541.15573; found, 541.15537; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.89–7.87 (m, 2H), 7.47–7.46 (m, 1H), 7.27–7.19 (m, 3H), 4.11–4.06 (m, 2H), 3.94 (s, 3H), 3.86–3.81 (m, 1H), 3.75–3.69 (m, 1H), 3.68 (s, 3H), 2.60 (s, 3H), 2.19–2.11 (m, 1H), 2.00–1.92 (m, 1H), 1.83–1.66 (m, 2H), 1.48–1.38 (m, 1H), 0.99 (d, <i>J</i> = 6.63 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 166.3, 159.3, 154.2, 152.2, 151.4, 140.4, 137.98, 137.95, 135.6, 124.6, 119.0, 117.3, 116.3, 112.4, 111.1, 107.4, 74.8, 52.7, 49.2, 34.3, 33.2, 30.7, 27.2, 24.7, 17.4.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>R</i>)-2-(5-((5-(2-Amino-6-bromo-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinic Acid (<b>22a′</b>)</h4><div class="NLM_p last">Methyl (<i>R</i>)-2-(5-((5-(2-amino-6-bromo-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)-4-methylpentyl)oxy)-1-methyl-1<i>H</i>-pyrazol-4-yl)-6-methylisonicotinate <b>22a</b> (1.80 g, 3.32 mmol) was dissolved in THF (30 mL). To the reaction mixture was added a solution of NaOH pellets (0.53 g, 13.3 mmol) in water (30 mL). The reaction mixture was stirred at room temperature for 45 min, and then the THF was removed by distillation under reduced pressure. The solution was acidified with 6 M aqueous HCl to pH = 5, resulting in the formation of a slurry. The solid was filtered and washed with water, and dried under vacuum to yield the title compound (1.71 g, 3.24 mmol, 98%) as a dark solid. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>28</sub>BrN<sub>6</sub>O<sub>3</sub>, 527.14008; found, 527.13971; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.89–7.84 (m, 2H), 7.70–7.53 (m, 2H), 7.46 (m, 2H), 7.12 (br s, 2H), 4.07 (br, 2H), 3.98–3.84 (m, 2H), 3.63 (s, 3H), 2.51 (s, 3H), 2.12–2.00 (m, 1H), 1.99–1.85 (m, 1H), 1.82–1.67 (m, 1H), 1.66–1.50 (m, 1H), 1.47–1.29 (m, 1H), 0.83 (d, <i>J</i> = 6.26 Hz, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.5, 158.7, 155.0, 151.6, 151.5, 142.1, 137.6, 137.5, 135.1, 124.4, 119.5, 116.2, 115.3, 112.0, 111.8, 107.6, 75.4, 48.0, 34.5, 32.5, 30.1, 27.1, 24.7, 16.7.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>R</i>,<i>E</i>)-11,26,7-Trimethyl-3-oxo-52,53-dihydro-11<i>H</i>,51<i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphane-56-carbaldehyde (<b>27</b>)</h4><div class="NLM_p last">(<i>R</i>,<i>E</i>)-5<sup>6</sup>-Bromo-1<sup>1</sup>,2<sup>6</sup>,7-trimethyl-5<sup>2</sup>,5<sup>3</sup>-dihydro-11<i>H</i>,51<i>H</i>-11-oxa-4-aza-5(2,1)-benzo[<i>d</i>]imidazola-2(2,4)-pyridina-1(4,5)-pyrazolacycloundecaphan-3-one <b>9Br</b> (2.27 g, 4.46 mmol), Pd(OAc)<sub>2</sub> (50.0 mg, 0.223 mmol), di(1-adamantyl)-<i>n</i>-butylphosphine (240 mg, 0.668 mmol), dioxane (34 mL), and TMEDA (1.34 mL, 8.91 mmol) were charged to a HEL reactor under nitrogen. The reaction mixture was heated to 100 °C for 24 h under 80 psi of CO/H<sub>2</sub> syngas. After being cooled to room temperature, the reaction was filtered through a filter paper to remove precipitates, and the filtrate was concentrated under reduced pressure. The crude residue was purified by flash chromatography on SiO<sub>2</sub> using an elution gradient of 0–4% MeOH in CH<sub>2</sub>Cl<sub>2</sub>. The title compound was obtained as a white solid (2.00 g, 3.80 mmol, 85%). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub>, 459.21392; found, 459.21363; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 12.27 (br s, 1H), 10.04 (s, 1H), 8.47 (s, 1H), 8.16 (s, 1H), 7.83 (d, <i>J</i> = 0.9 Hz, 1H), 7.77 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.64 (d, <i>J</i> = 0.9 Hz, 1H), 7.47 (d, <i>J</i> = 8.1 Hz, 1H), 4.45 (m, 1H), 4.38 (m, 1H), 3.89 (m, 1H), 3.78 (two overlapping peaks, 4H), 2.86 (m, 1H), 2.63 (s, 3H), 2.28 (m, 1H), 2.1 (m, 1H), 1.98 (m, 1H), 1.55 (m, 1H), 0.93 (d, <i>J</i> = 6.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.0, 175.2, 159.0, 154.4, 151.3, 151.2, 145.3, 138.4, 133.2, 132.5, 131.5, 127.3, 118.8, 116.8, 111.5, 108.9, 71.3, 50.6, 34.3, 29.61, 29.59, 26.4, 24.9, 17.7.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>R</i>)-5-((5-Bromo-2-nitrophenyl)amino)-4-methylpentan-1-ol (<b>42</b>)</h4><div class="NLM_p">4-Bromo-2-fluoro-1-nitrobenzene <b>41</b> (14.0 g, 63.6 mmol), (<i>R</i>)-5-amino-4-methylpentan-1-ol hydrochloride <b>43</b> (10.5 g, 97.7 wt %, 66.8 mmol), and K<sub>2</sub>CO<sub>3</sub> (19.3 g, 140.0 mmol) were stirred in DMF (42 mL) for 24 h at room temperature. The reaction mixture was then diluted with water and extracted with methyl <i>tert</i>-butyl ether. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to yield the title compound (20.0 g, 63.2 mmol, 99%) as an orange oil. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calculated for C<sub>12</sub>H<sub>18</sub>BrN<sub>2</sub>O<sub>3</sub>, 317.04953; found, 317.04942; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10 (br, 1H), 7.96 (d, <i>J</i> = 9.14 Hz, 1H), 6.95 (d, <i>J</i> = 1.98 Hz, 1H), 6.68 (dd, <i>J</i> = 1.95, 9.08 Hz, 1H), 3.63 (t, <i>J</i> = 6.39 Hz, 2H), 3.21–3.15 (m, 1H), 3.08–3.02 (m, 1H), 2.04 (s, 1H), 1.91–1.83 (m, 1H), 1.71–1.48 (m, 3H), 1.35–1.26 (m, 1H), 1.03 (d, <i>J</i> = 6.74 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 146.0, 131.8, 130.7, 128.1, 118.5, 116.4, 62.8, 49.2, 32.5, 30.7, 29.9, 18.0.</div><div id="sec5_1_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Protein Production, Crystallization, and Structure Determination</h5><div class="NLM_p">An EGFR kinase construct comprising amino acids 696–1022 was expressed as a GST-fusion protein in insect cells. In addition to the mutations T790M, L858R, the construct also contained three mutations to improve crystallization with “EEK” (865–867) mutated to “AAA” as described by Hanan et al., 2004.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Protein was purified by a three-step procedure using a 20 mL GSTrap-column (GE Health Care), followed by tag-cleavage with thrombin, a second passage over the GSTrap column, and a final gel filtration step on a Superdex75 26/60 column (GE Health Care). Pure and monomeric protein was pooled, buffer exchanged into 25 mM TRIS/HCl, pH = 8.0, 100 mM NaCl, 2 mM DTT, 2 mM TCEP, concentrated to 11 mg/mL, and stored in aliquots at −80 °C until crystallization.</div><div class="NLM_p">For crystallization, the protein was diluted to 8 mg/mL. Crystals were grown at 20 °C from 10% PEG10000, 8% ethylene glycol, 0.10 M HEPES pH 7.5 by hanging drop method. For crystallization, 1 μL of the protein solution was mixed with 0.5 μL of the reservoir solution and placed over 300 μL of the reservoir solution in 15-well plates (Qiagen). Ligand complexes were generated by soaking apo crystals with 5 mM of the respective ligand for 3 h. For cryo protection, crystals were briefly immersed in a reservoir solution containing 20% (v/v) <span class="smallcaps smallerCapital">l</span>-(+)-2,3-butanediol and frozen in liquid nitrogen.</div><div class="NLM_p">Diffraction data were measured at 100 K at the Swiss Light Source (beamline PXI/X06SA). Data were integrated with XDS and scaled with XSCALE.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Molecular replacement was performed with MOLREP.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The structures were refined with REFMAC.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p last">Protein crystallography has been done by Proteros Biostructures (Martinsried). Coordinates and structure factors have been deposited at the PDB with PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a> (compound <b>1</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9C">6S9C</a> (compound <b>5</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D">6S9D</a> (compound <b>6</b>).</div></div><div id="sec5_1_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Biochemical EGFR Inhibition Assays</h5><div class="NLM_p">These assays measure the inhibitory effect of compounds on the phosphorylation activity of EGFR enzyme forms on poly-GT substrate in the presence of ATP.</div><div class="NLM_p">The following enzyme forms of EGFR have been used in these assays at the given concentrations: EGFR WT (Life Technologies; PV4190), final assay concentration 1.5 nM; and EGFR (d746-750 T790M C797S) (SignalChem; E10-12UG), final assay concentration 15 nM.</div><div class="NLM_p">Test compounds dissolved in DMSO were dispensed onto assay plates (Proxiplate 384 PLUS, white, PerkinElmer; 6008289) using an Access Labcyte Workstation with the Labcyte Echo 55x. For the chosen highest assay concentration of 100 μM, 150 nL of compound solution was transferred from a 10 mM DMSO compound stock solution. A series of 11 5-fold dilutions per compound was transferred to the assay plate, and compound dilutions were tested in duplicates. DMSO was added as backfill to a total volume of 150 nL. The assay runs on a fully automated robotic system.</div><div class="NLM_p">5 μL of EGFR enzyme form in assay buffer (50 mM HEPES pH 7.3, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.01% Tween 20, 2 mM DTT) was dispensed into columns 1–23, and then 5 μL of ATP and ULight-poly-GT substrate (PertkinElmer; TRF0100-M) mixed in assay buffer was added to all wells (final assay concentration of ATP 100 μM and ULight-poly-GT substrate 200 nM).</div><div class="NLM_p">After 90 min incubation at room temperature, 5 μL of EDTA (final assay concentration 50 mM) and LANCE Eu-anti-P-Tyr (PT66) antibody (PerkinElmer, AD0069) (final assay concentration 6 nM) mix were added to stop the reaction and start the binding of the antibody.</div><div class="NLM_p">After an additional 60 min incubation at room temperature, the signal was measured in a PerkinElmer Envision HTS Multilabel Reader using the TR-FRET LANCE Ultra specs of PerkinElmer (used wavelengths: excitation 320 nm, emission1 665 nm, emission2 615 nm).</div><div class="NLM_p">Each plate contains 16 wells of a negative control (diluted DMSO instead of test compound; with EGFR enzyme form; column 23) and 16 wells of a positive control (diluted DMSO instead of test compound; without EGFR enzyme form; column 24).</div><div class="NLM_p">Negative and positive control values were used for normalization, and IC<sub>50</sub> values were calculated and analyzed using a 4 parametric logistic model.</div><div class="NLM_p last">These biochemical EGFR enzyme form compound dose–response assays quantify the kinase activity via phosphorylation of a tagged poly-GT substrate. The results of the assay are provided as IC<sub>50</sub> values. The lower were the reported biochemical EGFR enzyme form IC<sub>50</sub> values for a given compound, the more potent the compound inhibits the EGFR enzyme form kinase activity on poly-GT substrate.</div></div><div id="sec5_1_21_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Ba/F3 Proliferation Data</h5><div class="NLM_p last">Ba/F3 cells (purchased from DSMZ, cat. no. ACC300) were grown in RPMI-1640 medium supplemented with 10% FCS at 37 °C in 5% CO<sub>2</sub> atmosphere in the presence of 10 ng/mL IL-3 (purchased from R&D). To generate Ba/F3 EGFR models, Ba/F3 cells were transduced with retroviruses encoding the Green Fluorescent Protein (GFP) and EGFR isoforms EGFRwt, EGFRdel19, or EGFRdel19 TM CS. Platinum-E cells (Cell Biolabs) were used for retrovirus packaging. Ba/F3 cells were transduced with a retrovirus encoding only GFP to generate EGFR-independent Ba/F3 cells. Retrovirus and 4 μg/mL Polybrene was added to Ba/F3 cells for spinfection. Infection efficiency was confirmed by measuring GFP-positive cells using a cell analyzer. Cells with an infection efficiency of 10–20% were further cultivated in the presence of Puromycin (1 μg/mL) to select for transduced cells. Following selection, IL-3 was withdrawn from transgenic Ba/F3 cells expressing the oncogenic EGFR alleles EGFRdel19 and EGFRdel19 TM CS to render the growth of the cells dependent on transgenic EGFR activity. At IL-3 withdrawal EGF ligand (conc., source) was added to cells expressing EGFRwt, which are dependent on ligand stimulation in the absence of IL-3. Empty vector-transduced cells were maintained in medium containing IL-3 to generate EGFR-independent control cells. For proliferation assays, BaF/3 cells were seeded into a 96-well plates at 5 × 103/100 μL in growth media. Compounds were added by using a HP D3000 Digital Dispenser. All treatments were performed in technical and biological triplicates. Treated cells were incubated for 72 h at 37 °C with 5% CO<sub>2</sub>. CellTiter-Glo Luminescent Cell Viability Assay (Promega) was performed, and chemoluminescence was measured by using the multilabel Plate Reader VICTOR X4. The raw data were imported into and analyzed with the Boehringer Ingelheim proprietary software MegaLab (curve fitting based on the program PRISM, GraphPad Inc.).</div></div><div id="sec5_1_21_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> Ba/F3 p-EGFR Biomarker Assay</h5><div class="NLM_p last">60.000 Ba/F3 EGFRdel19 TM CS expressing cells were seeded in 60 μL of DMEM with 10% FBS per well into a TC 384-well plate (Greiner 781182). 60 nL of compound solution was added with the Echo Access System (Labcyte). All treatments were done in technical and biological duplicates. Treated cells were incubated for 4 h at 37 °C with 5% CO<sub>2</sub>. Plates were then centrifuged for 10 min, and medium was removed by the EL406 Washer and replaced by 20 μL of a 1.6-fold lysis buffer of the p-EGF Receptor (p-Tyr1068) TGRERS kit (PerkinElmer). After incubation at rt with agitation on a plate shaker (700 rpm) for 20 min, plates were centrifuged for 5 min, and 4 μL of the lysate was transferred to a Proxiplate-384 Plus (PerkinElmer). Five microliters of Acceptor Mix (reaction buffer + activation buffer + AlphaScreen Acceptor beads, PerkinElmer) was added, and plates were shaken for 1 min (14 000 rpm) and incubated for 2 h at room temperature under subdued light. Three microliters of Donor Mix (dilution buffer + AlphaScreen Donor beads, PerkinElmer 6760002) were added per well, and plates were shaken for 1 min. After 2 h at rt, plates were read on an Envision2 (PerkinElmer) using standard 384 AlphaScreen settings. The raw data were imported into and analyzed with the Boehringer Ingelheim proprietary software MegaLab (curve fitting based on the program PRISM, GraphPad Inc.).</div></div><div id="sec5_1_21_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Proliferation Assays with A431 and PC-9<sup>del19 T790M C797S</sup> Cells</h5><div class="NLM_p">A431 cells were obtained from ATCC (CRL-1555 lot no. 1179038) and cultured in DMEM containing 10% FBS and supplemented with sodium pyruvate. Parental PC-9 cells were purchased from ECACC (90071810 lot no. 14A030) and cultured in RPMI (Gibco 61870) containing 10% FBS. Genome engineering was used to insert the mutations T790M and C797S into exon 20 of the endogenous EGFR locus, resulting in the isolation of the PC-9<sup>del19 T790M C797S</sup> variant. Successful introduction of the two mutations was verified using DNA sequencing, RNA sequencing, and dose–response treatments with EGFR TKI.</div><div class="NLM_p last">5000 A431 cells and 2000 PC-9<sup>del19 T790M C797S</sup> cells were plated per well in a 96-well plate. Twenty-four hours after plating, cells were treated with compounds. All treatments were performed in technical and biological triplicates. Treated cells were incubated for 96 h at 37 °C with 5% CO<sub>2</sub>. CellTiter-Glo Luminescent Cell Viability Assay (Promega, #G7572) was performed, and luminescence signalsS were detected by using the multilabel Plate Reader VICTOR X4. Quantifications of viable cells were calculated by normalization of compound treated cells to DMSO treated cells. IC<sub>50</sub> values were calculated using Megalab Software (Boehringer Ingelheim).</div></div><div id="sec5_1_21_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> In Vivo Studies in Mice</h5><div class="NLM_p">Mice were group-housed (8–10 mice per cage) under pathogen-free and controlled environmental conditions (21 ± 1.5 °C temperature, 55 ± 10% humidity) and handled according to the institutional, governmental, and European Union guidelines (Austrian Animal Protection Laws, GV-SOLAS, and FELASA guidelines). Animal studies were approved by the internal ethics committee and the local governmental committee. For the biomarker and xenograft studies, 6–8 week old females BomTac:NMRI-<i>Foxn1</i><sup><i>nu</i></sup> mice; Taconic, Denmark) were engrafted subcutaneously with 5 × 10<sup>6</sup>PC-9<sup>del19 T790M C797S</sup> cells. Animals were randomized according to tumor size 7 days after cell injection (<i>N</i> = 8/group for compound and <i>N</i> = 10 for vehicle treated mice). Animals were treated daily with 25 mg/kg osimertinib, 10 mg/kg BI-4020, or with the vehicle (Natrosol 0.5%) only. Tumor size and body weight were measured three times weekly. Animals were examined daily and sacrificed on the basis of severity criteria including tumor size exceeding 1500 mm<sup>3</sup> or tumor necrosis. For the biomarker experiment, animals were randomized 17 days after cell injection (<i>N</i> = 4) and once treated 1 day later with 10 mg/kg <b>BI-4020</b> or with the vehicle only. Tumor samples were harvested 6, 18, and 24 h later and frozen in liquid nitrogen for analysis.</div><div class="NLM_p last">One-sided decreasing Mann–Whitney tests were used to compare tumor volumes. The <i>p</i> values were adjusted for multiple comparisons according to Bonferroni–Holm. For all analysis, <i>p</i> values under 0.05 represented a statistically significant effect.</div></div><div id="sec5_1_21_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> In Vivo p-EGFR Biomarker Experiments</h5><div class="NLM_p last">Proteins from PC-9<sup>del19 T790M C797S</sup> tumor samples were extracted using ReadyPrep Mini Grinders (BioRad, #1632146). Tumor tissue was disrupted with a pestle in Tris Lysis Buffer (MSD, #R60TX-2) supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (100X) (Thermo Scientific, #78446). After 10 min of incubation on ice, samples were centrifuged at 13 000 rpm for 5 min at 4 °C. Supernatant was shock frozen in LN2 and stored at −80 °C overnight. Protein concentrations were determined using Bradford assay. For Wes Protein Simple analysis, 0.5 μg of total protein was analyzed using EGFR, p-EGFR, and GAPDH antibodies (EGF Receptor (D38B1) XP Rabbit mAb #4267; Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb #3777, Cell Signaling Technology) (Anti-GAPDH antibody - Loading Control (ab9485), abam). Protein levels were quantified using Wes Protein Simple Compass Software.</div></div><div id="sec5_1_21_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> DMPK Assays</h5><div class="NLM_p">Aqueous solubility was determined from 1 mg/mL solid compound dispensed into aqueous McIlvaine buffer (pH 4.5 or 6.8), or dissolved in acetonitrile/water (1:1) as reference. Dissolved concentrations were determined with an Agilent 1200 HPLC/DAD-UV system.</div><div class="NLM_p">Plasma protein binding (PPB) was determined by equilibrium dialysis. Plasma was spiked with EGFR TKI and dialyzed against Soerensen buffer (pH 7.4) for 3 h at 37 °C. PPB was calculated by quantifying EGFR TKI concentrations in plasma and buffer by HPLC/MS–MS. In vivo hepatic clearance (CL) was predicted by in vitro incubations of 1 μM EGFR TKI with cryopreserved hepatocytes (Celsis IVT) and measured depletion over 240 min by quantitation of EGFR TKI by LC/MS/MS and using the well-stirred model. Data for hepatic CL were reported as %QH values. %QH values were determined by normalizing the hepatic CL by the respective blood follow through the liver (e.g., 90 mL/min/kg for mouse, 20.7 mL/min/kg for human). For <b>BI-4020</b>, the predicted CL by human hepatocytes is 9.7 mL/min/kg. This corresponds to a clearance of (9.7 mL/min/kg/20.7 mL/min/kg = 0.47) 47%QH.</div><div class="NLM_p">PAMPA parameters were determined by using a chamber separated by a microfilter disc (coated with structured layers of immobilized artificial phospholipid membranes) into a donor and an acceptor area. The time-dependent compound concentrations between the two champers are measured by LC/MS and compared to the concentration in the donor compartment prior to incubation. From this information, the permeability coefficient through the artificial membrane is calculated.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p last">For mouse pharmacokinetics (PK) analysis, NMRI mice (<i>n</i> = 3 per group) were dosed with <b>BI-4042</b> orally (10 mg/kg) or intravenously (1 mg/kg). Five plasma samples were obtained per mouse at defined time points. After precipitation of the plasma protein with acetonitrile, the concentrations of <b>BI-4020</b> were measured using LC–MS/MS against a calibration curve to calculate the concentration in plasma. The obtained concentration–time profiles are displayed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Figure S4</a>.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01169" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01169" class="ext-link">10.1021/acs.jmedchem.9b01169</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Details for the QM-calculation for <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>; description of the analytic and preparative HPLC methods as well as synthesis and analytic data (RT, MS, HRMS, and <sup>1</sup>H NMR) of compounds <b>13a</b>, <b>13e</b>, <b>16b</b>, <b>16c</b>, <b>20a</b>, <b>20b</b>, <b>22b</b>, <b>22c</b>, <b>24</b>, <b>25a</b>, <b>25</b>, <b>26</b>, <b>34</b>, <b>35</b>, <b>35a</b>, <b>36</b>, <b>37</b>, <b>39</b>, <b>40</b>, <b>43</b>, and <b>44</b>; X-ray data collection and refinement statistics for compounds <b>1</b>, <b>5</b>, <b>6</b>, and <b>9Br</b>; HPLC-traces for compounds <b>1</b>, <b>2</b>, <b>3</b>, <b>3a</b>, <b>4</b>, <b>5</b>, <b>6</b>, <b>7</b>, <b>8</b>, <b>9</b>, <b>9Br</b>, and <b>BI-4020</b>; list of kinases of the kinase selectivity panels; and biochemical data for <b>6–BI-4020</b> and PK graphs of <b>BI-4020</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf">jm9b01169_si_001.pdf (1.28 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_002.csv">jm9b01169_si_002.csv (0.88 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors have been deposited at the PDB/CCDC with PDB/CCDC codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a> (compound <b>1</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9C">6S9C</a> (compound <b>5</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D">6S9D</a> (compound <b>6</b>), and 1941612 (compound <b>9Br</b>). We will release coordinates and experimental data upon publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01169" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harald Engelhardt</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8170-1893" title="Orcid link">http://orcid.org/0000-0001-8170-1893</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a7cfc6d5c6cbc389c2c9c0c2cbcfc6d5c3d3e7c5c8c2cfd5cec9c0c2d58acec9c0c2cbcfc2ceca89c4c8ca"><span class="__cf_email__" data-cfemail="94fcf5e6f5f8f0baf1faf3f1f8fcf5e6f0e0d4f6fbf1fce6fdfaf3f1e6b9fdfaf3f1f8fcf1fdf9baf7fbf9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dietrich Böse</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span>; 
    <span>Present Address:
                        Merck Healthcare KGaA, Frankfurter Strasse 250, Darmstadt 64293, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Petronczki</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dirk Scharn</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerd Bader</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anke Baum</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Bergner</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eugene Chong</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5038-0131" title="Orcid link">http://orcid.org/0000-0002-5038-0131</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Döbel</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Georg Egger</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Engelhardt</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Ettmayer</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8422-2625" title="Orcid link">http://orcid.org/0000-0002-8422-2625</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julian E. Fuchs</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Gerstberger</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nina Gonnella</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8944-7180" title="Orcid link">http://orcid.org/0000-0001-8944-7180</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Grimm</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elisabeth Grondal</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nizar Haddad</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Hopfgartner</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roland Kousek</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mariusz Krawiec</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Monika Kriz</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lyne Lamarre</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joyce Leung</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Moriz Mayer</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nitinchandra D. Patel</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9571-6658" title="Orcid link">http://orcid.org/0000-0001-9571-6658</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Biljana Peric Simov</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan T. Reeves</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3051-3304" title="Orcid link">http://orcid.org/0000-0002-3051-3304</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renate Schnitzer</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Schrenk</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bernadette Sharps</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Flavio Solca</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heinz Stadtmüller</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhulin Tan</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, Connecticut 06877, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tobias Wunberg</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andreas Zoephel</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darryl B. McConnell</span> - <span class="hlFld-Affiliation affiliation">Boehringer
Ingelheim RCV GmbH & Co KG, Dr-Boehringer-Gasse 5-11, Vienna 1120, Austria</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>H.E. and D.B. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank Amy Gao, Gabriele Glendinning, Christoph Harrer, Susanne Mayer, Julia Mosler, Scott Pennino, Christian Salamon, Markus Spina, Elisabeth Traxler, June Wang, and Anika Weiss for excellent project support. This work was supported by the Austrian Research Promotion Agency (FFG) [grant number 872827].</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84577" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84577" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 65 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R. J.</span></span> <span> </span><span class="NLM_article-title">There are 49 FDA-Approved Small Molecule Protein Kinase Inhibitors as of 12 April</span> <span class="NLM_year">2019</span>. <a href="http://www.brimr.org/PKI/PKIs.htm" class="extLink">http://www.brimr.org/PKI/PKIs.htm</a> (accessed May 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+J.+Roskoski&title=There+are+49+FDA-Approved+Small+Molecule+Protein+Kinase+Inhibitors+as+of+12+April"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%2BJ.%26atitle%3DThere%2520are%252049%2520FDA-Approved%2520Small%2520Molecule%2520Protein%2520Kinase%2520Inhibitors%2520as%2520of%252012%2520April%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Measuring and Interpreting the Selectivity of Protein Kinase Inhibitors</span>. <i>Journal of chemical biology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1007/s12154-009-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1007%2Fs12154-009-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=19568781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=131-151&issue=3&author=L.+A.+Smythauthor=I.+Collins&title=Measuring+and+Interpreting+the+Selectivity+of+Protein+Kinase+Inhibitors&doi=10.1007%2Fs12154-009-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring and interpreting the selectivity of protein kinase inhibitors</span></div><div class="casAuthors">Smyth Lynette A; Collins Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-51</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly for the treatment of cancer.  Achieving inhibitor selectivity for particular protein kinases often remains a significant challenge in the development of new small molecules as drugs or as tools for chemical biology research.  This review summarises the methodologies available for measuring kinase inhibitor selectivity, both in vitro and in cells.  The interpretation of kinase inhibitor selectivity data is discussed, particularly with reference to the structural biology of the protein targets.  Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzU9rA5WZcz9FxYDaSSP8XfW6udTcc2eYTwA0sWKAtf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D&md5=f78ff1202a949a71ffd65e804298c37f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs12154-009-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-009-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DL.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMeasuring%2520and%2520Interpreting%2520the%2520Selectivity%2520of%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DJournal%2520of%2520chemical%2520biology%26date%3D2009%26volume%3D2%26issue%3D3%26spage%3D131%26epage%3D151%26doi%3D10.1007%2Fs12154-009-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastassiadis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1039</span>, <span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039&issue=11&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+Assay+of+Kinase+Catalytic+Activity+Reveals+Features+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0liWy8FxjtWFww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520Assay%2520of%2520Kinase%2520Catalytic%2520Activity%2520Reveals%2520Features%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26issue%3D11%26spage%3D1039%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. J.</span></span> <span> </span><span class="NLM_article-title">Osimertinib Resistance in Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.canlet.2018.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29425688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2018&pages=242-246&author=Z.+H.+Tangauthor=J.+J.+Lu&title=Osimertinib+Resistance+in+Non-Small+Cell+Lung+Cancer%3A+Mechanisms+and+Therapeutic+Strategies&doi=10.1016%2Fj.canlet.2018.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies</span></div><div class="casAuthors">Tang, Zheng-Hai; Lu, Jin-Jian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-246</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Given the successful identification of epidermal growth factor receptor EGFR T790M, the third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation.  OSI was approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.  However, the disease would progress after the patient received OSI treatment for approx. 10 mo.  Resistance mechanisms to OSI, such as addnl. mutation of EGFR and alternative kinase activation, were recently identified, and some novel therapeutic strategies were proposed to overcome OSI resistance.  In this review, the resistance mechanisms and therapeutic strategies for OSI-resistant NSCLC were summarized to direct further use of OSI and aid in the development of novel drugs or strategies for OSI-resistant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MEZOSD4CQrVg90H21EOLACvtfcHk0liWy8FxjtWFww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D&md5=a2f1d0d576a24d137bd23584f40df973</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%2BH.%26aulast%3DLu%26aufirst%3DJ.%2BJ.%26atitle%3DOsimertinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Mechanisms%2520and%2520Therapeutic%2520Strategies%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D420%26spage%3D242%26epage%3D246%26doi%3D10.1016%2Fj.canlet.2018.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricordel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790M-Mutant Lung Cancer</span>. <i>Annals of Oncology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">i28-i37</span> <span class="refDoi"> DOI: 10.1093/annonc/mdx705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1093%2Fannonc%2Fmdx705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29462256" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&author=C.+Ricordelauthor=L.+Fribouletauthor=F.+Facchinettiauthor=J.+C.+Soria&title=Molecular+Mechanisms+of+Acquired+Resistance+to+Third-Generation+EGFR-TKIs+in+EGFR+T790M-Mutant+Lung+Cancer&doi=10.1093%2Fannonc%2Fmdx705"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx705%26sid%3Dliteratum%253Aachs%26aulast%3DRicordel%26aufirst%3DC.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Third-Generation%2520EGFR-TKIs%2520in%2520EGFR%2520T790M-Mutant%2520Lung%2520Cancer%26jtitle%3DAnnals%2520of%2520Oncology%26date%3D2018%26volume%3D29%26doi%3D10.1093%2Fannonc%2Fmdx705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1002/anie.201710398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1002%2Fanie.201710398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2307-2313&issue=9&author=J.+Lategahnauthor=M.+Keulauthor=D.+Rauh&title=Lessons+to+be+Learned%3A+The+Molecular+Basis+of+Kinase-Targeted+Therapies+and+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1002%2Fanie.201710398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2313</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The treatment of non-small cell lung cancer (NSCLC) is currently experiencing a revolution.  Over the last decade, the knowledge gained about the biochem. features of biomarkers and their predictive abilities has led to the development of targeted small-mol. inhibitors that present an alternative to harsh chemotherapy.  The use of these new therapies has improved the quality of life and increased the survival of patients.  The occurrence of inevitable drug resistance requires the const. development of precision medicine.  The detailed understanding of the target biol. and the search for innovative chem. approaches has encouraged investigations in this field.  Herein, the authors review selected aspects of the mol. targets and present an overview of current topics and challenges in the rational development of small mols. to target NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowadpmmNyvGbVg90H21EOLACvtfcHk0lhQqpz2mxgl5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D&md5=78d3ce523d076c820cb7fcbf9a321e63</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710398%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DLessons%2520to%2520be%2520Learned%253A%2520The%2520Molecular%2520Basis%2520of%2520Kinase-Targeted%2520Therapies%2520and%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26issue%3D9%26spage%3D2307%26epage%3D2313%26doi%3D10.1002%2Fanie.201710398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into Drug Development Strategy Targeting EGFR T790M/C797S</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">13652</span>– <span class="NLM_lpage">13665</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.24113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.18632%2Foncotarget.24113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29568384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=13652-13665&issue=17&author=S.+J.+Zhuauthor=P.+Zhaoauthor=J.+Yangauthor=R.+Maauthor=X.+E.+Yanauthor=S.+Y.+Yangauthor=J.+W.+Yangauthor=C.+H.+Yun&title=Structural+Insights+into+Drug+Development+Strategy+Targeting+EGFR+T790M%2FC797S&doi=10.18632%2Foncotarget.24113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into drug development strategy targeting EGFR T790M/C797S</span></div><div class="casAuthors">Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Yang Jiao; Yang Sheng-Yong; Yang Jing-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">13652-13665</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation.  Though WZ4002/CO-1686/AZD9291 are effective in overcoming EGFR T790M by targeting Cys797 via covalent bonding, their efficacy is again limited due to the emergence of C797S mutation.  New agents effectively inhibiting EGFR T790M without covalent linkage through Cys 797 may solve this problem.  We presented here crystal structures of EGFR activating/drug-resistant mutants in complex with a panel of reversible inhibitors along with mutagenesis and enzyme kinetic data.  These data revealed a previously un-described hydrophobic clamp structure in the EGFR kinase which may be exploited to facilitate development of next generation drugs targeting EGFR T790M with or without concomitant C797S.  Interestingly, mutations in the hydrophobic clamp that hinder drug binding often also weaken ATP binding and/or abolish kinase activity, thus do not readily result in resistance to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRatiF0vPAX33ELvajU9pjPfW6udTcc2ea2jgF6fX0aFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D&md5=7502a50efce99f712a54003680a95bde</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24113%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520Insights%2520into%2520Drug%2520Development%2520Strategy%2520Targeting%2520EGFR%2520T790M%252FC797S%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26issue%3D17%26spage%3D13652%26epage%3D13665%26doi%3D10.18632%2Foncotarget.24113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepetov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Haj Zen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Characterization of the Published Kinase Inhibitor Set</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1038/nbt.3374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnbt.3374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26501955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=95-103&issue=1&author=J.+M.+Elkinsauthor=V.+Fedeleauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=E.+Salahauthor=J.+Mikolajczykauthor=S.+Romanovauthor=N.+Sepetovauthor=X.-P.+Huangauthor=B.+L.+Rothauthor=A.+Al+Haj+Zenauthor=D.+Fourchesauthor=E.+Muratovauthor=A.+Tropshaauthor=J.+Morrisauthor=B.+A.+Teicherauthor=M.+Kunkelauthor=E.+Polleyauthor=K.+E.+Lackeyauthor=F.+L.+Atkinsonauthor=J.+P.+Overingtonauthor=P.+Bamboroughauthor=S.+Mullerauthor=D.+J.+Priceauthor=T.+M.+Willsonauthor=D.+H.+Drewryauthor=S.+Knappauthor=W.+J.+Zuercher&title=Comprehensive+Characterization+of+the+Published+Kinase+Inhibitor+Set&doi=10.1038%2Fnbt.3374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive characterization of the Published Kinase Inhibitor Set</span></div><div class="casAuthors">Elkins, Jonathan M.; Fedele, Vita; Szklarz, Marta; Abdul Azeez, Kamal R.; Salah, Eidarus; Mikolajczyk, Jowita; Romanov, Sergei; Sepetov, Nikolai; Huang, Xi-Ping; Roth, Bryan L.; Al Haj Zen, Ayman; Fourches, Denis; Muratov, Eugene; Tropsha, Alex; Morris, Joel; Teicher, Beverly A.; Kunkel, Mark; Polley, Eric; Lackey, Karen E.; Atkinson, Francis L.; Overington, John P.; Bamborough, Paul; Muller, Susanne; Price, Daniel J.; Willson, Timothy M.; Drewry, David H.; Knapp, Stefan; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the success of protein kinase inhibitors as approved therapeutics, drug discovery has focused on a small subset of kinase targets.  Here we provide a thorough characterization of the Published Kinase Inhibitor Set (PKIS), a set of 367 small-mol. ATP-competitive kinase inhibitors that was recently made freely available with the aim of expanding research in this field and as an expt. in open-source target validation.  We screen the set in activity assays with 224 recombinant kinases and 24 G protein-coupled receptors and in cellular assays of cancer cell proliferation and angiogenesis.  We identify chem. starting points for designing new chem. probes of orphan kinases and illustrate the utility of these leads by developing a selective inhibitor for the previously untargeted kinases LOK and SLK.  Our cellular screens reveal compds. that modulate cancer cell growth and angiogenesis in vitro.  These reagents and assocd. data illustrate an efficient way forward to increasing understanding of the historically untargeted kinome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4P1WN3gdiXbVg90H21EOLACvtfcHk0lhaQhUImkFlAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM&md5=3f15096e79632dbaaadf4460a6848e60</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3374%26sid%3Dliteratum%253Aachs%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFedele%26aufirst%3DV.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DMikolajczyk%26aufirst%3DJ.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DSepetov%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAl%2BHaj%2BZen%26aufirst%3DA.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DTropsha%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DKunkel%26aufirst%3DM.%26aulast%3DPolley%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DAtkinson%26aufirst%3DF.%2BL.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DComprehensive%2520Characterization%2520of%2520the%2520Published%2520Kinase%2520Inhibitor%2520Set%26jtitle%3DNat.%2520Biotechnol.%26date%3D2016%26volume%3D34%26issue%3D1%26spage%3D95%26epage%3D103%26doi%3D10.1038%2Fnbt.3374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span> <span> </span><span class="NLM_article-title">Progress Towards a Public Chemogenomic Set for Protein Kinases and a Call for Contributions</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0181585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1371%2Fjournal.pone.0181585" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1-21&author=D.+H.+Drewryauthor=C.+I.+Wellsauthor=D.+M.+Andrewsauthor=R.+Angellauthor=H.+Al-Aliauthor=A.+D.+Axtmanauthor=S.+J.+Capuzziauthor=J.+M.+Elkinsauthor=P.+Ettmayerauthor=M.+Frederiksenauthor=O.+Gileadiauthor=N.+Grayauthor=A.+Hooperauthor=S.+Knappauthor=S.+Lauferauthor=U.+Lueckingauthor=S.+Muellerauthor=E.+Muratovauthor=R.+A.+Dennyauthor=K.+S.+Saikatenduauthor=D.+K.+Treiberauthor=W.+J.+Zuercherauthor=T.+M.+Willson&title=Progress+Towards+a+Public+Chemogenomic+Set+for+Protein+Kinases+and+a+Call+for+Contributions&doi=10.1371%2Fjournal.pone.0181585"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181585%26sid%3Dliteratum%253Aachs%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DAngell%26aufirst%3DR.%26aulast%3DAl-Ali%26aufirst%3DH.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26aulast%3DCapuzzi%26aufirst%3DS.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFrederiksen%26aufirst%3DM.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DHooper%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DLuecking%26aufirst%3DU.%26aulast%3DMueller%26aufirst%3DS.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DDenny%26aufirst%3DR.%2BA.%26aulast%3DSaikatendu%26aufirst%3DK.%2BS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26atitle%3DProgress%2520Towards%2520a%2520Public%2520Chemogenomic%2520Set%2520for%2520Protein%2520Kinases%2520and%2520a%2520Call%2520for%2520Contributions%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3D1%26epage%3D21%26doi%3D10.1371%2Fjournal.pone.0181585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driggers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span> <span> </span><span class="NLM_article-title">The Exploration of Macrocycles for Drug Discovery - An Underexploited Structural Class</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/nrd2590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnrd2590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=18591981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&issue=7&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+Exploration+of+Macrocycles+for+Drug+Discovery+-+An+Underexploited+Structural+Class&doi=10.1038%2Fnrd2590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The exploration of macrocycles for drug discovery - an underexploited structural class</span></div><div class="casAuthors">Driggers, Edward M.; Hale, Stephen P.; Lee, Jinbo; Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">608-624</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products comprised of a macrocycle ring structure have proven their therapeutic applications as antibiotics, immunosuppressants as well as anticancer agents.  Despite this, macrocyclic compds. remain under-explored.  Terrett and colleagues review the properties and features of current macrocycle drugs, emphasizing the vast potential of synthetic macrocycles in drug discovery.  Macrocyclic natural products have evolved to fulfil numerous biochem. functions, and their profound pharmacol. properties have led to their development as drugs.  A macrocycle provides diverse functionality and stereochem. complexity in a conformationally pre-organized ring structure.  This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations.  Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery.  This is in part due to concerns about synthetic intractability and non-drug-like properties.  This Review describes the growing body of data in favor of macrocyclic therapeutics, and demonstrates that this class of compds. can be both fully drug-like in its properties and readily prepd. owing to recent advances in synthetic medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDtW8LpE4ru7Vg90H21EOLACvtfcHk0lhaQhUImkFlAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D&md5=16e091818053e5b163b81078a8d03094</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd2590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2590%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520Exploration%2520of%2520Macrocycles%2520for%2520Drug%2520Discovery%2520-%2520An%2520Underexploited%2520Structural%2520Class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26issue%3D7%26spage%3D608%26epage%3D624%26doi%3D10.1038%2Fnrd2590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lhaXDe5eZSa3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Midha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, R.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: a Systematic Review and Global Map by Ethnicity (mutMapII)</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26609494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=2892-2911&author=A.+Midhaauthor=S.+Deardenauthor=R.+McCormack&title=EGFR+Mutation+Incidence+in+Non-Small-Cell+Lung+Cancer+of+Adenocarcinoma+Histology%3A+a+Systematic+Review+and+Global+Map+by+Ethnicity+%28mutMapII%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)</span></div><div class="casAuthors">Midha Anita; Dearden Simon; McCormack Rose</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2892-911</span>
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) histology (NSCLC/ADC).  Robust data exist regarding the prevalence of EGFR mutations in Western and Asian patients with NSCLC/ADC, yet there is a lack of data for patients of other ethnicities.  This review collated available data with the aim of creating a complete, global picture of EGFR mutation frequency in patients with NSCLC/ADC by ethnicity.  Worldwide literature reporting EGFR mutation frequency in patients with NSCLC/ADC was reviewed, to create a map of the world populated with EGFR mutation frequency by country (a 'global EGFR mutMap').  A total of 151 worldwide studies (n=33162 patients with NSCLC/ADC, of which 9749 patients had EGFR mutation-positive NSCLC/ADC) were included.  There was substantial variation in EGFR mutation frequency between studies, even when grouped by geographic region or individual country.  As expected, the Asia-Pacific NSCLC/ADC subgroup had the highest EGFR mutation frequency (47% [5958/12819; 87 studies; range 20%-76%]) and the lowest EGFR mutation frequency occurred in the Oceania NSCLC/ADC subgroup (12% [69/570; 4 studies; range 7%-36%]); however, comparisons between regions were limited due to the varying sizes of the patient populations studied.  In all regional (geographic) subgroups where data were available, EGFR mutation frequency in NSCLC/ADC was higher in women compared with men, and in never-compared with ever-smokers.  This review provides the foundation for a global map of EGFR mutation frequency in patients with NSCLC/ADC.  The substantial lack of data from several large geographic regions of the world, notably Africa, the Middle East, Central Asia, and Central and South America, highlights a potential lack of routine mutation testing and the need for further investigations in these regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1x7LyD77C4UH3Rlp_k91zfW6udTcc2ebWmpGBA7UGELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D&md5=9ea4c9ffa42551cb066bb04142991fd4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMidha%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DR.%26atitle%3DEGFR%2520Mutation%2520Incidence%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520of%2520Adenocarcinoma%2520Histology%253A%2520a%2520Systematic%2520Review%2520and%2520Global%2520Map%2520by%2520Ethnicity%2520%2528mutMapII%2529%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26spage%3D2892%26epage%3D2911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konduri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitlitz, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddareddigari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaby-Sandy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vavala, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">EGFR Fusions as Novel Therapeutic Targets in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F2159-8290.CD-16-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27102076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Ggurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=601-611&issue=6&author=K.+Konduriauthor=J.-N.+Gallantauthor=Y.+K.+Chaeauthor=F.+J.+Gilesauthor=B.+J.+Gitlitzauthor=K.+Gowenauthor=E.+Ichiharaauthor=T.+K.+Owonikokoauthor=V.+Peddareddigariauthor=S.+S.+Ramalingamauthor=S.+K.+Reddyauthor=B.+Eaby-Sandyauthor=T.+Vavalaauthor=A.+Whiteleyauthor=H.+Chenauthor=Y.+Yanauthor=J.+H.+Sheehanauthor=J.+Meilerauthor=D.+Morosiniauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=C.+M.+Lovly&title=EGFR+Fusions+as+Novel+Therapeutic+Targets+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-16-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Fusions as Novel Therapeutic Targets in Lung Cancer</span></div><div class="casAuthors">Konduri, Kartik; Gallant, Jean-Nicolas; Chae, Young Kwang; Giles, Francis J.; Gitlitz, Barbara J.; Gowen, Kyle; Ichihara, Eiki; Owonikoko, Taofeek K.; Peddareddigari, Vijay; Ramalingam, Suresh S.; Reddy, Satyanarayan K.; Eaby-Sandy, Beth; Vavala, Tiziana; Whiteley, Andrew; Chen, Heidi; Yan, Yingjun; Sheehan, Jonathan H.; Meiler, Jens; Morosini, Deborah; Ross, Jeffrey S.; Stephens, Philip J.; Miller, Vincent A.; Ali, Siraj M.; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-611</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung cancer.  We describe five patients with metastatic lung cancer whose tumors harbored EGFR fusions, four of whom were treated with EGFR tyrosine kinase inhibitors (TKI) with documented antitumor responses.  In vitro, EGFR-RAD51 fusions are oncogenic and can be therapeutically targeted with available EGFR TKIs and therapeutic antibodies.  These results support the dependence of EGFR-rearranged tumors on EGFR-mediated signaling and suggest several therapeutic strategies for patients whose tumors harbor this novel alteration.  Significance: We report for the first time the identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer and document responses to the EGFR inhibitor erlotinib in 4 patients whose tumors harbored EGFR fusions.  Findings from these studies will be immediately translatable to the clinic, as there are already several approved EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoy2xrGmYZULVg90H21EOLACvtfcHk0lhhEfT0bTzPnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Ggurs%253D&md5=8491bbf3bcbe6699fa1c3df41860d32c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0075%26sid%3Dliteratum%253Aachs%26aulast%3DKonduri%26aufirst%3DK.%26aulast%3DGallant%26aufirst%3DJ.-N.%26aulast%3DChae%26aufirst%3DY.%2BK.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DGitlitz%26aufirst%3DB.%2BJ.%26aulast%3DGowen%26aufirst%3DK.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DPeddareddigari%26aufirst%3DV.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DReddy%26aufirst%3DS.%2BK.%26aulast%3DEaby-Sandy%26aufirst%3DB.%26aulast%3DVavala%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSheehan%26aufirst%3DJ.%2BH.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DMorosini%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DEGFR%2520Fusions%2520as%2520Novel%2520Therapeutic%2520Targets%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D6%26spage%3D601%26epage%3D611%26doi%3D10.1158%2F2159-8290.CD-16-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib Versus Cisplatin Plus Docetaxel in Patients With Non-Small-Cell Lung Cancer Harboring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): an Open Label, Randomised Phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70364-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2809%2970364-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=20022809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=121-128&issue=2&author=T.+Mitsudomiauthor=S.+Moritaauthor=Y.+Yatabeauthor=S.+Negoroauthor=I.+Okamotoauthor=J.+Tsurutaniauthor=T.+Setoauthor=M.+Satouchiauthor=H.+Tadaauthor=T.+Hirashimaauthor=K.+Asamiauthor=N.+Katakamiauthor=M.+Takadaauthor=H.+Yoshiokaauthor=K.+Shibataauthor=S.+Kudohauthor=E.+Shimizuauthor=H.+Saitoauthor=S.+Toyookaauthor=K.+Nakagawaauthor=M.+Fukuoka&title=Gefitinib+Versus+Cisplatin+Plus+Docetaxel+in+Patients+With+Non-Small-Cell+Lung+Cancer+Harboring+Mutations+of+the+Epidermal+Growth+Factor+Receptor+%28WJTOG3405%29%3A+an+Open+Label%2C+Randomised+Phase+3+trial&doi=10.1016%2FS1470-2045%2809%2970364-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span></div><div class="casAuthors">Mitsudomi, Tetsuya; Morita, Satoshi; Yatabe, Yasushi; Negoro, Shunichi; Okamoto, Isamu; Tsurutani, Junji; Seto, Takashi; Satouchi, Miyako; Tada, Hirohito; Hirashima, Tomonori; Asami, Kazuhiro; Katakami, Nobuyuki; Takada, Minoru; Yoshioka, Hiroshige; Shibata, Kazuhiko; Kudoh, Shinzoh; Shimizu, Eiji; Saito, Hiroshi; Toyooka, Shinichi; Nakagawa, Kazuhiko; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer harboring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib.  However, whether gefitinib is better than std. platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.  We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harboring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimization technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m2, i.v.) plus docetaxel (60 mg/m2, i.v.; n=89), administered every 21 days for three to six cycles.  The primary endpoint was progression-free survival.  Survival anal. was done with the modified intention-to-treat population.  This study is registered with UMIN (University Hospital Medical Information Network in Japan), no. 000000539.  Five patients were excluded (two patients were found to have thyroid and colon cancer after randomization, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel).  Thus, 172 patients (86 in each group) were included in the survival analyses.  The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel group, with a median progression-free survival time of 9.2 mo (95% CI 8.0-13.9) vs. 6.3 mo (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001).  Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhea were more frequent in the gefitinib group.  Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.  Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.  Funding: West Japan Oncol. Group (WJOG): a non-profit organization supported by unrestricted donations from several pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKXuDlK2x9o7Vg90H21EOLACvtfcHk0lhhEfT0bTzPnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D&md5=5856ce118d00919627e3f21525abe453</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970364-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970364-X%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNegoro%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DHirashima%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DK.%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520Versus%2520Cisplatin%2520Plus%2520Docetaxel%2520in%2520Patients%2520With%2520Non-Small-Cell%2520Lung%2520Cancer%2520Harboring%2520Mutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528WJTOG3405%2529%253A%2520an%2520Open%2520Label%252C%2520Randomised%2520Phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26issue%3D2%26spage%3D121%26epage%3D128%26doi%3D10.1016%2FS1470-2045%2809%2970364-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazulina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Afatinib Versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): a Phase 2B, Open-Label, Randomised Controlled Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30033-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2816%2930033-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27083334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=577-589&issue=5&author=K.+Parkauthor=E.-H.+Tanauthor=K.+O%E2%80%99Byrneauthor=L.+Zhangauthor=M.+Boyerauthor=T.+Mokauthor=V.+Hirshauthor=J.+C.-H.+Yangauthor=K.+H.+Leeauthor=S.+Luauthor=Y.+Shiauthor=S.-W.+Kimauthor=J.+Laskinauthor=D.-W.+Kimauthor=C.+D.+Arvisauthor=K.+Kolbeckauthor=S.+A.+Laurieauthor=C.-M.+Tsaiauthor=M.+Shahidiauthor=M.+Kimauthor=D.+Masseyauthor=V.+Zazulinaauthor=L.+Paz-Ares&title=Afatinib+Versus+Gefitinib+as+First-Line+Treatment+of+Patients+with+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28LUX-Lung+7%29%3A+a+Phase+2B%2C+Open-Label%2C+Randomised+Controlled+Trial&doi=10.1016%2FS1470-2045%2816%2930033-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial</span></div><div class="casAuthors">Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-589</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-pos. non-small-cell lung cancer (NSCLC).  We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.  This multicentre, international, open-label, exploratory, randomised controlled phase 2B trial (LUX-Lung 7) was done at 64 centers in 13 countries.  Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator.  Randomisation, stratified by EGFR mutation type and status of brain metastases, was done centrally using a validated no. generating system implemented via an interactive voice or web-based response system with a block size of four.  Clinicians and patients were not masked to treatment allocation; independent review of tumor response was done in a blinded manner.  Coprimary endpoints were progression-free survival by independent central review, time-to-treatment failure, and overall survival.  Efficacy analyses were done in the intention-to-treat population and safety analyses were done in patients who received at least one dose of study drug.  This ongoing study is registered with ClinicalTrials.gov, no. NCT01466660.  Between Dec 13, 2011, and Aug 8, 2013, 319 patients were randomly assigned (160 to afatinib and 159 to gefitinib).  Median follow-up was 27·3 mo (IQR 15·3-33·9).  Progression-free survival (median 11·0 mo [95% CI 10·6-12·9] with afatinib vs 10·9 mo [9·1-11·5] with gefitinib; hazard ratio [HR] 0·73 [95% CI 0·57-0·95], p=0·017) and time-to-treatment failure (median 13·7 mo [95% CI 11·9-15·0] with afatinib vs 11·5 mo [10·1-13·1] with gefitinib; HR 0·73 [95% CI 0·58-0·92], p=0·0073) were significantly longer with afatinib than with gefitinib.  Overall survival data are not mature.  The most common treatment-related grade 3 or 4 adverse events were diarrhoea (20 [13%] of 160 patients given afatinib vs two [1%] of 159 given gefitinib) and rash or acne (15 [9%] patients given afatinib vs five [3%] of those given gefitinib) and liver enzyme elevations (no patients given afatinib vs 14 [9%] of those given gefitinib).  Serious treatment-related adverse events occurred in 17 (11%) patients in the afatinib group and seven (4%) in the gefitinib group.  Ten (6%) patients in each group discontinued treatment due to drug-related adverse events. 15 (9%) fatal adverse events occurred in the afatinib group and ten (6%) in the gefitinib group.  All but one of these deaths were considered unrelated to treatment; one patient in the gefitinib group died from drug-related hepatic and renal failure.  Afatinib significantly improved outcomes in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable tolerability profile.  These data are potentially important for clin. decision making in this patient population.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSTXQpDomR7Vg90H21EOLACvtfcHk0liuxLXWQYR_9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D&md5=33d5697aa6a01e4f3fc89a34cb3b1e61</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930033-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930033-X%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DLaskin%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DKolbeck%26aufirst%3DK.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DMassey%26aufirst%3DD.%26aulast%3DZazulina%26aufirst%3DV.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DAfatinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520of%2520Patients%2520with%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528LUX-Lung%25207%2529%253A%2520a%2520Phase%25202B%252C%2520Open-Label%252C%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D5%26spage%3D577%26epage%3D589%26doi%3D10.1016%2FS1470-2045%2816%2930033-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.+C.+Suauthor=J.+E.+Grayauthor=S.+M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimertinib+in+Untreated+EGFR-Mutated+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0liuxLXWQYR_9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimertinib%2520in%2520Untreated%2520EGFR-Mutated%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, C.</span></span> <span> </span><span class="NLM_article-title">Erlotinib Versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): a Multicentre, Open-Label, Randomised, Phase 3 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70184-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2811%2970184-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=21783417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=735-742&issue=8&author=C.+Zhouauthor=Y.-L.+Wuauthor=G.+Chenauthor=J.+Fengauthor=X.-Q.+Liuauthor=C.+Wangauthor=S.+Zhangauthor=J.+Wangauthor=S.+Zhouauthor=S.+Renauthor=S.+Luauthor=L.+Zhangauthor=C.+Huauthor=C.+Huauthor=Y.+Luoauthor=L.+Chenauthor=M.+Yeauthor=J.+Huangauthor=X.+Zhiauthor=Y.+Zhangauthor=Q.+Xiuauthor=J.+Maauthor=L.+Zhangauthor=C.+You&title=Erlotinib+Versus+Chemotherapy+as+First-Line+Treatment+for+Patients+with+Advanced+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28OPTIMAL%2C+CTONG-0802%29%3A+a+Multicentre%2C+Open-Label%2C+Randomised%2C+Phase+3+Study&doi=10.1016%2FS1470-2045%2811%2970184-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study</span></div><div class="casAuthors">Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">735-742</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC).  The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib vs. std. chemotherapy in the first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  We undertook an open-label, randomised, phase 3 trial at 22 centers in China.  Patients older than 18 years with histol. confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received either oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects, or up to four cycles of gemcitabine plus carboplatin.  Patients were randomly assigned (1:1) with a minimization procedure and were stratified according to EGFR mutation type, histol. subtype (adenocarcinoma vs non-adenocarcinoma), and smoking status.  The primary outcome was progression-free survival, analyzed in patients with confirmed disease who received at least one dose of study treatment.  The trial is registered at ClinicalTrials.gov, no. NCT00874419, and has completed enrollment; patients are still in follow-up.  83 Patients were randomly assigned to receive erlotinib and 82 to receive gemcitabine plus carboplatin; 82 in the erlotinib group and 72 in the chemotherapy group were included in anal. of the primary endpoint.  Median progression-free survival was significantly longer in erlotinib-treated patients than in those on chemotherapy (13.1 [95% CI 10.58-16.53] vs 4.6 [4.21-5.42] months; hazard ratio 0.16, 95% CI 0.10-0.26; p<0.0001).  Chemotherapy was assocd. with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concns. (three [4%] of 83 patients) and skin rash (two [2%] patients).  Chemotherapy was also assocd. with increased treatment-related serious adverse events (ten [14%] of 72 patients [decreased platelet count, n = 8; decreased neutrophil count, n = 1; hepatic dysfunction, n = 1] vs two [2%] of 83 patients [both hepatic dysfunction]).  Compared with std. chemotherapy, erlotinib conferred a significant progression-free survival benefit in patients with advanced EGFR mutation-pos. NSCLC and was assocd. with more favorable tolerability.  These findings suggest that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  Funding: F Hoffmann-La Roche Ltd (China); Science and Technol. Commission of Shanghai Municipality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNzw1hk1km7Vg90H21EOLACvtfcHk0liDVck3q3IkPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D&md5=92097cc6e942e9137a40fd6cae675297</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970184-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970184-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.-Q.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DC.%26atitle%3DErlotinib%2520Versus%2520Chemotherapy%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520Advanced%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528OPTIMAL%252C%2520CTONG-0802%2529%253A%2520a%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26issue%3D8%26spage%3D735%26epage%3D742%26doi%3D10.1016%2FS1470-2045%2811%2970184-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): a Randomised, Open-Label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&issue=11&author=Y.-L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+Versus+Gefitinib+as+First-Line+Treatment+for+Patients+with+EGFR-Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28ARCHER+1050%29%3A+a+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0liDVck3q3IkPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520EGFR-Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ARCHER%25201050%2529%253A%2520a%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">872</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F2159-8290.CD-12-0387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=23071030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=872-875&issue=10&author=C.+M.+Blakelyauthor=T.+G.+Bivona&title=Resiliency+of+Lung+Cancers+to+EGFR+Inhibitor+Treatment+Unveiled%2C+Offering+Opportunities+to+Divide+and+Conquer+EGFR+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-12-0387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span></div><div class="casAuthors">Blakely, Collin M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">872-875</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Summary: The clin. success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance.  Two reports in this issue of Cancer Discovery uncover addnl. mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment.  These findings pave the way for clin. testing of new rational therapeutic strategies to prevent or overcome resistance to EGFR kinase inhibitors in the clinic.  Cancer Discov; 2(10); 872-5. ©2012 AACR.  Commentary on Ercan et al., p. 934.  Commentary on Takezawa et al., p. 922.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiyRcMFbYgYrVg90H21EOLACvtfcHk0liDVck3q3IkPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM&md5=ec81e2c701acb7c836306926ca9b5074</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0387%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DResiliency%2520of%2520Lung%2520Cancers%2520to%2520EGFR%2520Inhibitor%2520Treatment%2520Unveiled%252C%2520Offering%2520Opportunities%2520to%2520Divide%2520and%2520Conquer%2520EGFR%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D10%26spage%3D872%26epage%3D875%26doi%3D10.1158%2F2159-8290.CD-12-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Jaenneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0liRWnvAIfJzzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Third-Generation Inhibitors Targeting EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34/1</span>– <span class="NLM_lpage">34/7</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=34%2F1-34%2F7&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-Generation+Inhibitors+Targeting+EGFR+T790M+Mutation+in+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-Generation%2520Inhibitors%2520Targeting%2520EGFR%2520T790M%2520Mutation%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D34%252F1%26epage%3D34%252F7%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0liRWnvAIfJzzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&issue=18&author=P.+A.+Janneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor-Resistant+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eZD1K0_pzgvGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor-Resistant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D18%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theelen, W. S. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebastian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1612674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa1612674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27959700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=629-640&issue=7&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=M.+J.+Ahnauthor=M.+C.+Garassinoauthor=H.+R.+Kimauthor=S.+S.+Ramalingamauthor=F.+A.+Shepherdauthor=Y.+Heauthor=H.+Akamatsuauthor=W.+S.+M.+E.+Theelenauthor=C.+K.+Leeauthor=M.+Sebastianauthor=A.+Templetonauthor=H.+Mannauthor=M.+Marottiauthor=S.+Ghiorghiuauthor=V.+A.+Papadimitrakopoulou&title=Osimertinib+or+Platinum-Pemetrexed+in+EGFR+T790M-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1612674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer</span></div><div class="casAuthors">Mok, T. S.; Wu, Y.-L.; Ahn, M.-J.; Garassino, M. C.; Kim, H. R.; Ramalingam, S. S.; Shepherd, F. A.; He, Y.; Akamatsu, H.; Theelen, W. S. M. E.; Lee, C. K.; Sebastian, M.; Templeton, A.; Mann, H.; Marotti, M.; Ghiorghiu, S.; Papadimitrakopoulou, V. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">629-640</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer.  The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown.  In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-pos. advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or i.v. pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 wk for up to six cycles; maintenance pemetrexed was allowed.  In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy.  The primary end point was investigator-assessed progression-free survival.  The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 mo vs. 4.4 mo; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001).  The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).  Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 mo vs. 4.2 mo; hazard ratio, 0.32; 95% CI, 0.21 to 0.49).  The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%).  Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-pos. advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruYSDfzF6p8LVg90H21EOLACvtfcHk0ljaepxN8GZMxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvI&md5=a8d0fa4c1289e0c81216497c362f4bcb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1612674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1612674%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DGarassino%26aufirst%3DM.%2BC.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DAkamatsu%26aufirst%3DH.%26aulast%3DTheelen%26aufirst%3DW.%2BS.%2BM.%2BE.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DSebastian%26aufirst%3DM.%26aulast%3DTempleton%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%2BA.%26atitle%3DOsimertinib%2520or%2520Platinum-Pemetrexed%2520in%2520EGFR%2520T790M-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26issue%3D7%26spage%3D629%26epage%3D640%26doi%3D10.1056%2FNEJMoa1612674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Cuesta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildhaus, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuernberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F1078-0432.CCR-15-1915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27252416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4837-4847&issue=19&author=S.+Ortiz-Cuaranauthor=M.+Schefflerauthor=D.+Plenkerauthor=l.+Dahmenauthor=A.+H.+Scheelauthor=L.+Fernandez-Cuestaauthor=L.+Mederauthor=C.+M.+Lovlyauthor=T.+Persigehlauthor=S.+Merkelbach-Bruseauthor=M.+Bosauthor=S.+Michelsauthor=R.+Fischerauthor=K.+Albusauthor=K.+Koenigauthor=H.-U.+Schildhausauthor=J.+Fassunkeauthor=M.+A.+Ihleauthor=H.+Pasternackauthor=C.+Heydtauthor=C.+Beckerauthor=J.+Altmuellerauthor=H.+Jiauthor=C.+Muellerauthor=A.+Florinauthor=J.+M.+Heuckmannauthor=P.+Nuernbergauthor=S.+Ansenauthor=L.+C.+Heukampauthor=J.+Bergauthor=W.+Paoauthor=M.+Peiferauthor=R.+Buettnerauthor=J.+Wolfauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Heterogeneous+Mechanisms+of+Primary+and+Acquired+Resistance+to+Third-Generation+EGFR+Inhibitors&doi=10.1158%2F1078-0432.CCR-15-1915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span></div><div class="casAuthors">Ortiz-Cuaran, Sandra; Scheffler, Matthias; Plenker, Dennis; Dahmen, llona; Scheel, Andreas H.; Fernandez-Cuesta, Lynnette; Meder, Lydia; Lovly, Christine M.; Persigehl, Thorsten; Merkelbach-Bruse, Sabine; Bos, Marc; Michels, Sebastian; Fischer, Rieke; Albus, Kerstin; Koenig, Katharina; Schildhaus, Hans-Ulrich; Fassunke, Jana; Ihle, Michaela A.; Pasternack, Helen; Heydt, Carina; Becker, Christian; Altmueller, Janine; Ji, Hongbin; Mueller, Christian; Florin, Alexandra; Heuckmann, Johannes M.; Nuernberg, Peter; Ansen, Sascha; Heukamp, Lukas C.; Berg, Johannes; Pao, William; Peifer, Martin; Buettner, Reinhard; Wolf, Juergen; Thomas, Roman K.; Sos, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4837-4847</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).  We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686).  Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models.  We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compds.  Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance.  Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS.  Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryi-78iIDGfrVg90H21EOLACvtfcHk0lgDA4UXulJr6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K&md5=b30908de40ff48f067e067cfc3520a7b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1915%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DDahmen%26aufirst%3Dl.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DMeder%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DAlbus%26aufirst%3DK.%26aulast%3DKoenig%26aufirst%3DK.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPasternack%26aufirst%3DH.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DAltmueller%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DA.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DNuernberg%26aufirst%3DP.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DHeterogeneous%2520Mechanisms%2520of%2520Primary%2520and%2520Acquired%2520Resistance%2520to%2520Third-Generation%2520EGFR%2520Inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D19%26spage%3D4837%26epage%3D4847%26doi%3D10.1158%2F1078-0432.CCR-15-1915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span> <span> </span><span class="NLM_article-title">Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e45-e47</span> <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.jtho.2015.12.093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&issue=4&author=H.-N.+Songauthor=K.+S.+Jungauthor=K.+H.+Yooauthor=J.+Choauthor=J.+Y.+Leeauthor=S.+H.+Limauthor=H.+S.+Kimauthor=J.-M.+Sunauthor=S.-H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.-L.+Choiauthor=W.+Parkauthor=M.-J.+Ahn&title=Acquired+C797S+Mutation+upon+Treatment+with+a+T790M-Specific+Third-Generation+EGFR+Inhibitor+%28HM61713%29+in+Non-Small+Cell+Lung+Cancer&doi=10.1016%2Fj.jtho.2015.12.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.093%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.-N.%26aulast%3DJung%26aufirst%3DK.%2BS.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSun%26aufirst%3DJ.-M.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.-L.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.-J.%26atitle%3DAcquired%2520C797S%2520Mutation%2520upon%2520Treatment%2520with%2520a%2520T790M-Specific%2520Third-Generation%2520EGFR%2520Inhibitor%2520%2528HM61713%2529%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D4%26doi%3D10.1016%2Fj.jtho.2015.12.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lgDA4UXulJr6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+Novel+Resistance+Mechanisms+to+Third-Generation+EGFR+Tyrosine+Kinase+Inhibitor+Osimertinib+in+Non-Small+Cell+Lung+Cancer+Patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lgeuFkuTA9lQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520Novel%2520Resistance%2520Mechanisms%2520to%2520Third-Generation%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitor%2520Osimertinib%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span>. <i>JAMA Oncol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26181354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=982-984&issue=7&author=H.+A.+Yuauthor=A.+E.+Drilonauthor=G.+J.+Rielyauthor=S.+K.+Tianauthor=L.+Borsuauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+Resistance+of+EGFR-Mutant+Lung+Cancer+to+a+T790M-Specific+EGFR+Inhibitor%3A+Emergence+of+a+Third+Mutation+%28C797S%29+in+the+EGFR+Tyrosine+Kinase+Domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span></div><div class="casAuthors">Yu Helena A; Drilon Alexander E; Riely Gregory J; Tian Shaozhou K; Borsu Laetitia; Arcila Maria E; Ladanyi Marc</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">982-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMt1QT_1O5WBYfW6udTcc2eYsfxlNVPYLYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D&md5=27ae39c3fce4067baca734fbc05101b5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520Resistance%2520of%2520EGFR-Mutant%2520Lung%2520Cancer%2520to%2520a%2520T790M-Specific%2520EGFR%2520Inhibitor%253A%2520Emergence%2520of%2520a%2520Third%2520Mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DJAMA%2520Oncol%26date%3D2015%26volume%3D1%26issue%3D7%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carl Barrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenne, P. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.7576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1200%2FJCO.2017.74.7576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28841389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=841-849&issue=9&author=S.+S.+Ramalingamauthor=J.+C.+H.+Yangauthor=C.+K.+Leeauthor=T.+Kurataauthor=D.-W.+Kimauthor=T.+Johnauthor=N.+Nogamiauthor=Y.+Oheauthor=H.+Mannauthor=Y.+Rukazenkovauthor=S.+Ghiorghiuauthor=D.+Stetsonauthor=A.+Markovetsauthor=J.+Carl+Barrettauthor=K.+S.+Thressauthor=P.+A.+Jaenne&title=Osimertinib+as+First-Line+Treatment+of+EGFR+Mutation-Positive+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.2017.74.7576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Yang, James C. H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Carl Barrett, J.; Thress, Kenneth S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">841-849</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-na.ovrddot.ive patients to examine clin. activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Sixty treatment-na.ovrddot.ive patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort).  End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation.  Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms.  Results At data cutoff (Nov. 1, 2016), median follow-up was 19.1 mo.  Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses.  Median PFS time was 22.1 mo (95% CI, 13.7 to 30.2 mo) in the 80-mg group, 19.3 mo (95% CI, 13.7 to 26.0 mo) in the 160-mg group, and 20.5 mo (95% CI, 15.0 to 26.1 mo) across doses.  Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA.  Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1).  Acquired EGFR T790M was not detected.  Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-na.ovrddot.ive patients with EGFRm advanced NSCLC.  There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqM3jWJfzwbVg90H21EOLACvtfcHk0lgeuFkuTA9lQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL&md5=e6b63846658632b5f79460ee29022835</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.7576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.7576%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DCarl%2BBarrett%26aufirst%3DJ.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26atitle%3DOsimertinib%2520as%2520First-Line%2520Treatment%2520of%2520EGFR%2520Mutation-Positive%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D9%26spage%3D841%26epage%3D849%26doi%3D10.1200%2FJCO.2017.74.7576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 2,9-Disubstituted 8-Phenylthio/Phenylsulfinyl-9H-Purine as New EGFR Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2173</span>– <span class="NLM_lpage">2185</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmc.2018.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29576272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2173-2185&issue=8&author=Y.+Y.+Heiauthor=Y.+Shenauthor=J.+Wangauthor=H.+Zhangauthor=H.+Y.+Zhaoauthor=M.+Xinauthor=Y.+X.+Caoauthor=Y.+Liauthor=S.+Q.+Zhang&title=Synthesis+and+Evaluation+of+2%2C9-Disubstituted+8-Phenylthio%2FPhenylsulfinyl-9H-Purine+as+New+EGFR+Inhibitors&doi=10.1016%2Fj.bmc.2018.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors</span></div><div class="casAuthors">Hei, Yuan-Yuan; Shen, Ying; Wang, Jin; Zhang, Hao; Zhao, Hong-Yi; Xin, Minhang; Cao, Yong-Xiao; Li, Yan; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2173-2185</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In present study, we described the synthesis and biol. evaluation of a new class of EGFR inhibitors contg. 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine scaffold.  Thirty-one compds. were synthesized.  Among them, compd. I displayed the IC50 of 29.4 nM against HCC827 cell line and 1.9 nM against EGFRL858R.  Compd. II showed moderate inhibitory activity against EGFRL858R/T790M/C797S (IC50 = 114 nM).  Western bolt assay suggested that compd. I significantly inhibited EGFR phosphorylation.  In vivo test, compd. I remarkably exhibited inhibitory effect on tumor growth at 5.0 mg/kg by oral administration in established nude mouse HCC827 xenograft model.  These results indicate that the 2,9-disubstituted 8-phenylsulfinyl/phenylsulfinyl-9H-purine derivs. can act as potent EGFR(L858R) inhibitors and effective anticancer agents.  Addnl., optimization of compd. C12 may result in discovering the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkK03__RHpv7Vg90H21EOLACvtfcHk0ljLi0THjkXEIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D&md5=e3c14297dde450c1b241946f9bb823a6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25202%252C9-Disubstituted%25208-Phenylthio%252FPhenylsulfinyl-9H-Purine%2520as%2520New%2520EGFR%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2173%26epage%3D2185%26doi%3D10.1016%2Fj.bmc.2018.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span> <span> </span><span class="NLM_article-title">Novel 4-Arylaminoquinazoline Derivatives with (E)-Propen-1-yl moiety as Potent EGFR Inhibitors with Enhanced Antiproliferative Activities Against Tumor Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">Supplement C</span>),  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.ejmech.2017.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28711703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=689-697&issue=Supplement+C&author=L.+Chenauthor=Y.+Zhangauthor=J.+Liuauthor=W.+Wangauthor=X.+Liauthor=L.+Zhaoauthor=W.+Wangauthor=B.+Li&title=Novel+4-Arylaminoquinazoline+Derivatives+with+%28E%29-Propen-1-yl+moiety+as+Potent+EGFR+Inhibitors+with+Enhanced+Antiproliferative+Activities+Against+Tumor+Cells&doi=10.1016%2Fj.ejmech.2017.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells</span></div><div class="casAuthors">Chen, Li; Zhang, Yaling; Liu, Juan; Wang, Weijia; Li, Xiabing; Zhao, Lijun; Wang, Wei; Li, Baolin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel 4-anilinoquinazoline derivs. with (E)-propen-1-yl moiety I (R1 = R2 = methoxy, 2-morpholinoethoxy, 3-morpholinopropoxy) were designed, synthesized and evaluated for biol. activities in vitro.  Most compds. exhibited high antiproliferative activities against all tested tumor cell lines including A431, A549, NCI-H1975 and SW480 cells.  Esp., compd. I (R1 = R2 = 3-morpholinopropoxy) not only presented strong antiproliferative activities against the tested four tumor cell lines (IC50 of 1.35, 8.83, 5.53 and 6.08 μM, resp.) which expressed wild type or L858R/T790M double mutant epidermal growth factor receptor (EGFR), but also showed potent inhibitory activity against wild type EGFR (IC50 = 20.72 nM).  The result of mol. docking with EGFR suggested the binding mode of compd. I (R1 = R2 = 3-morpholinopropoxy) was similar to gefitinib, but different from lapatinib.  Addnl., western blot anal. showed that compd. I (R1 = R2 = 3-morpholinopropoxy) inhibited the phosphorylation of EGFR and its downstream signaling proteins in lung cancer cells.  The work could be very useful starting point for developing a new series of tyrosine kinase inhibitors targeting EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB06gE-JAQSLVg90H21EOLACvtfcHk0ljLi0THjkXEIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7nI&md5=c87fb7dfb796076c10bf66bb193017dc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DB.%26atitle%3DNovel%25204-Arylaminoquinazoline%2520Derivatives%2520with%2520%2528E%2529-Propen-1-yl%2520moiety%2520as%2520Potent%2520EGFR%2520Inhibitors%2520with%2520Enhanced%2520Antiproliferative%2520Activities%2520Against%2520Tumor%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26issue%3DSupplement%2520C%26spage%3D689%26epage%3D697%26doi%3D10.1016%2Fj.ejmech.2017.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&issue=13&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+Pyridinylimidazoles+as+Potent+Inhibitors+of+the+Clinically+Resistant+L858R%2FT790M%2FC797S+EGFR+Mutant%3A+Targeting+of+Both+Hydrophobic+Regions+and+the+Phosphate+Binding+Site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0ljLi0THjkXEIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Pyridinylimidazoles%2520as%2520Potent%2520Inhibitors%2520of%2520the%2520Clinically%2520Resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520Mutant%253A%2520Targeting%2520of%2520Both%2520Hydrophobic%2520Regions%2520and%2520the%2520Phosphate%2520Binding%2520Site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oku, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwao, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of A-Ring-Modified Lamellarin N Analogues as Noncovalent Inhibitors of the EGFR T790M/L858R Mutant</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6563</span>– <span class="NLM_lpage">5680</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmc.2017.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29133033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2qt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6563-5680&issue=24&author=T.+Fukudaauthor=T.+Umekiauthor=K.+Tokushimaauthor=G.+Xiangauthor=Y.+Yoshidaauthor=F.+Ishibashiauthor=Y.+Okuauthor=N.+Nishiyaauthor=Y.+Ueharaauthor=M.+Iwao&title=Design%2C+Synthesis%2C+and+Evaluation+of+A-Ring-Modified+Lamellarin+N+Analogues+as+Noncovalent+Inhibitors+of+the+EGFR+T790M%2FL858R+Mutant&doi=10.1016%2Fj.bmc.2017.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant</span></div><div class="casAuthors">Fukuda, Tsutomu; Umeki, Teppei; Tokushima, Keiji; Xiang, Gao; Yoshida, Yuki; Ishibashi, Fumito; Oku, Yusuke; Nishiya, Naoyuki; Uehara, Yoshimasa; Iwao, Masatomo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6563-6580</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of A-ring-modified lamellarin N analogs were designed, synthesized, and evaluated as potential noncovalent inhibitors of the EGFR T790M/L858R mutant, a causal factor in the drug-resistant non-small cell lung cancer.  Several water-sol. ammonium- or guanidinium-tethered analogs exhibited good kinase inhibitory activities.  The most promising analog, 14f, displayed an excellent inhibitory profile against the T790M/L858R mutant [IC50 (WT) = 31.8 nM; IC50 (T790M/L858R) = 8.9 nM].  The effects of A-ring-substituents on activity were rationalized by docking studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5XVsxrAkmpLVg90H21EOLACvtfcHk0lhj5zK3Gbhl2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2qt7zP&md5=9686c83c5426d7f389ed885ff2b5ccf5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DUmeki%26aufirst%3DT.%26aulast%3DTokushima%26aufirst%3DK.%26aulast%3DXiang%26aufirst%3DG.%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DIshibashi%26aufirst%3DF.%26aulast%3DOku%26aufirst%3DY.%26aulast%3DNishiya%26aufirst%3DN.%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DIwao%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520A-Ring-Modified%2520Lamellarin%2520N%2520Analogues%2520as%2520Noncovalent%2520Inhibitors%2520of%2520the%2520EGFR%2520T790M%252FL858R%2520Mutant%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6563%26epage%3D5680%26doi%3D10.1016%2Fj.bmc.2017.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2,4,6-Trisubstitued Pyrido[3,4-d]pyrimidine Derivatives as new EGFR-TKIs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.ejmech.2018.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29466773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=221-237&author=H.+Zhangauthor=J.+Wangauthor=Y.+Shenauthor=H.+Y.+Wangauthor=W.+M.+Duanauthor=H.+Y.+Zhaoauthor=Y.+Y.+Heiauthor=M.+Xinauthor=Y.+X.+Caoauthor=S.+Q.+Zhang&title=Discovery+of+2%2C4%2C6-Trisubstitued+Pyrido%5B3%2C4-d%5Dpyrimidine+Derivatives+as+new+EGFR-TKIs&doi=10.1016%2Fj.ejmech.2018.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs</span></div><div class="casAuthors">Zhang, Hao; Wang, Jin; Shen, Ying; Wang, Hui-Yan; Duan, Wei-Ming; Zhao, Hong-Yi; Hei, Yuan-Yuan; Xin, Minhang; Cao, Yong-Xiao; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">221-237</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance is the major challenge in the treatment of EGFR-driven non-small cell lung cancer (NSCLC).  In this study, a novel class of compds. contg. pyrido[3,4-d]pyrimidine scaffold was designed as new generation EGFR-TKIs to overcome this challenge.  The most promising compd. I inhibited HCC827 and H1975 cells growth with the IC50 values of 0.044μM and 0.40μM, resp.  Meanwhile, I displayed potent inhibitory activity against the EGFRL858R (IC50=1.1nM) and EGFRL858R/T790M/C797S (IC50=7.2nM).  I could suppress EGFR phosphorylation in a dose-dependent manner in HCC827 cell line and significantly induce the apoptosis of HCC827 cells.  Mol. docking indicated that the hydroxyl in I could form addnl. hydrogen bond with mutant Ser797.  These findings strongly support our assumption that 2,4,6-trisubstitued pyrido[3,4-d] pyrimidine derivs. can serve as EGFR-TKIs.  The predicted hydrogen bond interaction formed by a small mol. inhibitor with mutant Ser797 is available to design the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3S8daGHVu6bVg90H21EOLACvtfcHk0lhj5zK3Gbhl2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D&md5=533499fed54c750cfde176522bbdfd52</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DDuan%26aufirst%3DW.%2BM.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%25202%252C4%252C6-Trisubstitued%2520Pyrido%255B3%252C4-d%255Dpyrimidine%2520Derivatives%2520as%2520new%2520EGFR-TKIs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237%26doi%3D10.1016%2Fj.ejmech.2018.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&issue=11&author=M.+Juchumauthor=M.+G%C3%BCntherauthor=E.+D%C3%B6ringauthor=A.+Sievers-Englerauthor=M.+L%C3%A4mmerhoferauthor=S.+Laufer&title=Trisubstituted+Imidazoles+with+a+Rigidized+Hinge+Binding+Motif+Act+As+Single+Digit+nM+Inhibitors+of+Clinically+Relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+Mutants%3A+An+Example+of+Target+Hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0lhj5zK3Gbhl2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Imidazoles%2520with%2520a%2520Rigidized%2520Hinge%2520Binding%2520Motif%2520Act%2520As%2520Single%2520Digit%2520nM%2520Inhibitors%2520of%2520Clinically%2520Relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520Mutants%253A%2520An%2520Example%2520of%2520Target%2520Hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&issue=11&author=X.+Luauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+New+EGFRC797S+Mutant+Inhibitor+with+In+Vivo+Monodrug+Efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0liX3xvm46ZVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520New%2520EGFRC797S%2520Mutant%2520Inhibitor%2520with%2520In%2520Vivo%2520Monodrug%2520Efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as Non-cCvalent Inhibitors of Mutant Epidermal Growth Factor Receptor Tyrosine Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmcl.2015.11.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26639762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFant7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=534-539&issue=2&author=E.+J.+Hananauthor=M.+Baumgardnerauthor=M.+C.+Bryanauthor=Y.+Chenauthor=C.+Eigenbrotauthor=P.+Fanauthor=X.+H.+Guauthor=H.+Laauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=S.+Siderisauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=4-Aminoindazolyl-dihydrofuro%5B3%2C4-d%5Dpyrimidines+as+Non-cCvalent+Inhibitors+of+Mutant+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase&doi=10.1016%2Fj.bmcl.2015.11.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Hanan, Emily J.; Baumgardner, Matt; Bryan, Marian C.; Chen, Yuan; Eigenbrot, Charles; Fan, Peter; Gu, Xiao-Hui; La, Hank; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Sideris, Steve; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-539</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung cancers with the T790M resistance mutation remains a significant unmet medical need.  The authors report the identification of 4-aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of EGFR, with excellent activity against the T790M resistance double mutants and initial single activating mutants.  Using an optimization strategy focused on structure-based design and improving PK properties through metabolite identification, the authors obtained advanced leads with high oral exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoXgVh2AtAg7Vg90H21EOLACvtfcHk0liX3xvm46ZVEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFant7vE&md5=1c4d8dd8b2b57b4480cc120a52b00c59</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.078%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DX.%2BH.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3D4-Aminoindazolyl-dihydrofuro%255B3%252C4-d%255Dpyrimidines%2520as%2520Non-cCvalent%2520Inhibitors%2520of%2520Mutant%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D534%26epage%3D539%26doi%3D10.1016%2Fj.bmcl.2015.11.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Fernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8877</span>– <span class="NLM_lpage">8895</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1emtbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8877-8895&issue=22&author=R.+Healdauthor=K.+K.+Bowmanauthor=M.+C.+Bryanauthor=D.+Burdickauthor=B.+Chanauthor=E.+Chanauthor=Y.+Chenauthor=S.+Clausenauthor=B.+Dominguez-Fernandezauthor=C.+Eigenbrotauthor=R.+Elliottauthor=E.+J.+Hananauthor=P.+Jacksonauthor=J.+Knightauthor=H.+Laauthor=M.+Lainchburyauthor=S.+Malekauthor=S.+Mannauthor=M.+Merchantauthor=K.+Mortaraauthor=H.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+Sewardauthor=S.+Siderisauthor=L.+Shaoauthor=S.+Wangauthor=K.+Yeapauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=Noncovalent+Mutant+Selective+Epidermal+Growth+Factor+Receptor+Inhibitors%3A+A+Lead+Optimization+Case+Study&doi=10.1021%2Facs.jmedchem.5b01412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study</span></div><div class="casAuthors">Heald, Robert; Bowman, Krista K.; Bryan, Marian C.; Burdick, Daniel; Chan, Bryan; Chan, Emily; Chen, Yuan; Clausen, Saundra; Dominguez-Fernandez, Belen; Eigenbrot, Charles; Elliott, Richard; Hanan, Emily J.; Jackson, Philip; Knight, Jamie; La, Hank; Lainchbury, Michael; Malek, Shiva; Mann, Sam; Merchant, Mark; Mortara, Kyle; Purkey, Hans; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen; Sideris, Steve; Shao, Lily; Wang, Shumei; Yeap, Kuen; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8877-8895</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of their increased activity against activating mutants, first-generation epidermal growth factor receptor (EGFR) kinase inhibitors have had remarkable success in treating non-small-cell lung cancer (NSCLC) patients, but acquired resistance, through a secondary mutation of the gatekeeper residue, means that clin. responses only last for 8-14 mo.  Addressing this unmet medical need requires agents that can target both of the most common double mutants: T790M/L858R (TMLR) and T790M/del(746-750) (TMdel).  Herein we describe how a noncovalent double mutant selective lead compd. was optimized using a strategy focused on the structure-guided increase in potency without added lipophilicity or redn. of three-dimensional character.  Following successive rounds of design and synthesis it was discovered that cis-fluoro substitution on 4-hydroxy- and 4-methoxypiperidinyl groups provided synergistic, substantial, and specific potency gain through direct interaction with the enzyme and/or effects on the proximal ligand oxygen atom.  Further development of the fluorohydroxypiperidine series resulted in the identification of a pair of diastereomers that showed 50-fold enzyme and cell based selectivity for T790M mutants over wild-type EGFR (wtEGFR) in vitro and pathway knock-down in an in vivo xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjYmZnCNtnWbVg90H21EOLACvtfcHk0liceY4alz7xpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1emtbnL&md5=18978e79a7bc894b91a0ab453b276dd6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01412%26sid%3Dliteratum%253Aachs%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DB.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DClausen%26aufirst%3DS.%26aulast%3DDominguez-Fernandez%26aufirst%3DB.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DJackson%26aufirst%3DP.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DS.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DPurkey%26aufirst%3DH.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DNoncovalent%2520Mutant%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitors%253A%2520A%2520Lead%2520Optimization%2520Case%2520Study%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D22%26spage%3D8877%26epage%3D8895%26doi%3D10.1021%2Facs.jmedchem.5b01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10176</span>– <span class="NLM_lpage">10191</span>, <span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&issue=23&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+Selective+and+Noncovalent+Diaminopyrimidine-Based+Inhibitors+of+Epidermal+Growth+Factor+Receptor+Containing+the+T790M+Resistance+Mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0liceY4alz7xpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520Selective%2520and%2520Noncovalent%2520Diaminopyrimidine-Based%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Containing%2520the%2520T790M%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=100-104&issue=1&author=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=S.+Clausenauthor=J.+Dotsonauthor=C.+Eigenbrotauthor=R.+Elliottauthor=E.+J.+Hananauthor=R.+Healdauthor=P.+Jacksonauthor=H.+Laauthor=M.+Lainchburyauthor=S.+Malekauthor=S.+E.+Mannauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+Sewardauthor=S.+Siderisauthor=S.+Wangauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=Pyridones+as+Highly+Selective%2C+Noncovalent+Inhibitors+of+T790M+Double+Mutants+of+EGFR&doi=10.1021%2Facsmedchemlett.5b00428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR</span></div><div class="casAuthors">Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Clausen, Saundra; Dotson, Jennafer; Eigenbrot, Charles; Elliott, Richard; Hanan, Emily J.; Heald, Robert; Jackson, Philip; La, Hank; Lainchbury, Michael; Malek, Shiva; Mann, Sam E.; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen; Sideris, Steve; Wang, Shumei; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-104</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rapid advancement of a series of noncovalent inhibitors of T790M mutants of EGFR is discussed.  The optimization of a nonselective high-throughput screening pyridone hit to potent mols. with high levels of selectivity over wtEGFR and the broader kinome is described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxw6S7lm_va7Vg90H21EOLACvtfcHk0liceY4alz7xpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqt7vK&md5=86cdd147b8fb9c5515dd9630584562ef</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00428%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DClausen%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DP.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DS.%2BE.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DPyridones%2520as%2520Highly%2520Selective%252C%2520Noncovalent%2520Inhibitors%2520of%2520T790M%2520Double%2520Mutants%2520of%2520EGFR%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D100%26epage%3D104%26doi%3D10.1021%2Facsmedchemlett.5b00428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF Receptor Inhibitors That Are Selective for the d746–750/T790M/C797S Mutant through Structure-Based de Novo Design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&issue=26&author=H.+Parkauthor=H.-Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+Receptor+Inhibitors+That+Are+Selective+for+the+d746%E2%80%93750%2FT790M%2FC797S+Mutant+through+Structure-Based+de+Novo+Design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0lgubSknpfJFBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520Receptor%2520Inhibitors%2520That%2520Are%2520Selective%2520for%2520the%2520d746%25E2%2580%2593750%252FT790M%252FC797S%2520Mutant%2520through%2520Structure-Based%2520de%2520Novo%2520Design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D26%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dela Vega, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">9080</span>– <span class="NLM_lpage">9093</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWlsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9080-9093&issue=19&author=B.+K.+Chanauthor=E.+J.+Hananauthor=K.+K.+Bowmanauthor=M.+C.+Bryanauthor=D.+Burdickauthor=E.+Chanauthor=Y.+Chenauthor=S.+Clausenauthor=T.+Dela+Vegaauthor=J.+Dotsonauthor=C.+Eigenbrotauthor=R.+L.+Elliottauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=J.+D.+Knightauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=L.+Shaoauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=Discovery+of+a+Noncovalent%2C+Mutant-Selective+Epidermal+Growth+Factor+Receptor+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Chan, Bryan K.; Hanan, Emily J.; Bowman, Krista K.; Bryan, Marian C.; Burdick, Daniel; Chan, Emily; Chen, Yuan; Clausen, Saundra; Dela Vega, Trisha; Dotson, Jennafer; Eigenbrot, Charles; Elliott, Richard L.; Heald, Robert A.; Jackson, Philip S.; Knight, Jamie D.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Shao, Lily; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9080-9093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant pos. nonsmall-cell lung cancer.  A secondary point mutation (T790M) in the inhibitor binding site has been linked to the acquired resistance against those first generation therapeutics.  Herein, the authors describe the lead optimization of a series of reversible, pan-mutant (L858R, del746-750, T790M/L858R, and T790M/del746-750) EGFR inhibitors.  By use of a noncovalent double mutant (T790M/L858R and T790M/del746-750) selective EGFR inhibitor I as a starting point, activities against the single mutants (L858R and del746-750) were introduced through a series of structure-guided modifications.  The in vitro ADME-PK properties of the lead mols. were further optimized through a no. of rational structural changes.  The resulting inhibitor II exhibited excellent cellular activity against both the single and double mutants of EGFR, demonstrating target engagement in vivo and ADME-PK properties that are suitable for further evaluation.  The reversible, noncovalent inhibitors described complement the covalent pan-mutant EGFR inhibitors that have shown encouraging results in recent clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgSFhbM4LOYrVg90H21EOLACvtfcHk0lgubSknpfJFBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWlsbnL&md5=7b17fcf5fc401843821445cf6e6e9f0b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00995%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DClausen%26aufirst%3DS.%26aulast%3DDela%2BVega%26aufirst%3DT.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DR.%2BL.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DKnight%26aufirst%3DJ.%2BD.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520Noncovalent%252C%2520Mutant-Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D19%26spage%3D9080%26epage%3D9093%26doi%3D10.1021%2Facs.jmedchem.6b00995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noolvi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Quinazolinones as EGFR Inhibitors to Overcome EGFR Resistance Obstacle</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2723</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmc.2017.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28366268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVCjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2713-2723&issue=10&author=H.+M.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=M.+Noolviauthor=S.+Surana&title=Design+and+Synthesis+of+Quinazolinones+as+EGFR+Inhibitors+to+Overcome+EGFR+Resistance+Obstacle&doi=10.1016%2Fj.bmc.2017.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle</span></div><div class="casAuthors">Patel, Harun M.; Pawara, Rahul; Ansari, Azim; Noolvi, Malleshappa; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2713-2723</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) T790M mutant is found in about 50% of clin. acquired resistance to gefitinib among patients with non-small cell lung cancer (NSCLC).  New derivs. of 4(3H)-quinazolinones were synthesized and evaluated for their inhibitory activity against NSCLC.  The results of the study demonstrated that compd. 79, 7-chloro-3-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylquinazolin-4(3H)-one was found to be the most potent compds. of the series with IC50 value of 0.031 μM against mutant T790M/L858R EGFR.  Compds. 15, 51, 73, 75, 78, 79 and 96 were less potent against A549 (WT EGFR and k-Ras mutation) and HT-29 (non-special gene type) cells, showing a high safety index.  The obtained results showed that compds. 15, 51, 73, 75, 78, 79 and 96 could be the promising template to overcome drug resistance mediated by the EGFR T790 Mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0aFIxV-do07Vg90H21EOLACvtfcHk0liI5C98bBXm8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVCjurk%253D&md5=33605a4dfa008b4e61ab4bb42b523a42</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BM.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DNoolvi%26aufirst%3DM.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Quinazolinones%2520as%2520EGFR%2520Inhibitors%2520to%2520Overcome%2520EGFR%2520Resistance%2520Obstacle%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D10%26spage%3D2713%26epage%3D2723%26doi%3D10.1016%2Fj.bmc.2017.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EAI045: The Fourth-Generation EGFR Inhibitor Overcoming T790M and C797S resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.canlet.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27840244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2017&pages=51-54&author=S.+Wangauthor=Y.+Songauthor=D.+Liu&title=EAI045%3A+The+Fourth-Generation+EGFR+Inhibitor+Overcoming+T790M+and+C797S+resistance&doi=10.1016%2Fj.canlet.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</span></div><div class="casAuthors">Wang, Shuhang; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-54</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M pos. non-small cell lung cancer (NSCLC).  However, resistance develops rapidly.  EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third-generation inhibitors.  This review summarizes the latest development on the discovery of a fourth-generation EGFR TKI, EAI045.3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2GMAIDfgfeLVg90H21EOLACvtfcHk0liI5C98bBXm8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM&md5=e429055412bec2ec2da28b2b959753ae</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEAI045%253A%2520The%2520Fourth-Generation%2520EGFR%2520Inhibitor%2520Overcoming%2520T790M%2520and%2520C797S%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D385%26spage%3D51%26epage%3D54%26doi%3D10.1016%2Fj.canlet.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spellmon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span> <span> </span><span class="NLM_article-title">Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1756</span>– <span class="NLM_lpage">1758</span>, <span class="refDoi"> DOI: 10.21037/jtd.2017.06.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.21037%2Fjtd.2017.06.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28839955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhsFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1756-1758&issue=7&author=N.+Spellmonauthor=C.+Liauthor=Z.+Yang&title=Allosterically+Targeting+EGFR+Drug-Resistance+Gatekeeper+Mutations&doi=10.21037%2Fjtd.2017.06.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Allosterically targeting EGFR drug-resistance gatekeeper mutations</span></div><div class="casAuthors">Spellmon Nicholas; Yang Zhe; Li Chunying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1756-1758</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMer61q-2iHLZpSb_XWfMrfW6udTcc2ebrbrPzZUBwprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhsFCmsg%253D%253D&md5=32e7407f858050a7ddbb026c5477d183</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.21037%2Fjtd.2017.06.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjtd.2017.06.43%26sid%3Dliteratum%253Aachs%26aulast%3DSpellmon%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26atitle%3DAllosterically%2520Targeting%2520EGFR%2520Drug-Resistance%2520Gatekeeper%2520Mutations%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2017%26volume%3D9%26issue%3D7%26spage%3D1756%26epage%3D1758%26doi%3D10.21037%2Fjtd.2017.06.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatachalam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, C.</span></span> <span> </span><span class="NLM_article-title">Conformational Landscape of the Epidermal Growth Factor Receptor Kinase Reveals a Mutant Specific Allosteric Pocket</span>. <i>Chemical Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5212</span>– <span class="NLM_lpage">5222</span>, <span class="refDoi"> DOI: 10.1039/C8SC01262H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1039%2FC8SC01262H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29997876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFCntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=5212-5222&issue=23&author=S.+Kannanauthor=G.+Venkatachalamauthor=H.+H.+Limauthor=U.+Suranaauthor=C.+Verma&title=Conformational+Landscape+of+the+Epidermal+Growth+Factor+Receptor+Kinase+Reveals+a+Mutant+Specific+Allosteric+Pocket&doi=10.1039%2FC8SC01262H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket</span></div><div class="casAuthors">Kannan, Srinivasaraghavan; Venkatachalam, Gireedhar; Lim, Hong Hwa; Surana, Uttam; Verma, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5212-5222</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain give rise to several cancers including Non-Small Cell Lung Cancer (NSCLC).  Small mol. inhibitors targeted at these mutants have proven to be clin. successful drugs.  These mols. are ATP competitive and rapidly result in the emergence of resistance.  We present here a study combining extensive mol. dynamics simulations with binding assays to provide a structural basis underlying the mechanism of binding of this mol.  It appears that in mutants, conformational destabilization of the short helix (that carries Leu858 in the wildtype), is key to the exposure of the allosteric pocket which otherwise is occluded by a set of sidechains including L858.  We extend this hypothesis to show that a similar mechanism would enable the mol. to inhibit EGFRL861Q which is another oncogenic mutant and validate this with binding expts.  The screening of the human structural kinome revealed at least 12 other oncogenic kinases which carry at least one activating mutant in this disorder-prone region and hence would be amenable to allosteric inhibition by mols. such as EAI045.  Our study characterizes a druggable allosteric pocket which appears to be specific to certain oncogenic mutants of the EGFR and holds therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJMPumMkZFbVg90H21EOLACvtfcHk0liI5C98bBXm8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFCntLo%253D&md5=57b221846f35482d03d19944ccc48919</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FC8SC01262H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC01262H%26sid%3Dliteratum%253Aachs%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DVenkatachalam%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DH.%2BH.%26aulast%3DSurana%26aufirst%3DU.%26aulast%3DVerma%26aufirst%3DC.%26atitle%3DConformational%2520Landscape%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Kinase%2520Reveals%2520a%2520Mutant%2520Specific%2520Allosteric%2520Pocket%26jtitle%3DChemical%2520Science%26date%3D2018%26volume%3D9%26issue%3D23%26spage%3D5212%26epage%3D5222%26doi%3D10.1039%2FC8SC01262H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caporuscio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinivella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semrau, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storici, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Identification of Small-Molecule EGFR Allosteric Inhibitors by High-Throughput Docking</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.4155/fmc-2018-0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.4155%2Ffmc-2018-0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29766737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1545-1553&issue=13&author=F.+Caporuscioauthor=A.+Tinivellaauthor=V.+Restelliauthor=M.+S.+Semrauauthor=L.+Pinziauthor=P.+Storiciauthor=M.+Brogginiauthor=G.+Rastelli&title=Identification+of+Small-Molecule+EGFR+Allosteric+Inhibitors+by+High-Throughput+Docking&doi=10.4155%2Ffmc-2018-0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking</span></div><div class="casAuthors">Caporuscio, Fabiana; Tinivella, Annachiara; Restelli, Valentina; Semrau, Marta S.; Pinzi, Luca; Storici, Paola; Broggini, Massimo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1545-1553</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Aim: The EGFR inhibitors represent the first-line treatment of non-small-cell lung cancer.  However, the emergence of resistance urgently requires the development of new inhibitors targeting drug-resistant mutants.  Methodol.: A recently released structure of an EGFR kinase domain in complex with an allosteric inhibitor and a mutant protein model derived from it were used to set up a low-cost high-throughput docking protocol for the fast identification of EGFR allosteric inhibitors.  Conclusion: The virtual screening of com. available compds. led to the identification of interesting new hit compds.  The most promising hit was confirmed to be a new allosteric inhibitor of wild-type and T790M/L858R double mutant EGFR which was able to inhibit the growth of  non-small-cell lung cancer cell lines.  Graphical abstr. :.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy2wOxQCD3n7Vg90H21EOLACvtfcHk0lgLYpi4N9NGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqurrJ&md5=4dc540ab8c42e50048b8f7f9f00a6a38</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0063%26sid%3Dliteratum%253Aachs%26aulast%3DCaporuscio%26aufirst%3DF.%26aulast%3DTinivella%26aufirst%3DA.%26aulast%3DRestelli%26aufirst%3DV.%26aulast%3DSemrau%26aufirst%3DM.%2BS.%26aulast%3DPinzi%26aufirst%3DL.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520Small-Molecule%2520EGFR%2520Allosteric%2520Inhibitors%2520by%2520High-Throughput%2520Docking%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26issue%3D13%26spage%3D1545%26epage%3D1553%26doi%3D10.4155%2Ffmc-2018-0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of EGFR T790M/C797S/V948R in Complex with EAI045</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>502</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.05.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bbrc.2018.05.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29802850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=502&publication_year=2018&pages=332-337&issue=3&author=P.+Zhaoauthor=M.+Y.+Yaoauthor=S.+J.+Zhuauthor=J.+Y.+Chenauthor=C.+H.+Yun&title=Crystal+Structure+of+EGFR+T790M%2FC797S%2FV948R+in+Complex+with+EAI045&doi=10.1016%2Fj.bbrc.2018.05.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045</span></div><div class="casAuthors">Zhao, Peng; Yao, Ming-Yu; Zhu, Su-Jie; Chen, Ji-Yun; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">502</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lung cancer is the leading cause of cancer deaths.  Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype of lung cancers.  Patients harboring most of these mutations respond well to the anti-EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib initially, but soon develop resistance to them in about half of the cases due to the emergence of the gatekeeper mutation T790M.  The third-generation TKIs such as AZD9291, HM61713, CO-1686 and WZ4002 can overcome T790M through covalent binding to the EGFR kinase through Cys 797, but ultimately lose their efficacy upon emergence of the C797S mutation that abolishes the covalent bonding.  Therefore to develop new TKIs to overcome EGFR drug-resistant mutants harboring T790M/C797S is urgently demanded.  EAI001 and EAI045 are a new type of EGFR TKIs that bind to EGFR reversibly and not relying on Cys 797.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR L858R/T790M and L858R/T790M/C797S.  Here we report the crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, and compare it to EGFR T790M/V948R in complex with EAI001.  The complex structure reveals why EAI045 binds tighter to EGFR than does EAI001, and why EAI001 and EAI045 prefer binding to EGFR T790M.  The knowledge may facilitate future drug development studies targeting this very important cancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouEvBqE0oB5LVg90H21EOLACvtfcHk0lgLYpi4N9NGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I&md5=b76b6a40ffef581fa2d5ca0a45bb8c14</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.05.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.05.154%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DCrystal%2520Structure%2520of%2520EGFR%2520T790M%252FC797S%252FV948R%2520in%2520Complex%2520with%2520EAI045%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D502%26issue%3D3%26spage%3D332%26epage%3D337%26doi%3D10.1016%2Fj.bbrc.2018.05.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="note"><p class="first last">To determine the kinase selectivity for a given compound, the “SelectScreen Kinase Profiling Services” from ThermoFisher was used. The activity of a compound was determined in biochemical assays using single concentration measurements. The results were provided as percent inhibition values. A compound displaying a percent inhibition value of greater 70% was defined as hit. Three different kinase panels were used (30 kinases, 238 kinases, and 393 kinases), and the lists of kinases for these repective panels are provided in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Tables S5–S7</a>. The EGFR<sup>L858R T790M C797S</sup> kinase assay was used as positive control.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(98)00044-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&issue=2%E2%80%933&author=P.+Traxlerauthor=P.+Furet&title=Strategies+Toward+the+Design+of+Novel+and+Selective+Protein+Tyrosine+Kinase+Inhibitors&doi=10.1016%2FS0163-7258%2898%2900044-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0lgLYpi4N9NGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520Toward%2520the%2520Design%2520of%2520Novel%2520and%2520Selective%2520Protein%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26issue%3D2%25E2%2580%25933%26spage%3D195%26epage%3D206%26doi%3D10.1016%2FS0163-7258%2898%2900044-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head-Gordon, M.</span></span> <span> </span><span class="NLM_article-title">Long-range Corrected Hybrid Density Functionals With Damped Atom-Atom Dispersion Corrections</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">6615</span>– <span class="NLM_lpage">6620</span>, <span class="refDoi"> DOI: 10.1039/b810189b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1039%2Fb810189b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=18989472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCksbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=6615-6620&issue=44&author=J.-D.+Chaiauthor=M.+Head-Gordon&title=Long-range+Corrected+Hybrid+Density+Functionals+With+Damped+Atom-Atom+Dispersion+Corrections&doi=10.1039%2Fb810189b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Long-range corrected hybrid density functionals with damped atom-atom dispersion corrections</span></div><div class="casAuthors">Chai, Jeng-Da; Head-Gordon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">6615-6620</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report re-optimization of a recently proposed long-range cor. (LC) hybrid d. functional [J.-D. Chai and M. Head-Gordon, J. Chem. Phys., 2008, 128, 084106] to include empirical atom-atom dispersion corrections.  The resulting functional, ωB97X-D yields satisfactory accuracy for thermochem., kinetics, and non-covalent interactions.  Tests show that for non-covalent systems, ωB97X-D shows slight improvement over other empirical dispersion-cor. d. functionals, while for covalent systems and kinetics it performs noticeably better.  Relative to our previous functionals, such as ωB97X, the new functional is significantly superior for non-bonded interactions, and very similar in performance for bonded interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRZ4m5IhMySbVg90H21EOLACvtfcHk0lj83Uq3CRK0vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCksbfO&md5=c7848f8bf050e11972d438aaebd68fdf</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2Fb810189b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb810189b%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DJ.-D.%26aulast%3DHead-Gordon%26aufirst%3DM.%26atitle%3DLong-range%2520Corrected%2520Hybrid%2520Density%2520Functionals%2520With%2520Damped%2520Atom-Atom%2520Dispersion%2520Corrections%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2008%26volume%3D10%26issue%3D44%26spage%3D6615%26epage%3D6620%26doi%3D10.1039%2Fb810189b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alihodžić, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukvić, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenkov, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutinec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koštrun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pešić, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomašković, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Žiher, D.</span></span> <span> </span><span class="NLM_article-title">Current Trends in Macrocyclic Drug Discovery and Beyond-Ro5</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/bs.pmch.2018.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fbs.pmch.2018.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29680148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltFOgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=113-233&author=S.+Alihod%C5%BEi%C4%87author=M.+Bukvi%C4%87author=I.+J.+Elenkovauthor=A.+Hutinecauthor=S.+Ko%C5%A1trunauthor=D.+Pe%C5%A1i%C4%87author=G.+Saxtyauthor=L.+Toma%C5%A1kovi%C4%87author=D.+%C5%BDiher&title=Current+Trends+in+Macrocyclic+Drug+Discovery+and+Beyond-Ro5&doi=10.1016%2Fbs.pmch.2018.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Current Trends in Macrocyclic Drug Discovery and beyond-Ro5</span></div><div class="casAuthors">Alihodzic Sulejman; Bukvic Mirjana; Elenkov Ivaylo J; Hutinec Antun; Kostrun Sanja; Pesic Dijana; Saxty Gordon; Tomaskovic Linda; Ziher Dinko</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-233</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">This chapter will discuss the recent literature of macrocycles and drug-like property space moving beyond the rule of five (bRo5).  Trends in chemical classes that fall within this definition are discussed and the impact of the latest technologies in the field assessed.  The physicochemical properties, which have provided both successes and challenges, especially in scale-up, are discussed.  A recent patent literature is reviewed and the chapter concludes with a perspective on the future of macrocyclic drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ9pfcWWVZ5hWfpMXQLRstfW6udTcc2eaU_Bj_cXqSyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltFOgsA%253D%253D&md5=ac41d1a69cb0056d106d554b0b323e61</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2018.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DAlihod%25C5%25BEi%25C4%2587%26aufirst%3DS.%26aulast%3DBukvi%25C4%2587%26aufirst%3DM.%26aulast%3DElenkov%26aufirst%3DI.%2BJ.%26aulast%3DHutinec%26aufirst%3DA.%26aulast%3DKo%25C5%25A1trun%26aufirst%3DS.%26aulast%3DPe%25C5%25A1i%25C4%2587%26aufirst%3DD.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DToma%25C5%25A1kovi%25C4%2587%26aufirst%3DL.%26aulast%3D%25C5%25BDiher%26aufirst%3DD.%26atitle%3DCurrent%2520Trends%2520in%2520Macrocyclic%2520Drug%2520Discovery%2520and%2520Beyond-Ro5%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D57%26spage%3D113%26epage%3D233%26doi%3D10.1016%2Fbs.pmch.2018.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viarengo, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span> <span> </span><span class="NLM_article-title">Progress Towards the Broad Use of Non-Peptide Synthetic Macrocycles in Drug Discovery</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">7729</span>– <span class="NLM_lpage">7735</span>, <span class="refDoi"> DOI: 10.1039/C7OB00056A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1039%2FC7OB00056A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28876025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKgsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=7729-7735&issue=37&author=A.+Whittyauthor=L.+A.+Viarengoauthor=M.+Zhong&title=Progress+Towards+the+Broad+Use+of+Non-Peptide+Synthetic+Macrocycles+in+Drug+Discovery&doi=10.1039%2FC7OB00056A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Progress towards the broad use of non-peptide synthetic macrocycles in drug discovery</span></div><div class="casAuthors">Whitty, Adrian; Viarengo, Lauren A.; Zhong, Mengqi</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">7729-7735</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The authors discuss progress towards addressing three key questions pertaining to the design of screening libraries of synthetic nonpeptidic macrocycles (MCs) for drug discovery: What structural and physicochem. properties of MCs maximize the likelihood of achieving strong and specific binding to protein targets.  What features render a protein target suitable for binding MCs, and can this information be used to identify suitable targets for inhibition by MCs.  What properties of synthetic MCs confer good pharmaceutical properties, and particularly good aq. soly. coupled with passive membrane permeability.  The authors addnl. discuss how the criteria that define a meaningful MC screening hit are linked to the size of the screening library and the synthetic methodol. employed in its prepn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeNdUQVdF6FrVg90H21EOLACvtfcHk0lj83Uq3CRK0vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKgsLrO&md5=451ddddc4457d5a2ee84b384aa15508e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1039%2FC7OB00056A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7OB00056A%26sid%3Dliteratum%253Aachs%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DViarengo%26aufirst%3DL.%2BA.%26aulast%3DZhong%26aufirst%3DM.%26atitle%3DProgress%2520Towards%2520the%2520Broad%2520Use%2520of%2520Non-Peptide%2520Synthetic%2520Macrocycles%2520in%2520Drug%2520Discovery%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26issue%3D37%26spage%3D7729%26epage%3D7735%26doi%3D10.1039%2FC7OB00056A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ermert, P.</span></span> <span> </span><span class="NLM_article-title">Design, Properties and Recent Application of Macrocycles in Medicinal Chemistry</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.2533/chimia.2017.678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.2533%2Fchimia.2017.678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29070413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=678-702&issue=10&author=P.+Ermert&title=Design%2C+Properties+and+Recent+Application+of+Macrocycles+in+Medicinal+Chemistry&doi=10.2533%2Fchimia.2017.678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Design, properties and recent application of macrocycles in medicinal chemistry</span></div><div class="casAuthors">Ermert, Philipp</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">678-702</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclic compds. have recently received increasing attention in drug discovery as these compds. offer the potential to modulate difficult targets and to access novel chemotypes.  Approaches towards libraries of macrocyclic compds. based on modular org. synthesis and applications of these technol. platforms to find and improve biol. active compds. are introduced in this minireview.  Alternatively, lead compds. may be obtained by truncation and modification of macrocyclic natural products.  Selected medicinal chem. programs are discussed, illustrating a macrocyclization approach toward ligands with improved properties.  The design of such ligands is often informed by X-ray crystal structures of protein-ligand complexes.  Efforts to understand cellular permeability and oral bioavailability of cyclic peptides and non-peptidic macrocycles are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo_L_ef2BYLrVg90H21EOLACvtfcHk0lj83Uq3CRK0vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFeitbg%253D&md5=aca0ab87a30863de362d9002c3d9f6cc</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2017.678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2017.678%26sid%3Dliteratum%253Aachs%26aulast%3DErmert%26aufirst%3DP.%26atitle%3DDesign%252C%2520Properties%2520and%2520Recent%2520Application%2520of%2520Macrocycles%2520in%2520Medicinal%2520Chemistry%26jtitle%3DChimia%26date%3D2017%26volume%3D71%26issue%3D10%26spage%3D678%26epage%3D702%26doi%3D10.2533%2Fchimia.2017.678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labute, P.</span></span> <span> </span><span class="NLM_article-title">LowModeMD - Implicit Low-Mode Velocity Filtering Applied to Conformational Search of Macrocycles and Protein Loops</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1021/ci900508k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900508k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=792-800&issue=5&author=P.+Labute&title=LowModeMD+-+Implicit+Low-Mode+Velocity+Filtering+Applied+to+Conformational+Search+of+Macrocycles+and+Protein+Loops&doi=10.1021%2Fci900508k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">LowModeMD - Implicit Low-Mode Velocity Filtering Applied to Conformational Search of Macrocycles and Protein Loops</span></div><div class="casAuthors">Labute, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">792-800</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a method for conformational search of complex mol. systems such as macrocycles and protein loops.  The method is based on perturbing an existing conformation along a mol. dynamics trajectory using initial at. velocities with kinetic energy concd. on the low-frequency vibrational modes, followed by energy minimization.  A novel Chebyshev polynomial filter is used to heavily dampen the high-frequency components of a randomly generated Maxwell-Boltzmann velocity vector.  The method is very efficient, even for large systems; it is straightforward to implement and requires only std. force-field energy and gradient evaluations.  The results of several computational expts. suggest that the method is capable of efficiently sampling low-strain energy conformations of complex systems with nontrivial nonbonded interaction networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfWZjZhFqqUbVg90H21EOLACvtfcHk0ljwhJHy5mvkgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSksrk%253D&md5=bb800eb2f9635a661578b978dae9da0a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fci900508k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900508k%26sid%3Dliteratum%253Aachs%26aulast%3DLabute%26aufirst%3DP.%26atitle%3DLowModeMD%2520-%2520Implicit%2520Low-Mode%2520Velocity%2520Filtering%2520Applied%2520to%2520Conformational%2520Search%2520of%2520Macrocycles%2520and%2520Protein%2520Loops%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26issue%3D5%26spage%3D792%26epage%3D800%26doi%3D10.1021%2Fci900508k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamenik, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedl, K. R.</span></span> <span> </span><span class="NLM_article-title">Peptidic Macrocycles - Conformational Sampling and Thermodynamic Characterization</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFantrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=982-992&issue=5&author=A.+S.+Kamenikauthor=U.+Lesselauthor=J.+E.+Fuchsauthor=T.+Foxauthor=K.+R.+Liedl&title=Peptidic+Macrocycles+-+Conformational+Sampling+and+Thermodynamic+Characterization&doi=10.1021%2Facs.jcim.8b00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidic Macrocycles - Conformational Sampling and Thermodynamic Characterization</span></div><div class="casAuthors">Kamenik, Anna S.; Lessel, Uta; Fuchs, Julian E.; Fox, Thomas; Liedl, Klaus R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">982-992</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocycles are of considerable interest as highly specific drug candidates, yet they challenge std. conformer generators with their large no. of rotatable bonds and conformational restrictions.  Here, we present a mol. dynamics-based routine that bypasses current limitations in conformational sampling and extensively profiles the free energy landscape of peptidic macrocycles in soln.  We perform accelerated mol. dynamics simulations to capture a diverse conformational ensemble.  By applying an energetic cutoff, followed by geometric clustering, we demonstrate the striking robustness and efficiency of the approach in identifying highly populated conformational states of cyclic peptides.  The resulting structural and thermodn. information is benchmarked against interproton distances from NMR expts. and conformational states identified by X-ray crystallog.  Using three different model systems of varying size and flexibility, we show that the method reliably reproduces exptl. detd. structural ensembles and is capable of identifying key conformational states that include the bioactive conformation.  Thus, the described approach is a robust method to generate conformations of peptidic macrocycles and holds promise for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFlE0cJ41tmrVg90H21EOLACvtfcHk0ljwhJHy5mvkgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFantrY%253D&md5=4c582a4036f17ac76c05d3e9e8718c02</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00097%26sid%3Dliteratum%253Aachs%26aulast%3DKamenik%26aufirst%3DA.%2BS.%26aulast%3DLessel%26aufirst%3DU.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DFox%26aufirst%3DT.%26aulast%3DLiedl%26aufirst%3DK.%2BR.%26atitle%3DPeptidic%2520Macrocycles%2520-%2520Conformational%2520Sampling%2520and%2520Thermodynamic%2520Characterization%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26issue%3D5%26spage%3D982%26epage%3D992%26doi%3D10.1021%2Facs.jcim.8b00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span>, <span class="NLM_string-name">Mueller, G.</span>, <span class="NLM_string-name">Hamacher, M.</span></span>, Eds. <span> </span><span class="NLM_article-title">Protein Kinases as Drug Targets</span>.  <i>Methods and Principles in Medicinal Chemistry</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim</span>, <span class="NLM_year">2011</span>; Vol.  <span class="NLM_volume">49</span>, 373 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=B.+Klebl&author=G.+Mueller&author=M.+Hamacher&title=Methods+and+Principles+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKlebl%26aufirst%3DB.%26atitle%3DProtein%2520Kinases%2520as%2520Drug%2520Targets%26btitle%3DMethods%2520and%2520Principles%2520in%2520Medicinal%2520Chemistry%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2011%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span> <span> </span><span class="NLM_article-title">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=36-44&issue=1&author=J.+B.+Baellauthor=J.+W.+M.+Nissink&title=Seven+Year+Itch%3A+Pan-Assay+Interference+Compounds+%28PAINS%29+in+2017-Utility+and+Limitations&doi=10.1021%2Facschembio.7b00903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span></div><div class="casAuthors">Baell, Jonathan B.; Nissink, J. Willem M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on all necessary considerations for the appropriate use of PAINs filters formulated to process hundreds and thousands of compds. in seconds, and identify PAINS in order to exclude them from further anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocZ7E_j7zxfbVg90H21EOLACvtfcHk0liCkRJAQ10QiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK&md5=051115704137d6a91b8271702c619682</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00903%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26atitle%3DSeven%2520Year%2520Itch%253A%2520Pan-Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520in%25202017-Utility%2520and%2520Limitations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D36%26epage%3D44%26doi%3D10.1021%2Facschembio.7b00903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0liCkRJAQ10QiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10176</span>– <span class="NLM_lpage">10191</span>, <span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&issue=23&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+Selective+and+Noncovalent+Diaminopyrimidine-Based+Inhibitors+of+Epidermal+Growth+Factor+Receptor+Containing+the+T790M+Resistance+Mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0lgyon8RTIn-8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520Selective%2520and%2520Noncovalent%2520Diaminopyrimidine-Based%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Containing%2520the%2520T790M%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">Pt 2</span>),  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&issue=Pt+2&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lgyon8RTIn-8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3DPt%25202%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 Suite and Current Developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&issue=4&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+Suite+and+Current+Developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lgyon8RTIn-8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520Suite%2520and%2520Current%2520Developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26issue%3D4%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">REFMAC5 Dictionary: Organization of Prior Chemical Knowledge and Guidelines for its Use</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>D60</i></span> (<span class="NLM_issue">12, Pt. 1</span>),  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2195</span>, <span class="refDoi"> DOI: 10.1107/S0907444904023510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1107%2FS0907444904023510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2184-2195&issue=12%2C+Pt.+1&author=A.+A.+Vaginauthor=R.+A.+Steinerauthor=A.+A.+Lebedevauthor=L.+Pottertonauthor=S.+McNicholasauthor=F.+Longauthor=G.+N.+Murshudov&title=REFMAC5+Dictionary%3A+Organization+of+Prior+Chemical+Knowledge+and+Guidelines+for+its+Use&doi=10.1107%2FS0907444904023510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span></div><div class="casAuthors">Vagin, Alexei A.; Steiner, Roberto A.; Lebedev, Andrey A.; Potterton, Liz; McNicholas, Stuart; Long, Fei; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2184-2195</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">One of the most important aspects of macromol. structure refinement is the use of prior chem. knowledge.  Bond lengths, bond angles and other chem. properties are used in restrained refinement as subsidiary conditions.  This contribution describes the organization and some aspects of the use of the flexible and human/machine-readable dictionary of prior chem. knowledge used by the max.-likelihood macromol.-refinement program REFMAC5.  The dictionary stores information about monomers which represent the constitutive building blocks of biol. macromols. (amino acids, nucleic acids and saccharides) and about numerous org./inorg. compds. commonly found in macromol. crystallog.  It also describes the modifications the building blocks undergo as a result of chem. reactions and the links required for polymer formation.  More than 2000 monomer entries, 100 modification entries and 200 link entries are currently available.  Algorithms and tools for updating and adding new entries to the dictionary have also been developed and are presented here.  In many cases, the REFMAC5 dictionary allows entirely automatic generation of restraints within REFMAC5 refinement runs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjDd-k3YHGrVg90H21EOLACvtfcHk0lh1TSqVpJGViA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F&md5=005910422c5fb72fe2434c39b5321bf4</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1107%2FS0907444904023510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904023510%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPotterton%26aufirst%3DL.%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DREFMAC5%2520Dictionary%253A%2520Organization%2520of%2520Prior%2520Chemical%2520Knowledge%2520and%2520Guidelines%2520for%2520its%2520Use%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26issue%3D12%252C%2520Pt.%25201%26spage%3D2184%26epage%3D2195%26doi%3D10.1107%2FS0907444904023510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luippold, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhold, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suessmuth, R. D.</span></span> <span> </span><span class="NLM_article-title">Application of a Rapid and Integrated Analysis System (RIAS) as a High-Throughput Processing Tool For In Vitro ADME Samples by Liquid Chromatography/tandem Mass Spectrometry</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1177/1087057110397358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1177%2F1087057110397358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=21335598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktl2ltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=370-377&issue=3&author=A.+H.+Luippoldauthor=T.+Arnholdauthor=W.+Joergauthor=B.+Kruegerauthor=R.+D.+Suessmuth&title=Application+of+a+Rapid+and+Integrated+Analysis+System+%28RIAS%29+as+a+High-Throughput+Processing+Tool+For+In+Vitro+ADME+Samples+by+Liquid+Chromatography%2Ftandem+Mass+Spectrometry&doi=10.1177%2F1087057110397358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a Rapid and Integrated Analysis System (RIAS) as a high-throughput processing tool for in vitro ADME samples by liquid chromatography/tandem mass spectrometry</span></div><div class="casAuthors">Luippold, Andreas H.; Arnhold, Thomas; Joerg, Wolfgang; Krueger, Beate; Suessmuth, Roderich D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-377</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Over the past decade, drug discovery programs have started to address the optimization of key ADME properties already at an early stage of the process.  Hence, anal. chemists have been confronted with tremendously rising sample nos. and have had to develop methodologies accelerating quant. liq. chromatog./tandem mass spectrometry (LC/MS/MS).  This article focuses on the application of a generic and fully automated LC/MS/MS, named Rapid and Integrated Anal. System (RIAS), as a high-throughput platform for the rapid quantification of drug-like compds. in various in vitro ADME assays.  Previous efforts were dedicated to the setup and feasibility study of a workflow-integrated platform combining a modified high-throughput liq. handling LC/MS/MS system controlled by a customized software interface and a customized data-processing and reporting tool.  Herein the authors present an extension of this previously developed basic application to a broad set of ADME screening campaigns, covering CYP inhibition, Caco-2, and PAMPA assays.  The platform is capable of switching automatically between various ADME assays, performs MS compd. optimization if required, and provides a speed of 8 s from sample to sample, independently of the type of ADME assay.  Quantification and peak review are adopted to the high-throughput environment and tested against a std. HPLC-ESI technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbv6ToQVM4JLVg90H21EOLACvtfcHk0lh1TSqVpJGViA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktl2ltrk%253D&md5=1ba4e5b3957219231afa698a0695e6f5</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1177%2F1087057110397358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110397358%26sid%3Dliteratum%253Aachs%26aulast%3DLuippold%26aufirst%3DA.%2BH.%26aulast%3DArnhold%26aufirst%3DT.%26aulast%3DJoerg%26aufirst%3DW.%26aulast%3DKrueger%26aufirst%3DB.%26aulast%3DSuessmuth%26aufirst%3DR.%2BD.%26atitle%3DApplication%2520of%2520a%2520Rapid%2520and%2520Integrated%2520Analysis%2520System%2520%2528RIAS%2529%2520as%2520a%2520High-Throughput%2520Processing%2520Tool%2520For%2520In%2520Vitro%2520ADME%2520Samples%2520by%2520Liquid%2520Chromatography%252Ftandem%2520Mass%2520Spectrometry%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2011%26volume%3D16%26issue%3D3%26spage%3D370%26epage%3D377%26doi%3D10.1177%2F1087057110397358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':[],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jennifer Alisa Amrhein, Stefan Knapp, <span class="NLM_string-name hlFld-ContribAuthor">Thomas Hanke</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7991-8009. <a href="https://doi.org/10.1021/acs.jmedchem.1c00217" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00217%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BOpportunities%252Band%252BChallenges%252Bfor%252BMacrocyclic%252BKinase%252BInhibitors%26aulast%3DAmrhein%26aufirst%3DJennifer%2BAlisa%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04022021%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7991%26epage%3D8009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tao Yang, Mengshi Hu, Yong Chen, Mingli Xiang, Minghai Tang, Wenyan Qi, Mingsong Shi, Jun He, Xue Yuan, Chufeng Zhang, Kongjun Liu, Jiewen Li, Zhuang Yang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14921-14936. <a href="https://doi.org/10.1021/acs.jmedchem.0c01488" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01488%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-%252528Pyrimidin-2-yl%252529-1%25252C2%25252C3%25252C4-tetrahydroisoquinolin-6-amine%252BDerivatives%252Bas%252BSelective%252BJanus%252BKinase%252B2%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BMyeloproliferative%252BNeoplasms%26aulast%3DYang%26aufirst%3DTao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26082020%26date%3D30112020%26volume%3D63%26issue%3D23%26spage%3D14921%26epage%3D14936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anna S. Kamenik, Johannes Kraml, Florian Hofer, Franz Waibl, Patrick K. Quoika, Ursula Kahler, Michael Schauperl, <span class="NLM_string-name hlFld-ContribAuthor">Klaus R. Liedl</span>. </span><span class="cited-content_cbyCitation_article-title">Macrocycle Cell Permeability Measured by Solvation Free Energies in Polar and Apolar Environments. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (7)
                                     , 3508-3517. <a href="https://doi.org/10.1021/acs.jcim.0c00280" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00280%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMacrocycle%252BCell%252BPermeability%252BMeasured%252Bby%252BSolvation%252BFree%252BEnergies%252Bin%252BPolar%252Band%252BApolar%252BEnvironments%26aulast%3DKamenik%26aufirst%3DAnna%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19032020%26date%3D29062020%26date%3D18062020%26volume%3D60%26issue%3D7%26spage%3D3508%26epage%3D3517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David E. Heppner, Marcel Günther, Florian Wittlinger, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Eck</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4293-4305. <a href="https://doi.org/10.1021/acs.jmedchem.0c00200" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BEGFR%252BMutant%252BInhibition%252Bby%252BTrisubstituted%252BImidazole%252BInhibitors%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ibrahim  Abdelbaky</span>, <span class="hlFld-ContribAuthor ">Hilal  Tayara</span>, <span class="hlFld-ContribAuthor ">Kil To  Chong</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of kinase inhibitors binding modes with machine learning and reduced descriptor sets. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-80758-4" title="DOI URL">https://doi.org/10.1038/s41598-020-80758-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-80758-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-80758-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DPrediction%252Bof%252Bkinase%252Binhibitors%252Bbinding%252Bmodes%252Bwith%252Bmachine%252Blearning%252Band%252Breduced%252Bdescriptor%252Bsets%26aulast%3DAbdelbaky%26aufirst%3DIbrahim%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114643. <a href="https://doi.org/10.1016/j.bcp.2021.114643" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114643%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFighting%252Btertiary%252Bmutations%252Bin%252BEGFR-driven%252Blung-cancers%25253A%252BCurrent%252Badvances%252Band%252Bfuture%252Bperspectives%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DScalvini%26aufirst%3DLaura%26date%3D2021%26volume%3D190%26spage%3D114643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>. </span><span class="cited-content_cbyCitation_article-title">A structural perspective on targeting the
              RTK
              /Ras/
              MAP
              kinase pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2021,</strong> <em>30 </em>
                                    (8)
                                     , 1535-1553. <a href="https://doi.org/10.1002/pro.4125" title="DOI URL">https://doi.org/10.1002/pro.4125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.4125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.4125%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DA%252Bstructural%252Bperspective%252Bon%252Btargeting%252Bthe%252BRTK%252B%25252FRas%25252F%252BMAP%252Bkinase%252Bpathway%252Bin%252Bcancer%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D8%26spage%3D1535%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui-Fang  Dong</span>, <span class="hlFld-ContribAuthor ">Miao-Lin  Zhu</span>, <span class="hlFld-ContribAuthor ">Ming-Ming  Liu</span>, <span class="hlFld-ContribAuthor ">Yi-Ting  Xu</span>, <span class="hlFld-ContribAuthor ">Liu-Liu  Yuan</span>, <span class="hlFld-ContribAuthor ">Jing  Bian</span>, <span class="hlFld-ContribAuthor ">Yuan-Zheng  Xia</span>, <span class="hlFld-ContribAuthor ">Ling-Yi  Kong</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>167 </em>, 105583. <a href="https://doi.org/10.1016/j.phrs.2021.105583" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105583%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DEGFR%252Bmutation%252Bmediates%252Bresistance%252Bto%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bin%252BNSCLC%25253A%252BFrom%252Bmolecular%252Bmechanisms%252Bto%252Bclinical%252Bresearch%26aulast%3DDong%26aufirst%3DRui-Fang%26date%3D2021%26volume%3D167%26spage%3D105583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdulmalik S.  Altamimi</span>, <span class="hlFld-ContribAuthor ">Adel S.  El-Azab</span>, <span class="hlFld-ContribAuthor ">Sami G.  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Mubarak A.  Alamri</span>, <span class="hlFld-ContribAuthor ">Ashraf H.  Bayoumi</span>, <span class="hlFld-ContribAuthor ">Safar M.  Alqahtani</span>, <span class="hlFld-ContribAuthor ">Alhumaidi B.  Alabbas</span>, <span class="hlFld-ContribAuthor ">Ali I.  Altharawi</span>, <span class="hlFld-ContribAuthor ">Manal A.  Alossaimi</span>, <span class="hlFld-ContribAuthor ">Menshawy A.  Mohamed</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (10)
                                     , 2992. <a href="https://doi.org/10.3390/molecules26102992" title="DOI URL">https://doi.org/10.3390/molecules26102992</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26102992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26102992%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%25252C%252BAnticancer%252BScreening%252Bof%252BSome%252BNovel%252BTrimethoxy%252BQuinazolines%252Band%252BVEGFR2%25252C%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%252BAssay%25253B%252BMolecular%252BDocking%252BStudies%26aulast%3DAltamimi%26aufirst%3DAbdulmalik%2BS.%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D10%26spage%3D2992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean T  Toenjes</span>, <span class="hlFld-ContribAuthor ">Mariam  Basilaia</span>, <span class="hlFld-ContribAuthor ">Jeffrey L  Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging conformational control about a potential atropisomeric axis as a strategy in medical chemistry. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 443-446. <a href="https://doi.org/10.4155/fmc-2020-0348" title="DOI URL">https://doi.org/10.4155/fmc-2020-0348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0348%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DLeveraging%252Bconformational%252Bcontrol%252Babout%252Ba%252Bpotential%252Batropisomeric%252Baxis%252Bas%252Ba%252Bstrategy%252Bin%252Bmedical%252Bchemistry%26aulast%3DToenjes%26aufirst%3DSean%2BT%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D443%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parameshwara Chary  Jilloju</span>, <span class="hlFld-ContribAuthor ">Perugu  Shyam</span>, <span class="hlFld-ContribAuthor ">Ananthula  Sanjeev</span>, <span class="hlFld-ContribAuthor ">Rajeswar Rao  Vedula</span>. </span><span class="cited-content_cbyCitation_article-title">Four-component, one–pot synthesis of (E)-N-benzylidene-3-(benzylthio)-5-(3,5-dimethyl-1H-pyrazol-1-yl)-4H-1,2,4-triazol-4-amines and their DNA binding and molecular docking studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1225 </em>, 129140. <a href="https://doi.org/10.1016/j.molstruc.2020.129140" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.129140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.129140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.129140%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DFour-component%25252C%252Bone%2525E2%252580%252593pot%252Bsynthesis%252Bof%252B%252528E%252529-N-benzylidene-3-%252528benzylthio%252529-5-%2525283%25252C5-dimethyl-1H-pyrazol-1-yl%252529-4H-1%25252C2%25252C4-triazol-4-amines%252Band%252Btheir%252BDNA%252Bbinding%252Band%252Bmolecular%252Bdocking%252Bstudies%26aulast%3DJilloju%26aufirst%3DParameshwara%2BChary%26date%3D2021%26volume%3D1225%26spage%3D129140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannah L.  Tumbrink</span>, <span class="hlFld-ContribAuthor ">Alena  Heimsoeth</span>, <span class="hlFld-ContribAuthor ">Martin L.  Sos</span>. </span><span class="cited-content_cbyCitation_article-title">The next tier of EGFR resistance mutations in lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2021,</strong> <em>40 </em>
                                    (1)
                                     , 1-11. <a href="https://doi.org/10.1038/s41388-020-01510-w" title="DOI URL">https://doi.org/10.1038/s41388-020-01510-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-020-01510-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-020-01510-w%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DThe%252Bnext%252Btier%252Bof%252BEGFR%252Bresistance%252Bmutations%252Bin%252Blung%252Bcancer%26aulast%3DTumbrink%26aufirst%3DHannah%2BL.%26date%3D2021%26date%3D2020%26volume%3D40%26issue%3D1%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112995. <a href="https://doi.org/10.1016/j.ejmech.2020.112995" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112995%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bnew%252Bopportunities%252Bin%252Bmedicinal%252Bchemistry%252Bof%252Bfourth-generation%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BC797S%252Bmutation%26aulast%3DHe%26aufirst%3DJie%26date%3D2021%26volume%3D210%26spage%3D112995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenji  Kashima</span>, <span class="hlFld-ContribAuthor ">Hiroki  Kawauchi</span>, <span class="hlFld-ContribAuthor ">Hiromi  Tanimura</span>, <span class="hlFld-ContribAuthor ">Yukako  Tachibana</span>, <span class="hlFld-ContribAuthor ">Takashi  Chiba</span>, <span class="hlFld-ContribAuthor ">Takuya  Torizawa</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Sakamoto</span>. </span><span class="cited-content_cbyCitation_article-title">CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (11)
                                     , 2288-2297. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0229" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0229%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DCH7233163%252BOvercomes%252BOsimertinib-Resistant%252BEGFR-Del19%25252FT790M%25252FC797S%252BMutation%26aulast%3DKashima%26aufirst%3DKenji%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D11%26spage%3D2288%26epage%3D2297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maximilian J.  Hochmair</span>, <span class="hlFld-ContribAuthor ">Hannah  Fabikan</span>, <span class="hlFld-ContribAuthor ">Oliver  Illini</span>, <span class="hlFld-ContribAuthor ">Christoph  Weinlinger</span>, <span class="hlFld-ContribAuthor ">Ulrike  Setinek</span>, <span class="hlFld-ContribAuthor ">Dagmar  Krenbek</span>, <span class="hlFld-ContribAuthor ">Helmut  Prosch</span>, <span class="hlFld-ContribAuthor ">Markus  Rauter</span>, <span class="hlFld-ContribAuthor ">Michael  Schumacher</span>, <span class="hlFld-ContribAuthor ">Ewald  Wöll</span>, <span class="hlFld-ContribAuthor ">Romana  Wass</span>, <span class="hlFld-ContribAuthor ">Elmar  Brehm</span>, <span class="hlFld-ContribAuthor ">Gudrun  Absenger</span>, <span class="hlFld-ContribAuthor ">Tatjana  Bundalo</span>, <span class="hlFld-ContribAuthor ">Peter  Errhalt</span>, <span class="hlFld-ContribAuthor ">Matthias  Urban</span>, <span class="hlFld-ContribAuthor ">Arschang  Valipour</span>. </span><span class="cited-content_cbyCitation_article-title">Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (11)
                                     , 371. <a href="https://doi.org/10.3390/ph13110371" title="DOI URL">https://doi.org/10.3390/ph13110371</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13110371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13110371%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DLater-Line%252BTreatment%252Bwith%252BLorlatinib%252Bin%252BALK-%252Band%252BROS1-Rearrangement-Positive%252BNSCLC%25253A%252BA%252BRetrospective%25252C%252BMulticenter%252BAnalysis%26aulast%3DHochmair%26aufirst%3DMaximilian%2BJ.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D11%26spage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Min  Liu</span>, <span class="hlFld-ContribAuthor ">Chun-Nan  Kuo</span>, <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (5)
                                     , 351-373. <a href="https://doi.org/10.1080/13543776.2020.1738389" title="DOI URL">https://doi.org/10.1080/13543776.2020.1738389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1738389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1738389%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAnaplastic%252Blymphoma%252Bkinase%252Binhibitors%25253A%252Ban%252Bupdated%252Bpatent%252Breview%252B%2525282014%2525E2%252580%2525932018%252529%26aulast%3DLiu%26aufirst%3DYi-Min%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D5%26spage%3D351%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Fang  Xu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of selective degraders of EGFRL858R/T790M mutant. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112199. <a href="https://doi.org/10.1016/j.ejmech.2020.112199" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112199%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bselective%252Bdegraders%252Bof%252BEGFRL858R%25252FT790M%252Bmutant%26aulast%3DZhang%26aufirst%3DXin%26date%3D2020%26volume%3D192%26spage%3D112199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Overview of selected approved first, second, and third generation EGFR TKIs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overview of selected published EGFR inhibitors with inhibition data (<b>R1</b> = <b>31b</b>;<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a><b>R2</b> = <b>JND3229</b>;<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><b>R3</b> = <b>B30</b>;<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><b>R4</b> = <b>42</b>;<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a><b>R5</b> = <b>21</b>;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and <b>R6</b> = <b>19</b><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>). Compound <b>1</b> serves as a starting point for this work, and <b>BI-4020</b> demonstrates the superiority of the compounds reported by this work as compared to state of the art.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of ligand <b>1</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a>) bound to the ATP pocket of the EGFR<sup>L858R T790M</sup> protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. QM-torsion angle scans for compounds <b>1</b>, <b>3</b>, <b>3a</b>, <b>4</b>, and <b>5</b>. The baseline energy is set for each compound individually (to zero), and not deducted from the lowest energy of all compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray structure of compound <b>5</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9C">6S9C</a>) in complex with EGFR<sup>L858R T790M</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Two-Dimensional Representation of the Most Prevalent Conformations of Ligand <b>5</b> As Computationally Predicted and Detected in Solution by 2D-NMR<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Important ROE-correlations are displayed as arrows.</p></p></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Overlay of X-ray-based structure of compound <b>5</b> (orange) and calculated minimum conformation structure of macrocyclic ligand <b>6</b> (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. X-ray structure of compound <b>6</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D">6S9D</a>) in complex with EGFR<sup>L85R T790M</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Two calculated enantiotopic minimum energy conformations of compound <b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structure of <b>9Br</b> and comparison of small compound X-ray structure of <b>9Br</b> (brown, CCDC 1941612) with the calculated minimum energy conformation of <b>9</b> (cyan).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. In vivo biomarker modulation by macrocycle <b>BI-4020</b>; <i>x</i>-axis, time point of biomarker analysis after treatment with vehicle (control) or with 10 mg/kg <b>BI-4020</b> p.o.; <i>y</i>-axis, ratio of p-EGFR signal versus EGFR total signal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Xenograft model with PC-9 cells bearing a EGFR<sup>del19 T790M C797S</sup> protein; control group, 10 animals; treatment groups, 8 animals; animal type and strain, 6–8 week old, female BomTac:NMRI-Foxn1<sup>nu</sup> mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>1</b>–<b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd dppf, Cs<sub>2</sub>CO<sub>3</sub>, DME, water, 90 °C; 16 h; (ii) LiOH, THF, MeOH, 20 °C, 2 h; (iii) HATU, DIPEA, dioxane, 60 °C, 12 h.</p></p></figure><figure data-id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>6</b>–<b>9Br</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) DMF, K<sub>2</sub>CO<sub>3</sub>, 60°C, 16 h; (ii) Pt and V/C, 3 bar H<sub>2</sub>, MeOH, 20°C, 16 h; (iii) CN–Br, CH<sub>2</sub>Cl<sub>2</sub>, <i>t</i>-BuOH, 20°C, 18 h; (iv) ACN, K<sub>2</sub>CO<sub>3</sub>, reflux, 16 h; (v) ACN, K<sub>2</sub>CO<sub>3</sub>, 110 °C (MW), 16 h; (vi) NaOH, THF, water, 20 °C, 1 h; (vii) TBTU, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 20°C, 30 min; (viii) ACN, K<sub>2</sub>CO<sub>3</sub>, reflux, 16 h; (ix) HATU, EtNi–Pr<sub>2</sub>, dioxane, 20°C, 16 h; (x) HCl in dioxane, EtOH, 20 °C, 16 h; (xi) PPh<sub>3</sub>, DIAD, THF, 20 °C, 30 min.</p></p></figure><figure data-id="sch4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>9</b> and <b>BI-4020</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd/C, H<sub>2</sub>, MeOH, 20 °C, 4 h; (ii) Pd(OAc)<sub>2</sub>, di(1-adamantyl)-<i>n</i>-butylphosphine, TMEDA, H<sub>2</sub>/CO, dioxane, 100 °C, 24 h; (iii) NaBH(OAc)<sub>3</sub>, HOAc, CH<sub>2</sub>Cl<sub>2</sub>, 20 °C, 6 h.</p></p></figure><figure data-id="sch5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>16a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) PdCl<sub>2</sub>DPPF, anisole, Na<sub>2</sub>CO<sub>3</sub>, 130 °C, 16 h; (ii) PdCl<sub>2</sub>DPPF, dioxane, K<sub>2</sub>CO<sub>3</sub>, 90 °C, 16 h; (iii) (1,5-cyclooctadiene)(methoxy)iridium(I) dimer, 4,4′-di-<i>tert</i>-butyl-2,2′-bipyridyl, 20 °C, 90 h; (iv) PdCl<sub>2</sub>DPPF, dioxane, K<sub>2</sub>CO<sub>3</sub>, 90 °C, 1 h; (v) Pd/C, 5 bar H<sub>2</sub>, MeOH, 20 °C, 16 h.</p></p></figure><figure data-id="sch6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compound <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) SEM-Cl, K<sub>2</sub>CO<sub>3</sub>, ACN, 20 °C, 14 h; (ii) NIS, ACN, 0–20 °C, 2 h; (iii) (1,5-cyclooctadiene)(methoxy)iridium(I) dimer, 4,4′-di-<i>tert</i>-butyl-2,2′-bipyridyl, 20 °C, 66 h; (iv) tris(dibenzylideneacetone)dipalladium, di(1-adamantyl)-<i>n</i>-butylphosphine, Cs<sub>2</sub>CO<sub>3</sub>, toluene, water, 50 °C, 2 h; (v) trimethylboroxine, tris(dibenzylideneacetone)dipalladium, di(1-adamantyl)-<i>n</i>-butylphosphine, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C, 18 h; (vi) NaOH, THF, 20 °C, 1 h.</p></p></figure><figure data-id="sch7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/medium/jm9b01169_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compound <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-22/acs.jmedchem.9b01169/20191122/images/large/jm9b01169_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01169&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, DMF, 20 °C, 24 h; (ii) MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 1 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 65 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R. J.</span></span> <span> </span><span class="NLM_article-title">There are 49 FDA-Approved Small Molecule Protein Kinase Inhibitors as of 12 April</span> <span class="NLM_year">2019</span>. <a href="http://www.brimr.org/PKI/PKIs.htm" class="extLink">http://www.brimr.org/PKI/PKIs.htm</a> (accessed May 3, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+J.+Roskoski&title=There+are+49+FDA-Approved+Small+Molecule+Protein+Kinase+Inhibitors+as+of+12+April"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%2BJ.%26atitle%3DThere%2520are%252049%2520FDA-Approved%2520Small%2520Molecule%2520Protein%2520Kinase%2520Inhibitors%2520as%2520of%252012%2520April%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span> <span> </span><span class="NLM_article-title">Measuring and Interpreting the Selectivity of Protein Kinase Inhibitors</span>. <i>Journal of chemical biology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1007/s12154-009-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1007%2Fs12154-009-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=19568781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=131-151&issue=3&author=L.+A.+Smythauthor=I.+Collins&title=Measuring+and+Interpreting+the+Selectivity+of+Protein+Kinase+Inhibitors&doi=10.1007%2Fs12154-009-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring and interpreting the selectivity of protein kinase inhibitors</span></div><div class="casAuthors">Smyth Lynette A; Collins Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-51</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly for the treatment of cancer.  Achieving inhibitor selectivity for particular protein kinases often remains a significant challenge in the development of new small molecules as drugs or as tools for chemical biology research.  This review summarises the methodologies available for measuring kinase inhibitor selectivity, both in vitro and in cells.  The interpretation of kinase inhibitor selectivity data is discussed, particularly with reference to the structural biology of the protein targets.  Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzU9rA5WZcz9FxYDaSSP8XfW6udTcc2eYIhfydeO-wYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D&md5=f78ff1202a949a71ffd65e804298c37f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs12154-009-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-009-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DL.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMeasuring%2520and%2520Interpreting%2520the%2520Selectivity%2520of%2520Protein%2520Kinase%2520Inhibitors%26jtitle%3DJournal%2520of%2520chemical%2520biology%26date%3D2009%26volume%3D2%26issue%3D3%26spage%3D131%26epage%3D151%26doi%3D10.1007%2Fs12154-009-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anastassiadis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deacon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1039</span>, <span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039&issue=11&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+Assay+of+Kinase+Catalytic+Activity+Reveals+Features+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0lhW51RohYEURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520Assay%2520of%2520Kinase%2520Catalytic%2520Activity%2520Reveals%2520Features%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26issue%3D11%26spage%3D1039%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. J.</span></span> <span> </span><span class="NLM_article-title">Osimertinib Resistance in Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.canlet.2018.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29425688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2018&pages=242-246&author=Z.+H.+Tangauthor=J.+J.+Lu&title=Osimertinib+Resistance+in+Non-Small+Cell+Lung+Cancer%3A+Mechanisms+and+Therapeutic+Strategies&doi=10.1016%2Fj.canlet.2018.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies</span></div><div class="casAuthors">Tang, Zheng-Hai; Lu, Jin-Jian</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">242-246</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Given the successful identification of epidermal growth factor receptor EGFR T790M, the third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (OSI, AZD9291), was developed to target EGFR T790M mutation.  OSI was approved for the treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.  However, the disease would progress after the patient received OSI treatment for approx. 10 mo.  Resistance mechanisms to OSI, such as addnl. mutation of EGFR and alternative kinase activation, were recently identified, and some novel therapeutic strategies were proposed to overcome OSI resistance.  In this review, the resistance mechanisms and therapeutic strategies for OSI-resistant NSCLC were summarized to direct further use of OSI and aid in the development of novel drugs or strategies for OSI-resistant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MEZOSD4CQrVg90H21EOLACvtfcHk0lhW51RohYEURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtFalt74%253D&md5=a2f1d0d576a24d137bd23584f40df973</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DZ.%2BH.%26aulast%3DLu%26aufirst%3DJ.%2BJ.%26atitle%3DOsimertinib%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Mechanisms%2520and%2520Therapeutic%2520Strategies%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D420%26spage%3D242%26epage%3D246%26doi%3D10.1016%2Fj.canlet.2018.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricordel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friboulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790M-Mutant Lung Cancer</span>. <i>Annals of Oncology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>, <span class="NLM_elocation-id">i28-i37</span> <span class="refDoi"> DOI: 10.1093/annonc/mdx705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1093%2Fannonc%2Fmdx705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29462256" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&author=C.+Ricordelauthor=L.+Fribouletauthor=F.+Facchinettiauthor=J.+C.+Soria&title=Molecular+Mechanisms+of+Acquired+Resistance+to+Third-Generation+EGFR-TKIs+in+EGFR+T790M-Mutant+Lung+Cancer&doi=10.1093%2Fannonc%2Fmdx705"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx705%26sid%3Dliteratum%253Aachs%26aulast%3DRicordel%26aufirst%3DC.%26aulast%3DFriboulet%26aufirst%3DL.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Acquired%2520Resistance%2520to%2520Third-Generation%2520EGFR-TKIs%2520in%2520EGFR%2520T790M-Mutant%2520Lung%2520Cancer%26jtitle%3DAnnals%2520of%2520Oncology%26date%3D2018%26volume%3D29%26doi%3D10.1093%2Fannonc%2Fmdx705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1002/anie.201710398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1002%2Fanie.201710398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2307-2313&issue=9&author=J.+Lategahnauthor=M.+Keulauthor=D.+Rauh&title=Lessons+to+be+Learned%3A+The+Molecular+Basis+of+Kinase-Targeted+Therapies+and+Drug+Resistance+in+Non-Small+Cell+Lung+Cancer&doi=10.1002%2Fanie.201710398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2313</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The treatment of non-small cell lung cancer (NSCLC) is currently experiencing a revolution.  Over the last decade, the knowledge gained about the biochem. features of biomarkers and their predictive abilities has led to the development of targeted small-mol. inhibitors that present an alternative to harsh chemotherapy.  The use of these new therapies has improved the quality of life and increased the survival of patients.  The occurrence of inevitable drug resistance requires the const. development of precision medicine.  The detailed understanding of the target biol. and the search for innovative chem. approaches has encouraged investigations in this field.  Herein, the authors review selected aspects of the mol. targets and present an overview of current topics and challenges in the rational development of small mols. to target NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowadpmmNyvGbVg90H21EOLACvtfcHk0lhW51RohYEURw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D&md5=78d3ce523d076c820cb7fcbf9a321e63</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710398%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DLessons%2520to%2520be%2520Learned%253A%2520The%2520Molecular%2520Basis%2520of%2520Kinase-Targeted%2520Therapies%2520and%2520Drug%2520Resistance%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26issue%3D9%26spage%3D2307%26epage%3D2313%26doi%3D10.1002%2Fanie.201710398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into Drug Development Strategy Targeting EGFR T790M/C797S</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">13652</span>– <span class="NLM_lpage">13665</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.24113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.18632%2Foncotarget.24113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29568384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=13652-13665&issue=17&author=S.+J.+Zhuauthor=P.+Zhaoauthor=J.+Yangauthor=R.+Maauthor=X.+E.+Yanauthor=S.+Y.+Yangauthor=J.+W.+Yangauthor=C.+H.+Yun&title=Structural+Insights+into+Drug+Development+Strategy+Targeting+EGFR+T790M%2FC797S&doi=10.18632%2Foncotarget.24113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into drug development strategy targeting EGFR T790M/C797S</span></div><div class="casAuthors">Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Yang Jiao; Yang Sheng-Yong; Yang Jing-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">13652-13665</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation.  Though WZ4002/CO-1686/AZD9291 are effective in overcoming EGFR T790M by targeting Cys797 via covalent bonding, their efficacy is again limited due to the emergence of C797S mutation.  New agents effectively inhibiting EGFR T790M without covalent linkage through Cys 797 may solve this problem.  We presented here crystal structures of EGFR activating/drug-resistant mutants in complex with a panel of reversible inhibitors along with mutagenesis and enzyme kinetic data.  These data revealed a previously un-described hydrophobic clamp structure in the EGFR kinase which may be exploited to facilitate development of next generation drugs targeting EGFR T790M with or without concomitant C797S.  Interestingly, mutations in the hydrophobic clamp that hinder drug binding often also weaken ATP binding and/or abolish kinase activity, thus do not readily result in resistance to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRatiF0vPAX33ELvajU9pjPfW6udTcc2ebHBz2sIUBf-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D&md5=7502a50efce99f712a54003680a95bde</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24113%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520Insights%2520into%2520Drug%2520Development%2520Strategy%2520Targeting%2520EGFR%2520T790M%252FC797S%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26issue%3D17%26spage%3D13652%26epage%3D13665%26doi%3D10.18632%2Foncotarget.24113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikolajczyk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepetov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Haj Zen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourches, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tropsha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teicher, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Characterization of the Published Kinase Inhibitor Set</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1038/nbt.3374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnbt.3374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26501955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=95-103&issue=1&author=J.+M.+Elkinsauthor=V.+Fedeleauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=E.+Salahauthor=J.+Mikolajczykauthor=S.+Romanovauthor=N.+Sepetovauthor=X.-P.+Huangauthor=B.+L.+Rothauthor=A.+Al+Haj+Zenauthor=D.+Fourchesauthor=E.+Muratovauthor=A.+Tropshaauthor=J.+Morrisauthor=B.+A.+Teicherauthor=M.+Kunkelauthor=E.+Polleyauthor=K.+E.+Lackeyauthor=F.+L.+Atkinsonauthor=J.+P.+Overingtonauthor=P.+Bamboroughauthor=S.+Mullerauthor=D.+J.+Priceauthor=T.+M.+Willsonauthor=D.+H.+Drewryauthor=S.+Knappauthor=W.+J.+Zuercher&title=Comprehensive+Characterization+of+the+Published+Kinase+Inhibitor+Set&doi=10.1038%2Fnbt.3374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive characterization of the Published Kinase Inhibitor Set</span></div><div class="casAuthors">Elkins, Jonathan M.; Fedele, Vita; Szklarz, Marta; Abdul Azeez, Kamal R.; Salah, Eidarus; Mikolajczyk, Jowita; Romanov, Sergei; Sepetov, Nikolai; Huang, Xi-Ping; Roth, Bryan L.; Al Haj Zen, Ayman; Fourches, Denis; Muratov, Eugene; Tropsha, Alex; Morris, Joel; Teicher, Beverly A.; Kunkel, Mark; Polley, Eric; Lackey, Karen E.; Atkinson, Francis L.; Overington, John P.; Bamborough, Paul; Muller, Susanne; Price, Daniel J.; Willson, Timothy M.; Drewry, David H.; Knapp, Stefan; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the success of protein kinase inhibitors as approved therapeutics, drug discovery has focused on a small subset of kinase targets.  Here we provide a thorough characterization of the Published Kinase Inhibitor Set (PKIS), a set of 367 small-mol. ATP-competitive kinase inhibitors that was recently made freely available with the aim of expanding research in this field and as an expt. in open-source target validation.  We screen the set in activity assays with 224 recombinant kinases and 24 G protein-coupled receptors and in cellular assays of cancer cell proliferation and angiogenesis.  We identify chem. starting points for designing new chem. probes of orphan kinases and illustrate the utility of these leads by developing a selective inhibitor for the previously untargeted kinases LOK and SLK.  Our cellular screens reveal compds. that modulate cancer cell growth and angiogenesis in vitro.  These reagents and assocd. data illustrate an efficient way forward to increasing understanding of the historically untargeted kinome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4P1WN3gdiXbVg90H21EOLACvtfcHk0liS2FJG6zwGQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslantL%252FM&md5=3f15096e79632dbaaadf4460a6848e60</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3374%26sid%3Dliteratum%253Aachs%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFedele%26aufirst%3DV.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DSalah%26aufirst%3DE.%26aulast%3DMikolajczyk%26aufirst%3DJ.%26aulast%3DRomanov%26aufirst%3DS.%26aulast%3DSepetov%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAl%2BHaj%2BZen%26aufirst%3DA.%26aulast%3DFourches%26aufirst%3DD.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DTropsha%26aufirst%3DA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DKunkel%26aufirst%3DM.%26aulast%3DPolley%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26aulast%3DAtkinson%26aufirst%3DF.%2BL.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DPrice%26aufirst%3DD.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DComprehensive%2520Characterization%2520of%2520the%2520Published%2520Kinase%2520Inhibitor%2520Set%26jtitle%3DNat.%2520Biotechnol.%26date%3D2016%26volume%3D34%26issue%3D1%26spage%3D95%26epage%3D103%26doi%3D10.1038%2Fnbt.3374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luecking, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span> <span> </span><span class="NLM_article-title">Progress Towards a Public Chemogenomic Set for Protein Kinases and a Call for Contributions</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0181585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1371%2Fjournal.pone.0181585" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1-21&author=D.+H.+Drewryauthor=C.+I.+Wellsauthor=D.+M.+Andrewsauthor=R.+Angellauthor=H.+Al-Aliauthor=A.+D.+Axtmanauthor=S.+J.+Capuzziauthor=J.+M.+Elkinsauthor=P.+Ettmayerauthor=M.+Frederiksenauthor=O.+Gileadiauthor=N.+Grayauthor=A.+Hooperauthor=S.+Knappauthor=S.+Lauferauthor=U.+Lueckingauthor=S.+Muellerauthor=E.+Muratovauthor=R.+A.+Dennyauthor=K.+S.+Saikatenduauthor=D.+K.+Treiberauthor=W.+J.+Zuercherauthor=T.+M.+Willson&title=Progress+Towards+a+Public+Chemogenomic+Set+for+Protein+Kinases+and+a+Call+for+Contributions&doi=10.1371%2Fjournal.pone.0181585"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181585%26sid%3Dliteratum%253Aachs%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DAngell%26aufirst%3DR.%26aulast%3DAl-Ali%26aufirst%3DH.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26aulast%3DCapuzzi%26aufirst%3DS.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFrederiksen%26aufirst%3DM.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DHooper%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLaufer%26aufirst%3DS.%26aulast%3DLuecking%26aufirst%3DU.%26aulast%3DMueller%26aufirst%3DS.%26aulast%3DMuratov%26aufirst%3DE.%26aulast%3DDenny%26aufirst%3DR.%2BA.%26aulast%3DSaikatendu%26aufirst%3DK.%2BS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26atitle%3DProgress%2520Towards%2520a%2520Public%2520Chemogenomic%2520Set%2520for%2520Protein%2520Kinases%2520and%2520a%2520Call%2520for%2520Contributions%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3D1%26epage%3D21%26doi%3D10.1371%2Fjournal.pone.0181585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Driggers, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span> <span> </span><span class="NLM_article-title">The Exploration of Macrocycles for Drug Discovery - An Underexploited Structural Class</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1038/nrd2590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnrd2590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=18591981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=608-624&issue=7&author=E.+M.+Driggersauthor=S.+P.+Haleauthor=J.+Leeauthor=N.+K.+Terrett&title=The+Exploration+of+Macrocycles+for+Drug+Discovery+-+An+Underexploited+Structural+Class&doi=10.1038%2Fnrd2590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The exploration of macrocycles for drug discovery - an underexploited structural class</span></div><div class="casAuthors">Driggers, Edward M.; Hale, Stephen P.; Lee, Jinbo; Terrett, Nicholas K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">608-624</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products comprised of a macrocycle ring structure have proven their therapeutic applications as antibiotics, immunosuppressants as well as anticancer agents.  Despite this, macrocyclic compds. remain under-explored.  Terrett and colleagues review the properties and features of current macrocycle drugs, emphasizing the vast potential of synthetic macrocycles in drug discovery.  Macrocyclic natural products have evolved to fulfil numerous biochem. functions, and their profound pharmacol. properties have led to their development as drugs.  A macrocycle provides diverse functionality and stereochem. complexity in a conformationally pre-organized ring structure.  This can result in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular locations.  Despite these valuable characteristics, and the proven success of more than 100 marketed macrocycle drugs derived from natural products, this structural class has been poorly explored within drug discovery.  This is in part due to concerns about synthetic intractability and non-drug-like properties.  This Review describes the growing body of data in favor of macrocyclic therapeutics, and demonstrates that this class of compds. can be both fully drug-like in its properties and readily prepd. owing to recent advances in synthetic medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDtW8LpE4ru7Vg90H21EOLACvtfcHk0lgQNMbwyVxa0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFShsbc%253D&md5=16e091818053e5b163b81078a8d03094</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd2590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2590%26sid%3Dliteratum%253Aachs%26aulast%3DDriggers%26aufirst%3DE.%2BM.%26aulast%3DHale%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26atitle%3DThe%2520Exploration%2520of%2520Macrocycles%2520for%2520Drug%2520Discovery%2520-%2520An%2520Underexploited%2520Structural%2520Class%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26issue%3D7%26spage%3D608%26epage%3D624%26doi%3D10.1038%2Fnrd2590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingardo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4720</span>– <span class="NLM_lpage">4744</span>, <span class="refDoi"> DOI: 10.1021/jm500261q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500261q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4720-4744&issue=11&author=T.+W.+Johnsonauthor=P.+F.+Richardsonauthor=S.+Baileyauthor=A.+Broounauthor=B.+J.+Burkeauthor=M.+R.+Collinsauthor=J.+J.+Cuiauthor=J.+G.+Dealauthor=Y.-L.+Dengauthor=D.+Dinhauthor=L.+D.+Engstromauthor=M.+Heauthor=J.+Hoffmanauthor=R.+L.+Hoffmanauthor=Q.+Huangauthor=R.+S.+Kaniaauthor=J.+C.+Kathauthor=H.+Lamauthor=J.+L.+Lamauthor=P.+T.+Leauthor=L.+Lingardoauthor=W.+Liuauthor=M.+McTigueauthor=C.+L.+Palmerauthor=N.+W.+Sachauthor=T.+Smealauthor=G.+L.+Smithauthor=A.+E.+Stewartauthor=S.+Timofeevskiauthor=H.+Zhuauthor=J.+Zhuauthor=H.+Y.+Zouauthor=M.+P.+Edwards&title=Discovery+of+%2810R%29-7-Amino-12-fluoro-2%2C10%2C16-trimethyl-15-oxo-10%2C15%2C16%2C17-tetrahydro-2H-8%2C4-%28metheno%29pyrazolo%5B4%2C3-h%5D%5B2%2C5%2C11%5D-benzoxadiazacyclotetradecine-3-carbonitrile+%28PF-06463922%29%2C+a+Macrocyclic+Inhibitor+of+Anaplastic+Lymphoma+Kinase+%28ALK%29+and+c-ros+Oncogene+1+%28ROS1%29+with+Preclinical+Brain+Exposure+and+Broad-Spectrum+Potency+against+ALK-Resistant+Mutations&doi=10.1021%2Fjm500261q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations</span></div><div class="casAuthors">Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4720-4744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although crizotinib demonstrates robust efficacy in anaplastic lymphoma kinase (ALK)-pos. non-small-cell lung carcinoma patients, progression during treatment eventually develops.  Resistant patient samples revealed a variety of point mutations in the kinase domain of ALK, including the L1196M gatekeeper mutation.  In addn., some patients progress due to cancer metastasis in the brain.  Using structure-based drug design, lipophilic efficiency, and phys.-property-based optimization, highly potent macrocyclic ALK inhibitors were prepd. with good absorption, distribution, metab., and excretion (ADME), low propensity for p-glycoprotein 1-mediated efflux, and good passive permeability.  These structurally unusual macrocyclic inhibitors were potent against wild-type ALK and clin. reported ALK kinase domain mutations.  Significant synthetic challenges were overcome, utilizing novel transformations to enable the use of these macrocycles in drug discovery paradigms.  This work led to the discovery of 8k (PF-06463922), combining broad-spectrum potency, central nervous system ADME, and a high degree of kinase selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXkb49ad31bVg90H21EOLACvtfcHk0lgQNMbwyVxa0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvVSgtL4%253D&md5=db21844f8e9a2f9ca5953bca56ad7b1c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm500261q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500261q%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DRichardson%26aufirst%3DP.%2BF.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBrooun%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DB.%2BJ.%26aulast%3DCollins%26aufirst%3DM.%2BR.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DDeal%26aufirst%3DJ.%2BG.%26aulast%3DDeng%26aufirst%3DY.-L.%26aulast%3DDinh%26aufirst%3DD.%26aulast%3DEngstrom%26aufirst%3DL.%2BD.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DJ.%2BL.%26aulast%3DLe%26aufirst%3DP.%2BT.%26aulast%3DLingardo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DC.%2BL.%26aulast%3DSach%26aufirst%3DN.%2BW.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DG.%2BL.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520of%2520%252810R%2529-7-Amino-12-fluoro-2%252C10%252C16-trimethyl-15-oxo-10%252C15%252C16%252C17-tetrahydro-2H-8%252C4-%2528metheno%2529pyrazolo%255B4%252C3-h%255D%255B2%252C5%252C11%255D-benzoxadiazacyclotetradecine-3-carbonitrile%2520%2528PF-06463922%2529%252C%2520a%2520Macrocyclic%2520Inhibitor%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%2520and%2520c-ros%2520Oncogene%25201%2520%2528ROS1%2529%2520with%2520Preclinical%2520Brain%2520Exposure%2520and%2520Broad-Spectrum%2520Potency%2520against%2520ALK-Resistant%2520Mutations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D11%26spage%3D4720%26epage%3D4744%26doi%3D10.1021%2Fjm500261q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Midha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, R.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: a Systematic Review and Global Map by Ethnicity (mutMapII)</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">2892</span>– <span class="NLM_lpage">2911</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26609494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=2892-2911&author=A.+Midhaauthor=S.+Deardenauthor=R.+McCormack&title=EGFR+Mutation+Incidence+in+Non-Small-Cell+Lung+Cancer+of+Adenocarcinoma+Histology%3A+a+Systematic+Review+and+Global+Map+by+Ethnicity+%28mutMapII%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)</span></div><div class="casAuthors">Midha Anita; Dearden Simon; McCormack Rose</div><div class="citationInfo"><span class="NLM_cas:title">American journal of cancer research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2892-911</span>
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) histology (NSCLC/ADC).  Robust data exist regarding the prevalence of EGFR mutations in Western and Asian patients with NSCLC/ADC, yet there is a lack of data for patients of other ethnicities.  This review collated available data with the aim of creating a complete, global picture of EGFR mutation frequency in patients with NSCLC/ADC by ethnicity.  Worldwide literature reporting EGFR mutation frequency in patients with NSCLC/ADC was reviewed, to create a map of the world populated with EGFR mutation frequency by country (a 'global EGFR mutMap').  A total of 151 worldwide studies (n=33162 patients with NSCLC/ADC, of which 9749 patients had EGFR mutation-positive NSCLC/ADC) were included.  There was substantial variation in EGFR mutation frequency between studies, even when grouped by geographic region or individual country.  As expected, the Asia-Pacific NSCLC/ADC subgroup had the highest EGFR mutation frequency (47% [5958/12819; 87 studies; range 20%-76%]) and the lowest EGFR mutation frequency occurred in the Oceania NSCLC/ADC subgroup (12% [69/570; 4 studies; range 7%-36%]); however, comparisons between regions were limited due to the varying sizes of the patient populations studied.  In all regional (geographic) subgroups where data were available, EGFR mutation frequency in NSCLC/ADC was higher in women compared with men, and in never-compared with ever-smokers.  This review provides the foundation for a global map of EGFR mutation frequency in patients with NSCLC/ADC.  The substantial lack of data from several large geographic regions of the world, notably Africa, the Middle East, Central Asia, and Central and South America, highlights a potential lack of routine mutation testing and the need for further investigations in these regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1x7LyD77C4UH3Rlp_k91zfW6udTcc2eaZRMxn9VQVPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgslSqsg%253D%253D&md5=9ea4c9ffa42551cb066bb04142991fd4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMidha%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DR.%26atitle%3DEGFR%2520Mutation%2520Incidence%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%2520of%2520Adenocarcinoma%2520Histology%253A%2520a%2520Systematic%2520Review%2520and%2520Global%2520Map%2520by%2520Ethnicity%2520%2528mutMapII%2529%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2015%26volume%3D5%26spage%3D2892%26epage%3D2911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konduri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitlitz, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddareddigari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaby-Sandy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vavala, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morosini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">EGFR Fusions as Novel Therapeutic Targets in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F2159-8290.CD-16-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27102076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1Ggurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=601-611&issue=6&author=K.+Konduriauthor=J.-N.+Gallantauthor=Y.+K.+Chaeauthor=F.+J.+Gilesauthor=B.+J.+Gitlitzauthor=K.+Gowenauthor=E.+Ichiharaauthor=T.+K.+Owonikokoauthor=V.+Peddareddigariauthor=S.+S.+Ramalingamauthor=S.+K.+Reddyauthor=B.+Eaby-Sandyauthor=T.+Vavalaauthor=A.+Whiteleyauthor=H.+Chenauthor=Y.+Yanauthor=J.+H.+Sheehanauthor=J.+Meilerauthor=D.+Morosiniauthor=J.+S.+Rossauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Aliauthor=C.+M.+Lovly&title=EGFR+Fusions+as+Novel+Therapeutic+Targets+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-16-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Fusions as Novel Therapeutic Targets in Lung Cancer</span></div><div class="casAuthors">Konduri, Kartik; Gallant, Jean-Nicolas; Chae, Young Kwang; Giles, Francis J.; Gitlitz, Barbara J.; Gowen, Kyle; Ichihara, Eiki; Owonikoko, Taofeek K.; Peddareddigari, Vijay; Ramalingam, Suresh S.; Reddy, Satyanarayan K.; Eaby-Sandy, Beth; Vavala, Tiziana; Whiteley, Andrew; Chen, Heidi; Yan, Yingjun; Sheehan, Jonathan H.; Meiler, Jens; Morosini, Deborah; Ross, Jeffrey S.; Stephens, Philip J.; Miller, Vincent A.; Ali, Siraj M.; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-611</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here, we report that novel epidermal growth factor receptor (EGFR) gene fusions comprising the N-terminal of EGFR linked to various fusion partners, most commonly RAD51, are recurrent in lung cancer.  We describe five patients with metastatic lung cancer whose tumors harbored EGFR fusions, four of whom were treated with EGFR tyrosine kinase inhibitors (TKI) with documented antitumor responses.  In vitro, EGFR-RAD51 fusions are oncogenic and can be therapeutically targeted with available EGFR TKIs and therapeutic antibodies.  These results support the dependence of EGFR-rearranged tumors on EGFR-mediated signaling and suggest several therapeutic strategies for patients whose tumors harbor this novel alteration.  Significance: We report for the first time the identification and therapeutic targeting of EGFR C-terminal fusions in patients with lung cancer and document responses to the EGFR inhibitor erlotinib in 4 patients whose tumors harbored EGFR fusions.  Findings from these studies will be immediately translatable to the clinic, as there are already several approved EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoy2xrGmYZULVg90H21EOLACvtfcHk0lgXeC-xJ0AyyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1Ggurs%253D&md5=8491bbf3bcbe6699fa1c3df41860d32c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-0075%26sid%3Dliteratum%253Aachs%26aulast%3DKonduri%26aufirst%3DK.%26aulast%3DGallant%26aufirst%3DJ.-N.%26aulast%3DChae%26aufirst%3DY.%2BK.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DGitlitz%26aufirst%3DB.%2BJ.%26aulast%3DGowen%26aufirst%3DK.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DPeddareddigari%26aufirst%3DV.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DReddy%26aufirst%3DS.%2BK.%26aulast%3DEaby-Sandy%26aufirst%3DB.%26aulast%3DVavala%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSheehan%26aufirst%3DJ.%2BH.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DMorosini%26aufirst%3DD.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DEGFR%2520Fusions%2520as%2520Novel%2520Therapeutic%2520Targets%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D6%26spage%3D601%26epage%3D611%26doi%3D10.1158%2F2159-8290.CD-16-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib Versus Cisplatin Plus Docetaxel in Patients With Non-Small-Cell Lung Cancer Harboring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): an Open Label, Randomised Phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70364-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2809%2970364-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=20022809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=121-128&issue=2&author=T.+Mitsudomiauthor=S.+Moritaauthor=Y.+Yatabeauthor=S.+Negoroauthor=I.+Okamotoauthor=J.+Tsurutaniauthor=T.+Setoauthor=M.+Satouchiauthor=H.+Tadaauthor=T.+Hirashimaauthor=K.+Asamiauthor=N.+Katakamiauthor=M.+Takadaauthor=H.+Yoshiokaauthor=K.+Shibataauthor=S.+Kudohauthor=E.+Shimizuauthor=H.+Saitoauthor=S.+Toyookaauthor=K.+Nakagawaauthor=M.+Fukuoka&title=Gefitinib+Versus+Cisplatin+Plus+Docetaxel+in+Patients+With+Non-Small-Cell+Lung+Cancer+Harboring+Mutations+of+the+Epidermal+Growth+Factor+Receptor+%28WJTOG3405%29%3A+an+Open+Label%2C+Randomised+Phase+3+trial&doi=10.1016%2FS1470-2045%2809%2970364-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span></div><div class="casAuthors">Mitsudomi, Tetsuya; Morita, Satoshi; Yatabe, Yasushi; Negoro, Shunichi; Okamoto, Isamu; Tsurutani, Junji; Seto, Takashi; Satouchi, Miyako; Tada, Hirohito; Hirashima, Tomonori; Asami, Kazuhiro; Katakami, Nobuyuki; Takada, Minoru; Yoshioka, Hiroshige; Shibata, Kazuhiko; Kudoh, Shinzoh; Shimizu, Eiji; Saito, Hiroshi; Toyooka, Shinichi; Nakagawa, Kazuhiko; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer harboring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib.  However, whether gefitinib is better than std. platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.  We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harboring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimization technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m2, i.v.) plus docetaxel (60 mg/m2, i.v.; n=89), administered every 21 days for three to six cycles.  The primary endpoint was progression-free survival.  Survival anal. was done with the modified intention-to-treat population.  This study is registered with UMIN (University Hospital Medical Information Network in Japan), no. 000000539.  Five patients were excluded (two patients were found to have thyroid and colon cancer after randomization, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel).  Thus, 172 patients (86 in each group) were included in the survival analyses.  The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel group, with a median progression-free survival time of 9.2 mo (95% CI 8.0-13.9) vs. 6.3 mo (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001).  Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhea were more frequent in the gefitinib group.  Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.  Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.  Funding: West Japan Oncol. Group (WJOG): a non-profit organization supported by unrestricted donations from several pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKXuDlK2x9o7Vg90H21EOLACvtfcHk0lhaEcGdgjNpTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D&md5=5856ce118d00919627e3f21525abe453</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970364-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970364-X%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNegoro%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DHirashima%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DK.%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520Versus%2520Cisplatin%2520Plus%2520Docetaxel%2520in%2520Patients%2520With%2520Non-Small-Cell%2520Lung%2520Cancer%2520Harboring%2520Mutations%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528WJTOG3405%2529%253A%2520an%2520Open%2520Label%252C%2520Randomised%2520Phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26issue%3D2%26spage%3D121%26epage%3D128%26doi%3D10.1016%2FS1470-2045%2809%2970364-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laskin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurie, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazulina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Afatinib Versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): a Phase 2B, Open-Label, Randomised Controlled Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(16)30033-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2816%2930033-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27083334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=577-589&issue=5&author=K.+Parkauthor=E.-H.+Tanauthor=K.+O%E2%80%99Byrneauthor=L.+Zhangauthor=M.+Boyerauthor=T.+Mokauthor=V.+Hirshauthor=J.+C.-H.+Yangauthor=K.+H.+Leeauthor=S.+Luauthor=Y.+Shiauthor=S.-W.+Kimauthor=J.+Laskinauthor=D.-W.+Kimauthor=C.+D.+Arvisauthor=K.+Kolbeckauthor=S.+A.+Laurieauthor=C.-M.+Tsaiauthor=M.+Shahidiauthor=M.+Kimauthor=D.+Masseyauthor=V.+Zazulinaauthor=L.+Paz-Ares&title=Afatinib+Versus+Gefitinib+as+First-Line+Treatment+of+Patients+with+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28LUX-Lung+7%29%3A+a+Phase+2B%2C+Open-Label%2C+Randomised+Controlled+Trial&doi=10.1016%2FS1470-2045%2816%2930033-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial</span></div><div class="casAuthors">Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">577-589</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-pos. non-small-cell lung cancer (NSCLC).  We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.  This multicentre, international, open-label, exploratory, randomised controlled phase 2B trial (LUX-Lung 7) was done at 64 centers in 13 countries.  Treatment-naive patients with stage IIIB or IV NSCLC and a common EGFR mutation (exon 19 deletion or Leu858Arg) were randomly assigned (1:1) to receive afatinib (40 mg per day) or gefitinib (250 mg per day) until disease progression, or beyond if deemed beneficial by the investigator.  Randomisation, stratified by EGFR mutation type and status of brain metastases, was done centrally using a validated no. generating system implemented via an interactive voice or web-based response system with a block size of four.  Clinicians and patients were not masked to treatment allocation; independent review of tumor response was done in a blinded manner.  Coprimary endpoints were progression-free survival by independent central review, time-to-treatment failure, and overall survival.  Efficacy analyses were done in the intention-to-treat population and safety analyses were done in patients who received at least one dose of study drug.  This ongoing study is registered with ClinicalTrials.gov, no. NCT01466660.  Between Dec 13, 2011, and Aug 8, 2013, 319 patients were randomly assigned (160 to afatinib and 159 to gefitinib).  Median follow-up was 27·3 mo (IQR 15·3-33·9).  Progression-free survival (median 11·0 mo [95% CI 10·6-12·9] with afatinib vs 10·9 mo [9·1-11·5] with gefitinib; hazard ratio [HR] 0·73 [95% CI 0·57-0·95], p=0·017) and time-to-treatment failure (median 13·7 mo [95% CI 11·9-15·0] with afatinib vs 11·5 mo [10·1-13·1] with gefitinib; HR 0·73 [95% CI 0·58-0·92], p=0·0073) were significantly longer with afatinib than with gefitinib.  Overall survival data are not mature.  The most common treatment-related grade 3 or 4 adverse events were diarrhoea (20 [13%] of 160 patients given afatinib vs two [1%] of 159 given gefitinib) and rash or acne (15 [9%] patients given afatinib vs five [3%] of those given gefitinib) and liver enzyme elevations (no patients given afatinib vs 14 [9%] of those given gefitinib).  Serious treatment-related adverse events occurred in 17 (11%) patients in the afatinib group and seven (4%) in the gefitinib group.  Ten (6%) patients in each group discontinued treatment due to drug-related adverse events. 15 (9%) fatal adverse events occurred in the afatinib group and ten (6%) in the gefitinib group.  All but one of these deaths were considered unrelated to treatment; one patient in the gefitinib group died from drug-related hepatic and renal failure.  Afatinib significantly improved outcomes in treatment-naive patients with EGFR-mutated NSCLC compared with gefitinib, with a manageable tolerability profile.  These data are potentially important for clin. decision making in this patient population.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSTXQpDomR7Vg90H21EOLACvtfcHk0lhaEcGdgjNpTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtFaqtbY%253D&md5=33d5697aa6a01e4f3fc89a34cb3b1e61</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930033-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930033-X%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DLaskin%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DArvis%26aufirst%3DC.%2BD.%26aulast%3DKolbeck%26aufirst%3DK.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DTsai%26aufirst%3DC.-M.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DMassey%26aufirst%3DD.%26aulast%3DZazulina%26aufirst%3DV.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DAfatinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520of%2520Patients%2520with%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528LUX-Lung%25207%2529%253A%2520a%2520Phase%25202B%252C%2520Open-Label%252C%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D5%26spage%3D577%26epage%3D589%26doi%3D10.1016%2FS1470-2045%2816%2930033-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vansteenkiste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reungwetwattana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewaskulyong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dechaphunkul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1713137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa1713137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29151359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=113-125&issue=2&author=J.+C.+Soriaauthor=Y.+Oheauthor=J.+Vansteenkisteauthor=T.+Reungwetwattanaauthor=B.+Chewaskulyongauthor=K.+H.+Leeauthor=A.+Dechaphunkulauthor=F.+Imamuraauthor=N.+Nogamiauthor=T.+Kurataauthor=I.+Okamotoauthor=C.+Zhouauthor=B.+C.+Choauthor=Y.+Chengauthor=E.+K.+Choauthor=P.+J.+Voonauthor=D.+Planchardauthor=W.+C.+Suauthor=J.+E.+Grayauthor=S.+M.+Leeauthor=R.+Hodgeauthor=M.+Marottiauthor=Y.+Rukazenkovauthor=S.+S.+Ramalingam&title=Osimertinib+in+Untreated+EGFR-Mutated+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1713137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K. H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; Okamoto, I.; Zhou, C.; Cho, B. C.; Cheng, Y.; Cho, E. K.; Voon, P. J.; Planchard, D.; Su, W.-C.; Gray, J. E.; Lee, S.-M.; Hodge, R.; Marotti, M.; Rukazenkov, Y.; Ramalingam, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-125</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations.  We compared osimertinib with std. EGFR-TKIs in patients with previously untreated, EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-pos. (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a std. EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily).  The primary end point was investigator-assessed progression-free survival.  RESULTS: The median progression-free survival was significantly longer with osimertinib than with std. EGFR-TKIs (18.9 mo vs. 10.2 mo; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001).  The objective response rate was similar in the two groups: 80% with osimertinib and 76% with std. EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P = 0.24).  The median duration of response was 17.2 mo (95% CI, 13.8 to 22.0) with osimertinib vs. 8.5 mo (95% CI, 7.3 to 9.8) with std. EGFR-TKIs.  Data on overall survival were immature at the interim anal. (25% maturity).  The survival rate at 18 mo was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with std. EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim anal.]).  Adverse events of grade 3 or higher were less frequent with osimertinib than with std. EGFR-TKIs (34% vs. 45%).  CONCLUSIONS: Osimertinib showed efficacy superior to that of std. EGFR-TKIs in the first-line treatment of EGFR mutation-pos. advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov no., NCT02296125.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC-szlfPjG9LVg90H21EOLACvtfcHk0li2GYq5-lzQCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKmtrY%253D&md5=a83147d4e067da1c11d2f096615b1cc8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1713137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1713137%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DVansteenkiste%26aufirst%3DJ.%26aulast%3DReungwetwattana%26aufirst%3DT.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DDechaphunkul%26aufirst%3DA.%26aulast%3DImamura%26aufirst%3DF.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DE.%2BK.%26aulast%3DVoon%26aufirst%3DP.%2BJ.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DOsimertinib%2520in%2520Untreated%2520EGFR-Mutated%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26issue%3D2%26spage%3D113%26epage%3D125%26doi%3D10.1056%2FNEJMoa1713137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, C.</span></span> <span> </span><span class="NLM_article-title">Erlotinib Versus Chemotherapy as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): a Multicentre, Open-Label, Randomised, Phase 3 Study</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70184-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2811%2970184-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=21783417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=735-742&issue=8&author=C.+Zhouauthor=Y.-L.+Wuauthor=G.+Chenauthor=J.+Fengauthor=X.-Q.+Liuauthor=C.+Wangauthor=S.+Zhangauthor=J.+Wangauthor=S.+Zhouauthor=S.+Renauthor=S.+Luauthor=L.+Zhangauthor=C.+Huauthor=C.+Huauthor=Y.+Luoauthor=L.+Chenauthor=M.+Yeauthor=J.+Huangauthor=X.+Zhiauthor=Y.+Zhangauthor=Q.+Xiuauthor=J.+Maauthor=L.+Zhangauthor=C.+You&title=Erlotinib+Versus+Chemotherapy+as+First-Line+Treatment+for+Patients+with+Advanced+EGFR+Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28OPTIMAL%2C+CTONG-0802%29%3A+a+Multicentre%2C+Open-Label%2C+Randomised%2C+Phase+3+Study&doi=10.1016%2FS1470-2045%2811%2970184-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study</span></div><div class="casAuthors">Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">735-742</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC).  The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib vs. std. chemotherapy in the first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  We undertook an open-label, randomised, phase 3 trial at 22 centers in China.  Patients older than 18 years with histol. confirmed stage IIIB or IV NSCLC and a confirmed activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) received either oral erlotinib (150 mg/day) until disease progression or unacceptable toxic effects, or up to four cycles of gemcitabine plus carboplatin.  Patients were randomly assigned (1:1) with a minimization procedure and were stratified according to EGFR mutation type, histol. subtype (adenocarcinoma vs non-adenocarcinoma), and smoking status.  The primary outcome was progression-free survival, analyzed in patients with confirmed disease who received at least one dose of study treatment.  The trial is registered at ClinicalTrials.gov, no. NCT00874419, and has completed enrollment; patients are still in follow-up.  83 Patients were randomly assigned to receive erlotinib and 82 to receive gemcitabine plus carboplatin; 82 in the erlotinib group and 72 in the chemotherapy group were included in anal. of the primary endpoint.  Median progression-free survival was significantly longer in erlotinib-treated patients than in those on chemotherapy (13.1 [95% CI 10.58-16.53] vs 4.6 [4.21-5.42] months; hazard ratio 0.16, 95% CI 0.10-0.26; p<0.0001).  Chemotherapy was assocd. with more grade 3 or 4 toxic effects than was erlotinib (including neutropenia in 30 [42%] of 72 patients and thrombocytopenia in 29 [40%] patients on chemotherapy vs no patients with either event on erlotinib); the most common grade 3 or 4 toxic effects with erlotinib were increased alanine aminotransferase concns. (three [4%] of 83 patients) and skin rash (two [2%] patients).  Chemotherapy was also assocd. with increased treatment-related serious adverse events (ten [14%] of 72 patients [decreased platelet count, n = 8; decreased neutrophil count, n = 1; hepatic dysfunction, n = 1] vs two [2%] of 83 patients [both hepatic dysfunction]).  Compared with std. chemotherapy, erlotinib conferred a significant progression-free survival benefit in patients with advanced EGFR mutation-pos. NSCLC and was assocd. with more favorable tolerability.  These findings suggest that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-pos. NSCLC.  Funding: F Hoffmann-La Roche Ltd (China); Science and Technol. Commission of Shanghai Municipality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosNzw1hk1km7Vg90H21EOLACvtfcHk0li2GYq5-lzQCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslKhsbY%253D&md5=92097cc6e942e9137a40fd6cae675297</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970184-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970184-X%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.-Q.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXiu%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DC.%26atitle%3DErlotinib%2520Versus%2520Chemotherapy%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520Advanced%2520EGFR%2520Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528OPTIMAL%252C%2520CTONG-0802%2529%253A%2520a%2520Multicentre%252C%2520Open-Label%252C%2520Randomised%252C%2520Phase%25203%2520Study%26jtitle%3DLancet%2520Oncol.%26date%3D2011%26volume%3D12%26issue%3D8%26spage%3D735%26epage%3D742%26doi%3D10.1016%2FS1470-2045%2811%2970184-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corral, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorino, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluzanski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbar, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadanaciva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib Versus Gefitinib as First-Line Treatment for Patients with EGFR-Mutation-Positive Non-Small-Cell Lung Cancer (ARCHER 1050): a Randomised, Open-Label, Phase 3 Trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1466</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30608-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS1470-2045%2817%2930608-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28958502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1454-1466&issue=11&author=Y.-L.+Wuauthor=Y.+Chengauthor=X.+Zhouauthor=K.+H.+Leeauthor=K.+Nakagawaauthor=S.+Nihoauthor=F.+Tsujiauthor=R.+Linkeauthor=R.+Rosellauthor=J.+Corralauthor=M.+R.+Migliorinoauthor=A.+Pluzanskiauthor=E.+I.+Sbarauthor=T.+Wangauthor=J.+L.+Whiteauthor=S.+Nadanacivaauthor=R.+Sandinauthor=T.+S.+Mok&title=Dacomitinib+Versus+Gefitinib+as+First-Line+Treatment+for+Patients+with+EGFR-Mutation-Positive+Non-Small-Cell+Lung+Cancer+%28ARCHER+1050%29%3A+a+Randomised%2C+Open-Label%2C+Phase+3+Trial&doi=10.1016%2FS1470-2045%2817%2930608-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Cheng, Ying; Zhou, Xiangdong; Lee, Ki Hyeong; Nakagawa, Kazuhiko; Niho, Seiji; Tsuji, Fumito; Linke, Rolf; Rosell, Rafael; Corral, Jesus; Migliorino, Maria Rita; Pluzanski, Adam; Sbar, Eric I.; Wang, Tao; White, Jane Liang; Nadanaciva, Sashi; Sandin, Rickard; Mok, Tony S.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1454-1466</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.  We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with advanced EGFR-mutation-pos. non-small-cell lung cancer (NSCLC).  In this international, multicenter, randomized, open-label, phase 3 study (ARCHER 1050), we enrolled adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centers and university hospitals in seven countries or special administrative regions.  We randomly assigned participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day (in 28-day cycles) until disease progression or another discontinuation criterion was met.  Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated random code assigned by a central interactive web response system.  The primary endpoint was progression-free survival assessed by masked independent review in the intention-to-treat population.  Safety was assessed in all patients who received at least one dose of study treatment.  This study is registered with ClinicalTrials.gov, no. NCT01774721, and is ongoing but no longer recruiting patients.  Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227) or gefitinib (n=225).  Median duration of follow-up for progression-free survival was 22·1 mo (95% CI 20·3-23·9).  Median progression-free survival according to masked independent review was 14·7 mo (95% CI 11·1-16·6) in the dacomitinib group and 9·2 mo (9·1-11·0) in the gefitinib group (hazard ratio 0·59, 95% CI 0·47-0·74; p<0·0001).  The most common grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 patients given gefitinib), diarrhea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).  Treatment-related serious adverse events were reported in 21 (9%) patients given dacomitinib and in ten (4%) patients given gefitinib.  Two treatment-related deaths occurred in the dacomitinib group (one related to untreated diarrhea and one to untreated cholelithases/liver disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by pneumonia).  Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of patients with EGFR-mutation-pos. NSCLC and should be considered as a new treatment option for this population.  SFJ Pharmaceuticals Group and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqZ8AKr7cDZLVg90H21EOLACvtfcHk0lhHgQlPtC4DlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntLfI&md5=89eb8749060bfa3dfe79a84537b2b27b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930608-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930608-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DNiho%26aufirst%3DS.%26aulast%3DTsuji%26aufirst%3DF.%26aulast%3DLinke%26aufirst%3DR.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCorral%26aufirst%3DJ.%26aulast%3DMigliorino%26aufirst%3DM.%2BR.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DJ.%2BL.%26aulast%3DNadanaciva%26aufirst%3DS.%26aulast%3DSandin%26aufirst%3DR.%26aulast%3DMok%26aufirst%3DT.%2BS.%26atitle%3DDacomitinib%2520Versus%2520Gefitinib%2520as%2520First-Line%2520Treatment%2520for%2520Patients%2520with%2520EGFR-Mutation-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528ARCHER%25201050%2529%253A%2520a%2520Randomised%252C%2520Open-Label%252C%2520Phase%25203%2520Trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D1454%26epage%3D1466%26doi%3D10.1016%2FS1470-2045%2817%2930608-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bivona, T. G.</span></span> <span> </span><span class="NLM_article-title">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">872</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F2159-8290.CD-12-0387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=23071030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=872-875&issue=10&author=C.+M.+Blakelyauthor=T.+G.+Bivona&title=Resiliency+of+Lung+Cancers+to+EGFR+Inhibitor+Treatment+Unveiled%2C+Offering+Opportunities+to+Divide+and+Conquer+EGFR+Inhibitor+Resistance&doi=10.1158%2F2159-8290.CD-12-0387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Resiliency of Lung Cancers to EGFR Inhibitor Treatment Unveiled, Offering Opportunities to Divide and Conquer EGFR Inhibitor Resistance</span></div><div class="casAuthors">Blakely, Collin M.; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">872-875</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Summary: The clin. success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance.  Two reports in this issue of Cancer Discovery uncover addnl. mechanisms by which EGFR-mutant lung cancers escape from EGFR kinase inhibitor treatment.  These findings pave the way for clin. testing of new rational therapeutic strategies to prevent or overcome resistance to EGFR kinase inhibitors in the clinic.  Cancer Discov; 2(10); 872-5. ©2012 AACR.  Commentary on Ercan et al., p. 934.  Commentary on Takezawa et al., p. 922.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiyRcMFbYgYrVg90H21EOLACvtfcHk0lhHgQlPtC4DlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFagtLrM&md5=ec81e2c701acb7c836306926ca9b5074</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0387%26sid%3Dliteratum%253Aachs%26aulast%3DBlakely%26aufirst%3DC.%2BM.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DResiliency%2520of%2520Lung%2520Cancers%2520to%2520EGFR%2520Inhibitor%2520Treatment%2520Unveiled%252C%2520Offering%2520Opportunities%2520to%2520Divide%2520and%2520Conquer%2520EGFR%2520Inhibitor%2520Resistance%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26issue%3D10%26spage%3D872%26epage%3D875%26doi%3D10.1158%2F2159-8290.CD-12-0387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayaram, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocher, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, B.</span></span> <span> </span><span class="NLM_article-title">EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Jaenneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+Mutation+and+Resistance+of+Non-Small-Cell+Lung+Cancer+to+Gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lhHgQlPtC4DlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520Mutation%2520and%2520Resistance%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%2520to%2520Gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Third-Generation Inhibitors Targeting EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">34/1</span>– <span class="NLM_lpage">34/7</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0268-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1186%2Fs13045-016-0268-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=34%2F1-34%2F7&author=S.+Wangauthor=S.+Cangauthor=D.+Liu&title=Third-Generation+Inhibitors+Targeting+EGFR+T790M+Mutation+in+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.1186%2Fs13045-016-0268-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0268-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0268-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DThird-Generation%2520Inhibitors%2520Targeting%2520EGFR%2520T790M%2520Mutation%2520in%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D34%252F1%26epage%3D34%252F7%26doi%3D10.1186%2Fs13045-016-0268-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lj0ifU642ecZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggstrom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span> <span> </span><span class="NLM_article-title">AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">1689</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&issue=18&author=P.+A.+Janneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+Inhibitor-Resistant+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eaYw7iQAUXEGLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520Inhibitor-Resistant%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26issue%3D18%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garassino, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theelen, W. S. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebastian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">640</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1612674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1056%2FNEJMoa1612674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27959700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=629-640&issue=7&author=T.+S.+Mokauthor=Y.+L.+Wuauthor=M.+J.+Ahnauthor=M.+C.+Garassinoauthor=H.+R.+Kimauthor=S.+S.+Ramalingamauthor=F.+A.+Shepherdauthor=Y.+Heauthor=H.+Akamatsuauthor=W.+S.+M.+E.+Theelenauthor=C.+K.+Leeauthor=M.+Sebastianauthor=A.+Templetonauthor=H.+Mannauthor=M.+Marottiauthor=S.+Ghiorghiuauthor=V.+A.+Papadimitrakopoulou&title=Osimertinib+or+Platinum-Pemetrexed+in+EGFR+T790M-Positive+Lung+Cancer&doi=10.1056%2FNEJMoa1612674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer</span></div><div class="casAuthors">Mok, T. S.; Wu, Y.-L.; Ahn, M.-J.; Garassino, M. C.; Kim, H. R.; Ramalingam, S. S.; Shepherd, F. A.; He, Y.; Akamatsu, H.; Theelen, W. S. M. E.; Lee, C. K.; Sebastian, M.; Templeton, A.; Mann, H.; Marotti, M.; Ghiorghiu, S.; Papadimitrakopoulou, V. A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">629-640</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer.  The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown.  In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-pos. advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or i.v. pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 wk for up to six cycles; maintenance pemetrexed was allowed.  In all the patients, disease had progressed during receipt of first-line EGFR-TKI therapy.  The primary end point was investigator-assessed progression-free survival.  The median duration of progression-free survival was significantly longer with osimertinib than with platinum therapy plus pemetrexed (10.1 mo vs. 4.4 mo; hazard ratio; 0.30; 95% confidence interval [CI], 0.23 to 0.41; P<0.001).  The objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with platinum therapy plus pemetrexed (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).  Among 144 patients with metastases to the central nervous system (CNS), the median duration of progression-free survival was longer among patients receiving osimertinib than among those receiving platinum therapy plus pemetrexed (8.5 mo vs. 4.2 mo; hazard ratio, 0.32; 95% CI, 0.21 to 0.49).  The proportion of patients with adverse events of grade 3 or higher was lower with osimertinib (23%) than with platinum therapy plus pemetrexed (47%).  Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-pos. advanced non-small-cell lung cancer (including those with CNS metastases) in whom disease had progressed during first-line EGFR-TKI therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruYSDfzF6p8LVg90H21EOLACvtfcHk0liIKRsPg5QOzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlyktbvI&md5=a8d0fa4c1289e0c81216497c362f4bcb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1612674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1612674%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DGarassino%26aufirst%3DM.%2BC.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DAkamatsu%26aufirst%3DH.%26aulast%3DTheelen%26aufirst%3DW.%2BS.%2BM.%2BE.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DSebastian%26aufirst%3DM.%26aulast%3DTempleton%26aufirst%3DA.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DMarotti%26aufirst%3DM.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%2BA.%26atitle%3DOsimertinib%2520or%2520Platinum-Pemetrexed%2520in%2520EGFR%2520T790M-Positive%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26issue%3D7%26spage%3D629%26epage%3D640%26doi%3D10.1056%2FNEJMoa1612674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Cuaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Cuesta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schildhaus, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuernberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heukamp, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">4837</span>– <span class="NLM_lpage">4847</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F1078-0432.CCR-15-1915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27252416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=4837-4847&issue=19&author=S.+Ortiz-Cuaranauthor=M.+Schefflerauthor=D.+Plenkerauthor=l.+Dahmenauthor=A.+H.+Scheelauthor=L.+Fernandez-Cuestaauthor=L.+Mederauthor=C.+M.+Lovlyauthor=T.+Persigehlauthor=S.+Merkelbach-Bruseauthor=M.+Bosauthor=S.+Michelsauthor=R.+Fischerauthor=K.+Albusauthor=K.+Koenigauthor=H.-U.+Schildhausauthor=J.+Fassunkeauthor=M.+A.+Ihleauthor=H.+Pasternackauthor=C.+Heydtauthor=C.+Beckerauthor=J.+Altmuellerauthor=H.+Jiauthor=C.+Muellerauthor=A.+Florinauthor=J.+M.+Heuckmannauthor=P.+Nuernbergauthor=S.+Ansenauthor=L.+C.+Heukampauthor=J.+Bergauthor=W.+Paoauthor=M.+Peiferauthor=R.+Buettnerauthor=J.+Wolfauthor=R.+K.+Thomasauthor=M.+L.+Sos&title=Heterogeneous+Mechanisms+of+Primary+and+Acquired+Resistance+to+Third-Generation+EGFR+Inhibitors&doi=10.1158%2F1078-0432.CCR-15-1915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors</span></div><div class="casAuthors">Ortiz-Cuaran, Sandra; Scheffler, Matthias; Plenker, Dennis; Dahmen, llona; Scheel, Andreas H.; Fernandez-Cuesta, Lynnette; Meder, Lydia; Lovly, Christine M.; Persigehl, Thorsten; Merkelbach-Bruse, Sabine; Bos, Marc; Michels, Sebastian; Fischer, Rieke; Albus, Kerstin; Koenig, Katharina; Schildhaus, Hans-Ulrich; Fassunke, Jana; Ihle, Michaela A.; Pasternack, Helen; Heydt, Carina; Becker, Christian; Altmueller, Janine; Ji, Hongbin; Mueller, Christian; Florin, Alexandra; Heuckmann, Johannes M.; Nuernberg, Peter; Ansen, Sascha; Heukamp, Lukas C.; Berg, Johannes; Pao, William; Peifer, Martin; Buettner, Reinhard; Wolf, Juergen; Thomas, Roman K.; Sos, Martin L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4837-4847</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686).  We analyzed tumor biopsies from seven patients obtained before, during, and/or after treatment with AZD9291 or rociletinib (CO-1686).  Targeted sequencing and FISH analyses were performed, and the relevance of candidate genes was functionally assessed in in vitro models.  We found recurrent amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compds.  Furthermore, we identified a KRASG12S mutation in a patient with acquired resistance to AZD9291 as a potential driver of acquired resistance.  Finally, we show that dual inhibition of EGFR/MEK might be a viable strategy to overcome resistance in EGFR-mutant cells expressing mutant KRAS.  Our data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryi-78iIDGfrVg90H21EOLACvtfcHk0liIKRsPg5QOzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhsb3K&md5=b30908de40ff48f067e067cfc3520a7b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1915%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DDahmen%26aufirst%3Dl.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DFernandez-Cuesta%26aufirst%3DL.%26aulast%3DMeder%26aufirst%3DL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DBos%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DR.%26aulast%3DAlbus%26aufirst%3DK.%26aulast%3DKoenig%26aufirst%3DK.%26aulast%3DSchildhaus%26aufirst%3DH.-U.%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPasternack%26aufirst%3DH.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DAltmueller%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DFlorin%26aufirst%3DA.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DNuernberg%26aufirst%3DP.%26aulast%3DAnsen%26aufirst%3DS.%26aulast%3DHeukamp%26aufirst%3DL.%2BC.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DHeterogeneous%2520Mechanisms%2520of%2520Primary%2520and%2520Acquired%2520Resistance%2520to%2520Third-Generation%2520EGFR%2520Inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D19%26spage%3D4837%26epage%3D4847%26doi%3D10.1158%2F1078-0432.CCR-15-1915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span> <span> </span><span class="NLM_article-title">Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>), <span class="NLM_elocation-id">e45-e47</span> <span class="refDoi"> DOI: 10.1016/j.jtho.2015.12.093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.jtho.2015.12.093" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&issue=4&author=H.-N.+Songauthor=K.+S.+Jungauthor=K.+H.+Yooauthor=J.+Choauthor=J.+Y.+Leeauthor=S.+H.+Limauthor=H.+S.+Kimauthor=J.-M.+Sunauthor=S.-H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=Y.-L.+Choiauthor=W.+Parkauthor=M.-J.+Ahn&title=Acquired+C797S+Mutation+upon+Treatment+with+a+T790M-Specific+Third-Generation+EGFR+Inhibitor+%28HM61713%29+in+Non-Small+Cell+Lung+Cancer&doi=10.1016%2Fj.jtho.2015.12.093"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.12.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.12.093%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.-N.%26aulast%3DJung%26aufirst%3DK.%2BS.%26aulast%3DYoo%26aufirst%3DK.%2BH.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DLim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DSun%26aufirst%3DJ.-M.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DY.-L.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DAhn%26aufirst%3DM.-J.%26atitle%3DAcquired%2520C797S%2520Mutation%2520upon%2520Treatment%2520with%2520a%2520T790M-Specific%2520Third-Generation%2520EGFR%2520Inhibitor%2520%2528HM61713%2529%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D4%26doi%3D10.1016%2Fj.jtho.2015.12.093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non-Small Cell Lung Cancer Harboring EGFR T790M</span>. <i>Nat. Med. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&issue=6&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+Mutation+Mediates+Resistance+to+AZD9291+in+Non-Small+Cell+Lung+Cancer+Harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0liWKpB-bX-fkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520Mutation%2520Mediates%2520Resistance%2520to%2520AZD9291%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2015%26volume%3D21%26issue%3D6%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&issue=13&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+Novel+Resistance+Mechanisms+to+Third-Generation+EGFR+Tyrosine+Kinase+Inhibitor+Osimertinib+in+Non-Small+Cell+Lung+Cancer+Patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0liWKpB-bX-fkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520Novel%2520Resistance%2520Mechanisms%2520to%2520Third-Generation%2520EGFR%2520Tyrosine%2520Kinase%2520Inhibitor%2520Osimertinib%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520Patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span>. <i>JAMA Oncol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">984</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2015.1066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1001%2Fjamaoncol.2015.1066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26181354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=982-984&issue=7&author=H.+A.+Yuauthor=A.+E.+Drilonauthor=G.+J.+Rielyauthor=S.+K.+Tianauthor=L.+Borsuauthor=M.+E.+Arcilaauthor=M.+Ladanyi&title=Acquired+Resistance+of+EGFR-Mutant+Lung+Cancer+to+a+T790M-Specific+EGFR+Inhibitor%3A+Emergence+of+a+Third+Mutation+%28C797S%29+in+the+EGFR+Tyrosine+Kinase+Domain&doi=10.1001%2Fjamaoncol.2015.1066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain</span></div><div class="casAuthors">Yu Helena A; Drilon Alexander E; Riely Gregory J; Tian Shaozhou K; Borsu Laetitia; Arcila Maria E; Ladanyi Marc</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">982-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbCCE_5v9wMt1QT_1O5WBYfW6udTcc2eZGQu1Xor_gy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FjsVKgtQ%253D%253D&md5=27ae39c3fce4067baca734fbc05101b5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2015.1066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2015.1066%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DDrilon%26aufirst%3DA.%2BE.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DBorsu%26aufirst%3DL.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DAcquired%2520Resistance%2520of%2520EGFR-Mutant%2520Lung%2520Cancer%2520to%2520a%2520T790M-Specific%2520EGFR%2520Inhibitor%253A%2520Emergence%2520of%2520a%2520Third%2520Mutation%2520%2528C797S%2529%2520in%2520the%2520EGFR%2520Tyrosine%2520Kinase%2520Domain%26jtitle%3DJAMA%2520Oncol%26date%3D2015%26volume%3D1%26issue%3D7%26spage%3D982%26epage%3D984%26doi%3D10.1001%2Fjamaoncol.2015.1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carl Barrett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaenne, P. A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">841</span>– <span class="NLM_lpage">849</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.74.7576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1200%2FJCO.2017.74.7576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28841389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=841-849&issue=9&author=S.+S.+Ramalingamauthor=J.+C.+H.+Yangauthor=C.+K.+Leeauthor=T.+Kurataauthor=D.-W.+Kimauthor=T.+Johnauthor=N.+Nogamiauthor=Y.+Oheauthor=H.+Mannauthor=Y.+Rukazenkovauthor=S.+Ghiorghiuauthor=D.+Stetsonauthor=A.+Markovetsauthor=J.+Carl+Barrettauthor=K.+S.+Thressauthor=P.+A.+Jaenne&title=Osimertinib+as+First-Line+Treatment+of+EGFR+Mutation-Positive+Advanced+Non-Small-Cell+Lung+Cancer&doi=10.1200%2FJCO.2017.74.7576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Yang, James C. H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Carl Barrett, J.; Thress, Kenneth S.; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">841-849</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-na.ovrddot.ive patients to examine clin. activity and safety of osimertinib (an epidermal growth factor receptor [EGFR] -tyrosine kinase inhibitor selective for EGFR-tyrosine kinase inhibitor sensitizing [EGFRm] and EGFR T790M resistance mutations) as first-line treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Sixty treatment-na.ovrddot.ive patients with locally advanced or metastatic EGFRm NSCLC received osimertinib 80 or 160 mg once daily (30 patients per cohort).  End points included investigator-assessed objective response rate (ORR), progression-free survival (PFS), and safety evaluation.  Plasma samples were collected at or after patients experienced disease progression, as defined by Response Evaluation Criteria in Solid Tumors (RECIST), to investigate osimertinib resistance mechanisms.  Results At data cutoff (Nov. 1, 2016), median follow-up was 19.1 mo.  Overall ORR was 67% (95% CI, 47% to 83%) in the 80-mg group, 87% (95% CI, 69% to 96%) in the 160-mg group, and 77% (95% CI, 64% to 87%) across doses.  Median PFS time was 22.1 mo (95% CI, 13.7 to 30.2 mo) in the 80-mg group, 19.3 mo (95% CI, 13.7 to 26.0 mo) in the 160-mg group, and 20.5 mo (95% CI, 15.0 to 26.1 mo) across doses.  Of 38 patients with postprogression plasma samples, 50% had no detectable circulating tumor DNA.  Nine of 19 patients had putative resistance mechanisms, including amplification of MET (n = 1); amplification of EGFR and KRAS (n = 1); MEK1, KRAS, or PIK3CA mutation (n = 1 each); EGFR C797S mutation (n = 2); JAK2 mutation (n = 1); and HER2 exon 20 insertion (n = 1).  Acquired EGFR T790M was not detected.  Conclusion Osimertinib demonstrated a robust ORR and prolonged PFS in treatment-na.ovrddot.ive patients with EGFRm advanced NSCLC.  There was no evidence of acquired EGFR T790M mutation in postprogression plasma samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMqM3jWJfzwbVg90H21EOLACvtfcHk0ljfKP4VjLy4dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1amsbzL&md5=e6b63846658632b5f79460ee29022835</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.74.7576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.74.7576%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DKurata%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DNogami%26aufirst%3DN.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DMann%26aufirst%3DH.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DCarl%2BBarrett%26aufirst%3DJ.%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26atitle%3DOsimertinib%2520as%2520First-Line%2520Treatment%2520of%2520EGFR%2520Mutation-Positive%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D9%26spage%3D841%26epage%3D849%26doi%3D10.1200%2FJCO.2017.74.7576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 2,9-Disubstituted 8-Phenylthio/Phenylsulfinyl-9H-Purine as New EGFR Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2173</span>– <span class="NLM_lpage">2185</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.03.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmc.2018.03.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29576272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=2173-2185&issue=8&author=Y.+Y.+Heiauthor=Y.+Shenauthor=J.+Wangauthor=H.+Zhangauthor=H.+Y.+Zhaoauthor=M.+Xinauthor=Y.+X.+Caoauthor=Y.+Liauthor=S.+Q.+Zhang&title=Synthesis+and+Evaluation+of+2%2C9-Disubstituted+8-Phenylthio%2FPhenylsulfinyl-9H-Purine+as+New+EGFR+Inhibitors&doi=10.1016%2Fj.bmc.2018.03.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors</span></div><div class="casAuthors">Hei, Yuan-Yuan; Shen, Ying; Wang, Jin; Zhang, Hao; Zhao, Hong-Yi; Xin, Minhang; Cao, Yong-Xiao; Li, Yan; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2173-2185</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In present study, we described the synthesis and biol. evaluation of a new class of EGFR inhibitors contg. 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine scaffold.  Thirty-one compds. were synthesized.  Among them, compd. I displayed the IC50 of 29.4 nM against HCC827 cell line and 1.9 nM against EGFRL858R.  Compd. II showed moderate inhibitory activity against EGFRL858R/T790M/C797S (IC50 = 114 nM).  Western bolt assay suggested that compd. I significantly inhibited EGFR phosphorylation.  In vivo test, compd. I remarkably exhibited inhibitory effect on tumor growth at 5.0 mg/kg by oral administration in established nude mouse HCC827 xenograft model.  These results indicate that the 2,9-disubstituted 8-phenylsulfinyl/phenylsulfinyl-9H-purine derivs. can act as potent EGFR(L858R) inhibitors and effective anticancer agents.  Addnl., optimization of compd. C12 may result in discovering the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkK03__RHpv7Vg90H21EOLACvtfcHk0lg1Zy5zVue90w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOhtrc%253D&md5=e3c14297dde450c1b241946f9bb823a6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.03.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.03.025%26sid%3Dliteratum%253Aachs%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25202%252C9-Disubstituted%25208-Phenylthio%252FPhenylsulfinyl-9H-Purine%2520as%2520New%2520EGFR%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D2173%26epage%3D2185%26doi%3D10.1016%2Fj.bmc.2018.03.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span> <span> </span><span class="NLM_article-title">Novel 4-Arylaminoquinazoline Derivatives with (E)-Propen-1-yl moiety as Potent EGFR Inhibitors with Enhanced Antiproliferative Activities Against Tumor Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">Supplement C</span>),  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.ejmech.2017.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28711703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=689-697&issue=Supplement+C&author=L.+Chenauthor=Y.+Zhangauthor=J.+Liuauthor=W.+Wangauthor=X.+Liauthor=L.+Zhaoauthor=W.+Wangauthor=B.+Li&title=Novel+4-Arylaminoquinazoline+Derivatives+with+%28E%29-Propen-1-yl+moiety+as+Potent+EGFR+Inhibitors+with+Enhanced+Antiproliferative+Activities+Against+Tumor+Cells&doi=10.1016%2Fj.ejmech.2017.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells</span></div><div class="casAuthors">Chen, Li; Zhang, Yaling; Liu, Juan; Wang, Weijia; Li, Xiabing; Zhao, Lijun; Wang, Wei; Li, Baolin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">689-697</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel 4-anilinoquinazoline derivs. with (E)-propen-1-yl moiety I (R1 = R2 = methoxy, 2-morpholinoethoxy, 3-morpholinopropoxy) were designed, synthesized and evaluated for biol. activities in vitro.  Most compds. exhibited high antiproliferative activities against all tested tumor cell lines including A431, A549, NCI-H1975 and SW480 cells.  Esp., compd. I (R1 = R2 = 3-morpholinopropoxy) not only presented strong antiproliferative activities against the tested four tumor cell lines (IC50 of 1.35, 8.83, 5.53 and 6.08 μM, resp.) which expressed wild type or L858R/T790M double mutant epidermal growth factor receptor (EGFR), but also showed potent inhibitory activity against wild type EGFR (IC50 = 20.72 nM).  The result of mol. docking with EGFR suggested the binding mode of compd. I (R1 = R2 = 3-morpholinopropoxy) was similar to gefitinib, but different from lapatinib.  Addnl., western blot anal. showed that compd. I (R1 = R2 = 3-morpholinopropoxy) inhibited the phosphorylation of EGFR and its downstream signaling proteins in lung cancer cells.  The work could be very useful starting point for developing a new series of tyrosine kinase inhibitors targeting EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB06gE-JAQSLVg90H21EOLACvtfcHk0lg1Zy5zVue90w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Wls7nI&md5=c87fb7dfb796076c10bf66bb193017dc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DB.%26atitle%3DNovel%25204-Arylaminoquinazoline%2520Derivatives%2520with%2520%2528E%2529-Propen-1-yl%2520moiety%2520as%2520Potent%2520EGFR%2520Inhibitors%2520with%2520Enhanced%2520Antiproliferative%2520Activities%2520Against%2520Tumor%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D138%26issue%3DSupplement%2520C%26spage%3D689%26epage%3D697%26doi%3D10.1016%2Fj.ejmech.2017.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&issue=13&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+Pyridinylimidazoles+as+Potent+Inhibitors+of+the+Clinically+Resistant+L858R%2FT790M%2FC797S+EGFR+Mutant%3A+Targeting+of+Both+Hydrophobic+Regions+and+the+Phosphate+Binding+Site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0lg1Zy5zVue90w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Pyridinylimidazoles%2520as%2520Potent%2520Inhibitors%2520of%2520the%2520Clinically%2520Resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520Mutant%253A%2520Targeting%2520of%2520Both%2520Hydrophobic%2520Regions%2520and%2520the%2520Phosphate%2520Binding%2520Site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D13%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokushima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishibashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oku, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwao, M.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of A-Ring-Modified Lamellarin N Analogues as Noncovalent Inhibitors of the EGFR T790M/L858R Mutant</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">6563</span>– <span class="NLM_lpage">5680</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.10.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmc.2017.10.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29133033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2qt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6563-5680&issue=24&author=T.+Fukudaauthor=T.+Umekiauthor=K.+Tokushimaauthor=G.+Xiangauthor=Y.+Yoshidaauthor=F.+Ishibashiauthor=Y.+Okuauthor=N.+Nishiyaauthor=Y.+Ueharaauthor=M.+Iwao&title=Design%2C+Synthesis%2C+and+Evaluation+of+A-Ring-Modified+Lamellarin+N+Analogues+as+Noncovalent+Inhibitors+of+the+EGFR+T790M%2FL858R+Mutant&doi=10.1016%2Fj.bmc.2017.10.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant</span></div><div class="casAuthors">Fukuda, Tsutomu; Umeki, Teppei; Tokushima, Keiji; Xiang, Gao; Yoshida, Yuki; Ishibashi, Fumito; Oku, Yusuke; Nishiya, Naoyuki; Uehara, Yoshimasa; Iwao, Masatomo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6563-6580</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of A-ring-modified lamellarin N analogs were designed, synthesized, and evaluated as potential noncovalent inhibitors of the EGFR T790M/L858R mutant, a causal factor in the drug-resistant non-small cell lung cancer.  Several water-sol. ammonium- or guanidinium-tethered analogs exhibited good kinase inhibitory activities.  The most promising analog, 14f, displayed an excellent inhibitory profile against the T790M/L858R mutant [IC50 (WT) = 31.8 nM; IC50 (T790M/L858R) = 8.9 nM].  The effects of A-ring-substituents on activity were rationalized by docking studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5XVsxrAkmpLVg90H21EOLACvtfcHk0lggyEdgW-cHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2qt7zP&md5=9686c83c5426d7f389ed885ff2b5ccf5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.10.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.10.030%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DUmeki%26aufirst%3DT.%26aulast%3DTokushima%26aufirst%3DK.%26aulast%3DXiang%26aufirst%3DG.%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DIshibashi%26aufirst%3DF.%26aulast%3DOku%26aufirst%3DY.%26aulast%3DNishiya%26aufirst%3DN.%26aulast%3DUehara%26aufirst%3DY.%26aulast%3DIwao%26aufirst%3DM.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520A-Ring-Modified%2520Lamellarin%2520N%2520Analogues%2520as%2520Noncovalent%2520Inhibitors%2520of%2520the%2520EGFR%2520T790M%252FL858R%2520Mutant%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D24%26spage%3D6563%26epage%3D5680%26doi%3D10.1016%2Fj.bmc.2017.10.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2,4,6-Trisubstitued Pyrido[3,4-d]pyrimidine Derivatives as new EGFR-TKIs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.02.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.ejmech.2018.02.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29466773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2018&pages=221-237&author=H.+Zhangauthor=J.+Wangauthor=Y.+Shenauthor=H.+Y.+Wangauthor=W.+M.+Duanauthor=H.+Y.+Zhaoauthor=Y.+Y.+Heiauthor=M.+Xinauthor=Y.+X.+Caoauthor=S.+Q.+Zhang&title=Discovery+of+2%2C4%2C6-Trisubstitued+Pyrido%5B3%2C4-d%5Dpyrimidine+Derivatives+as+new+EGFR-TKIs&doi=10.1016%2Fj.ejmech.2018.02.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs</span></div><div class="casAuthors">Zhang, Hao; Wang, Jin; Shen, Ying; Wang, Hui-Yan; Duan, Wei-Ming; Zhao, Hong-Yi; Hei, Yuan-Yuan; Xin, Minhang; Cao, Yong-Xiao; Zhang, San-Qi</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">221-237</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance is the major challenge in the treatment of EGFR-driven non-small cell lung cancer (NSCLC).  In this study, a novel class of compds. contg. pyrido[3,4-d]pyrimidine scaffold was designed as new generation EGFR-TKIs to overcome this challenge.  The most promising compd. I inhibited HCC827 and H1975 cells growth with the IC50 values of 0.044μM and 0.40μM, resp.  Meanwhile, I displayed potent inhibitory activity against the EGFRL858R (IC50=1.1nM) and EGFRL858R/T790M/C797S (IC50=7.2nM).  I could suppress EGFR phosphorylation in a dose-dependent manner in HCC827 cell line and significantly induce the apoptosis of HCC827 cells.  Mol. docking indicated that the hydroxyl in I could form addnl. hydrogen bond with mutant Ser797.  These findings strongly support our assumption that 2,4,6-trisubstitued pyrido[3,4-d] pyrimidine derivs. can serve as EGFR-TKIs.  The predicted hydrogen bond interaction formed by a small mol. inhibitor with mutant Ser797 is available to design the fourth-generation EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3S8daGHVu6bVg90H21EOLACvtfcHk0lggyEdgW-cHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1yru70%253D&md5=533499fed54c750cfde176522bbdfd52</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DDuan%26aufirst%3DW.%2BM.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DHei%26aufirst%3DY.%2BY.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DS.%2BQ.%26atitle%3DDiscovery%2520of%25202%252C4%252C6-Trisubstitued%2520Pyrido%255B3%252C4-d%255Dpyrimidine%2520Derivatives%2520as%2520new%2520EGFR-TKIs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237%26doi%3D10.1016%2Fj.ejmech.2018.02.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievers-Engler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lämmerhofer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">4636</span>– <span class="NLM_lpage">4656</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00178</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00178" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4636-4656&issue=11&author=M.+Juchumauthor=M.+G%C3%BCntherauthor=E.+D%C3%B6ringauthor=A.+Sievers-Englerauthor=M.+L%C3%A4mmerhoferauthor=S.+Laufer&title=Trisubstituted+Imidazoles+with+a+Rigidized+Hinge+Binding+Motif+Act+As+Single+Digit+nM+Inhibitors+of+Clinically+Relevant+EGFR+L858R%2FT790M+and+L858R%2FT790M%2FC797S+Mutants%3A+An+Example+of+Target+Hopping&doi=10.1021%2Facs.jmedchem.7b00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping</span></div><div class="casAuthors">Juchum, Michael; Guenther, Marcel; Doering, Eva; Sievers-Engler, Adrian; Laemmerhofer, Michael; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4636-4656</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trisubstituted imidazoles with a rigidized 7-azaindole hinge binding motif such as I were prepd. as inhibitors of EGFR tyrosine kinase with L858R/T790M/C797S mutations (against which current EGFR inhibitors are ineffective) for potential use in the treatment of non-small-cell lung cancer.  II [X = (CH2)2, (CH2)4] reversibly inhibited the clin. challenging EGFR tyrosine kinase triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.  I inhibited EGFR tyrosine kinase irreversibly with IC50 value of 1 nM against the EGFR L858R/T790M double mutant; I was selective for EGFR tyrosine kinase over other related kinases except for MAP4K4, MAP4K5, and MINK.  The kinetics of target inhibition, aq. soly, and metabolites were detd. for I and for selected compds.; mol. docking calcns. were also performed for selected compds. with EGFR isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzeDYy9aSCrLVg90H21EOLACvtfcHk0lggyEdgW-cHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnt1Ciu78%253D&md5=a7003c8160b506ce964edce6adf7c3ff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00178%26sid%3Dliteratum%253Aachs%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DSievers-Engler%26aufirst%3DA.%26aulast%3DL%25C3%25A4mmerhofer%26aufirst%3DM.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520Imidazoles%2520with%2520a%2520Rigidized%2520Hinge%2520Binding%2520Motif%2520Act%2520As%2520Single%2520Digit%2520nM%2520Inhibitors%2520of%2520Clinically%2520Relevant%2520EGFR%2520L858R%252FT790M%2520and%2520L858R%252FT790M%252FC797S%2520Mutants%253A%2520An%2520Example%2520of%2520Target%2520Hopping%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D11%26spage%3D4636%26epage%3D4656%26doi%3D10.1021%2Facs.jmedchem.7b00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1123</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1123-1127&issue=11&author=X.+Luauthor=T.+Zhangauthor=S.-J.+Zhuauthor=Q.+Xunauthor=L.+Tongauthor=X.+Huauthor=Y.+Liauthor=S.+Chanauthor=Y.+Suauthor=Y.+Sunauthor=Y.+Chenauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=K.+Ding&title=Discovery+of+JND3229+as+a+New+EGFRC797S+Mutant+Inhibitor+with+In+Vivo+Monodrug+Efficacy&doi=10.1021%2Facsmedchemlett.8b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy</span></div><div class="casAuthors">Lu, Xiaoyun; Zhang, Tao; Zhu, Su-Jie; Xun, Qiuju; Tong, Lingjiang; Hu, Xianglong; Li, Yan; Chan, Shingpan; Su, Yi; Sun, Yiming; Chen, Yi; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1123-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">EGFRC797S mutation inducing resistance against third generation EGFR inhibitor drugs is an emerging "unmet clin. need" for nonsmall cell lung cancer patients.  The pyrimidopyrimidinone deriv. JND3229 was identified as a new highly potent EGFRC797S inhibitor with single digit nM potency.  It also exhibited good in vitro and in vivo monodrug anticancer efficacy in a xenograft mouse model of BaF3/EGFR19D/T790M/C797S cells.  A high-resoln. x-ray crystallog. structure was also detd. to elucidate the interactions between JND3229 and EGFRT790M/C797S.  The study provides an important structural and chem. basis for future development of new generation EGFRC797S inhibitors as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOPToZCT3HBLVg90H21EOLACvtfcHk0ljgQXNZW9b8fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKqtrfP&md5=02505ac363697e9a5b1bbe2db0b0357b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DXun%26aufirst%3DQ.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520JND3229%2520as%2520a%2520New%2520EGFRC797S%2520Mutant%2520Inhibitor%2520with%2520In%2520Vivo%2520Monodrug%2520Efficacy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.8b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgardner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as Non-cCvalent Inhibitors of Mutant Epidermal Growth Factor Receptor Tyrosine Kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmcl.2015.11.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=26639762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFant7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=534-539&issue=2&author=E.+J.+Hananauthor=M.+Baumgardnerauthor=M.+C.+Bryanauthor=Y.+Chenauthor=C.+Eigenbrotauthor=P.+Fanauthor=X.+H.+Guauthor=H.+Laauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=S.+Siderisauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=4-Aminoindazolyl-dihydrofuro%5B3%2C4-d%5Dpyrimidines+as+Non-cCvalent+Inhibitors+of+Mutant+Epidermal+Growth+Factor+Receptor+Tyrosine+Kinase&doi=10.1016%2Fj.bmcl.2015.11.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Hanan, Emily J.; Baumgardner, Matt; Bryan, Marian C.; Chen, Yuan; Eigenbrot, Charles; Fan, Peter; Gu, Xiao-Hui; La, Hank; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Sideris, Steve; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-539</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The treatment of epidermal growth factor receptor (EGFR)-driven non-small cell lung cancers with the T790M resistance mutation remains a significant unmet medical need.  The authors report the identification of 4-aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of EGFR, with excellent activity against the T790M resistance double mutants and initial single activating mutants.  Using an optimization strategy focused on structure-based design and improving PK properties through metabolite identification, the authors obtained advanced leads with high oral exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoXgVh2AtAg7Vg90H21EOLACvtfcHk0ljgQXNZW9b8fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFant7vE&md5=1c4d8dd8b2b57b4480cc120a52b00c59</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.078%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DX.%2BH.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3D4-Aminoindazolyl-dihydrofuro%255B3%252C4-d%255Dpyrimidines%2520as%2520Non-cCvalent%2520Inhibitors%2520of%2520Mutant%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D2%26spage%3D534%26epage%3D539%26doi%3D10.1016%2Fj.bmcl.2015.11.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez-Fernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">8877</span>– <span class="NLM_lpage">8895</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01412</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01412" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1emtbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8877-8895&issue=22&author=R.+Healdauthor=K.+K.+Bowmanauthor=M.+C.+Bryanauthor=D.+Burdickauthor=B.+Chanauthor=E.+Chanauthor=Y.+Chenauthor=S.+Clausenauthor=B.+Dominguez-Fernandezauthor=C.+Eigenbrotauthor=R.+Elliottauthor=E.+J.+Hananauthor=P.+Jacksonauthor=J.+Knightauthor=H.+Laauthor=M.+Lainchburyauthor=S.+Malekauthor=S.+Mannauthor=M.+Merchantauthor=K.+Mortaraauthor=H.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+Sewardauthor=S.+Siderisauthor=L.+Shaoauthor=S.+Wangauthor=K.+Yeapauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=Noncovalent+Mutant+Selective+Epidermal+Growth+Factor+Receptor+Inhibitors%3A+A+Lead+Optimization+Case+Study&doi=10.1021%2Facs.jmedchem.5b01412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study</span></div><div class="casAuthors">Heald, Robert; Bowman, Krista K.; Bryan, Marian C.; Burdick, Daniel; Chan, Bryan; Chan, Emily; Chen, Yuan; Clausen, Saundra; Dominguez-Fernandez, Belen; Eigenbrot, Charles; Elliott, Richard; Hanan, Emily J.; Jackson, Philip; Knight, Jamie; La, Hank; Lainchbury, Michael; Malek, Shiva; Mann, Sam; Merchant, Mark; Mortara, Kyle; Purkey, Hans; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen; Sideris, Steve; Shao, Lily; Wang, Shumei; Yeap, Kuen; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8877-8895</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of their increased activity against activating mutants, first-generation epidermal growth factor receptor (EGFR) kinase inhibitors have had remarkable success in treating non-small-cell lung cancer (NSCLC) patients, but acquired resistance, through a secondary mutation of the gatekeeper residue, means that clin. responses only last for 8-14 mo.  Addressing this unmet medical need requires agents that can target both of the most common double mutants: T790M/L858R (TMLR) and T790M/del(746-750) (TMdel).  Herein we describe how a noncovalent double mutant selective lead compd. was optimized using a strategy focused on the structure-guided increase in potency without added lipophilicity or redn. of three-dimensional character.  Following successive rounds of design and synthesis it was discovered that cis-fluoro substitution on 4-hydroxy- and 4-methoxypiperidinyl groups provided synergistic, substantial, and specific potency gain through direct interaction with the enzyme and/or effects on the proximal ligand oxygen atom.  Further development of the fluorohydroxypiperidine series resulted in the identification of a pair of diastereomers that showed 50-fold enzyme and cell based selectivity for T790M mutants over wild-type EGFR (wtEGFR) in vitro and pathway knock-down in an in vivo xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjYmZnCNtnWbVg90H21EOLACvtfcHk0lg9Vb654dCCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1emtbnL&md5=18978e79a7bc894b91a0ab453b276dd6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01412%26sid%3Dliteratum%253Aachs%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DB.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DClausen%26aufirst%3DS.%26aulast%3DDominguez-Fernandez%26aufirst%3DB.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DJackson%26aufirst%3DP.%26aulast%3DKnight%26aufirst%3DJ.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DS.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DPurkey%26aufirst%3DH.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DNoncovalent%2520Mutant%2520Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitors%253A%2520A%2520Lead%2520Optimization%2520Case%2520Study%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D22%26spage%3D8877%26epage%3D8895%26doi%3D10.1021%2Facs.jmedchem.5b01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10176</span>– <span class="NLM_lpage">10191</span>, <span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&issue=23&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+Selective+and+Noncovalent+Diaminopyrimidine-Based+Inhibitors+of+Epidermal+Growth+Factor+Receptor+Containing+the+T790M+Resistance+Mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0lg9Vb654dCCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520Selective%2520and%2520Noncovalent%2520Diaminopyrimidine-Based%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Containing%2520the%2520T790M%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=100-104&issue=1&author=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=S.+Clausenauthor=J.+Dotsonauthor=C.+Eigenbrotauthor=R.+Elliottauthor=E.+J.+Hananauthor=R.+Healdauthor=P.+Jacksonauthor=H.+Laauthor=M.+Lainchburyauthor=S.+Malekauthor=S.+E.+Mannauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+Sewardauthor=S.+Siderisauthor=S.+Wangauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=Pyridones+as+Highly+Selective%2C+Noncovalent+Inhibitors+of+T790M+Double+Mutants+of+EGFR&doi=10.1021%2Facsmedchemlett.5b00428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR</span></div><div class="casAuthors">Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Clausen, Saundra; Dotson, Jennafer; Eigenbrot, Charles; Elliott, Richard; Hanan, Emily J.; Heald, Robert; Jackson, Philip; La, Hank; Lainchbury, Michael; Malek, Shiva; Mann, Sam E.; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen; Sideris, Steve; Wang, Shumei; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-104</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The rapid advancement of a series of noncovalent inhibitors of T790M mutants of EGFR is discussed.  The optimization of a nonselective high-throughput screening pyridone hit to potent mols. with high levels of selectivity over wtEGFR and the broader kinome is described herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxw6S7lm_va7Vg90H21EOLACvtfcHk0lg9Vb654dCCbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqt7vK&md5=86cdd147b8fb9c5515dd9630584562ef</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00428%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DClausen%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DP.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DMann%26aufirst%3DS.%2BE.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DPyridones%2520as%2520Highly%2520Selective%252C%2520Noncovalent%2520Inhibitors%2520of%2520T790M%2520Double%2520Mutants%2520of%2520EGFR%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D1%26spage%3D100%26epage%3D104%26doi%3D10.1021%2Facsmedchemlett.5b00428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of EGF Receptor Inhibitors That Are Selective for the d746–750/T790M/C797S Mutant through Structure-Based de Novo Design</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">26</span>),  <span class="NLM_fpage">7634</span>– <span class="NLM_lpage">7638</span>, <span class="refDoi"> DOI: 10.1002/anie.201703389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1002%2Fanie.201703389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=7634-7638&issue=26&author=H.+Parkauthor=H.-Y.+Jungauthor=S.+Mahauthor=S.+Hong&title=Discovery+of+EGF+Receptor+Inhibitors+That+Are+Selective+for+the+d746%E2%80%93750%2FT790M%2FC797S+Mutant+through+Structure-Based+de+Novo+Design&doi=10.1002%2Fanie.201703389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of EGF Receptor Inhibitors that are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design</span></div><div class="casAuthors">Park, Hwangseo; Jung, Hoi-Yun; Mah, Shinmee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7634-7638</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Next-generation epidermal growth factor receptor (EGFR) inhibitors against the d746-750/T790M/C797S mutation were discovered through two-track virtual screening and de novo design.  A no. of nanomolar inhibitors were identified using 2-aryl-4-aminoquinazoline as the mol. core and the modified binding energy function involving a proper dehydration term, which provides important structural insight into the key principles for high inhibitory activities against the d746-750/T790M/C797S mutant.  Furthermore, some of these EGFR inhibitors showed a greater than 1000-fold selectivity for the d746-750/T790M/C797S mutant over the wild type, as well as nanomolar activity against the mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGVR5gzqeK27Vg90H21EOLACvtfcHk0ljUpzowaoZQVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotF2jtLk%253D&md5=93fd25a8b5af1add58fe8b27723edb0e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fanie.201703389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201703389%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DH.-Y.%26aulast%3DMah%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520EGF%2520Receptor%2520Inhibitors%2520That%2520Are%2520Selective%2520for%2520the%2520d746%25E2%2580%2593750%252FT790M%252FC797S%2520Mutant%2520through%2520Structure-Based%2520de%2520Novo%2520Design%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D26%26spage%3D7634%26epage%3D7638%26doi%3D10.1002%2Fanie.201703389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dela Vega, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">9080</span>– <span class="NLM_lpage">9093</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWlsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9080-9093&issue=19&author=B.+K.+Chanauthor=E.+J.+Hananauthor=K.+K.+Bowmanauthor=M.+C.+Bryanauthor=D.+Burdickauthor=E.+Chanauthor=Y.+Chenauthor=S.+Clausenauthor=T.+Dela+Vegaauthor=J.+Dotsonauthor=C.+Eigenbrotauthor=R.+L.+Elliottauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=J.+D.+Knightauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=L.+Shaoauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=C.+Yuauthor=T.+P.+Heffron&title=Discovery+of+a+Noncovalent%2C+Mutant-Selective+Epidermal+Growth+Factor+Receptor+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor</span></div><div class="casAuthors">Chan, Bryan K.; Hanan, Emily J.; Bowman, Krista K.; Bryan, Marian C.; Burdick, Daniel; Chan, Emily; Chen, Yuan; Clausen, Saundra; Dela Vega, Trisha; Dotson, Jennafer; Eigenbrot, Charles; Elliott, Richard L.; Heald, Robert A.; Jackson, Philip S.; Knight, Jamie D.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Shao, Lily; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yu, Christine; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9080-9093</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors targeting the activating mutants of the epidermal growth factor receptor (EGFR) have found success in the treatment of EGFR mutant pos. nonsmall-cell lung cancer.  A secondary point mutation (T790M) in the inhibitor binding site has been linked to the acquired resistance against those first generation therapeutics.  Herein, the authors describe the lead optimization of a series of reversible, pan-mutant (L858R, del746-750, T790M/L858R, and T790M/del746-750) EGFR inhibitors.  By use of a noncovalent double mutant (T790M/L858R and T790M/del746-750) selective EGFR inhibitor I as a starting point, activities against the single mutants (L858R and del746-750) were introduced through a series of structure-guided modifications.  The in vitro ADME-PK properties of the lead mols. were further optimized through a no. of rational structural changes.  The resulting inhibitor II exhibited excellent cellular activity against both the single and double mutants of EGFR, demonstrating target engagement in vivo and ADME-PK properties that are suitable for further evaluation.  The reversible, noncovalent inhibitors described complement the covalent pan-mutant EGFR inhibitors that have shown encouraging results in recent clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgSFhbM4LOYrVg90H21EOLACvtfcHk0ljUpzowaoZQVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWlsbnL&md5=7b17fcf5fc401843821445cf6e6e9f0b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00995%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DBowman%26aufirst%3DK.%2BK.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DClausen%26aufirst%3DS.%26aulast%3DDela%2BVega%26aufirst%3DT.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DElliott%26aufirst%3DR.%2BL.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DKnight%26aufirst%3DJ.%2BD.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520Noncovalent%252C%2520Mutant-Selective%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D19%26spage%3D9080%26epage%3D9093%26doi%3D10.1021%2Facs.jmedchem.6b00995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noolvi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, S.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Quinazolinones as EGFR Inhibitors to Overcome EGFR Resistance Obstacle</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2723</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.03.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bmc.2017.03.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28366268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVCjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=2713-2723&issue=10&author=H.+M.+Patelauthor=R.+Pawaraauthor=A.+Ansariauthor=M.+Noolviauthor=S.+Surana&title=Design+and+Synthesis+of+Quinazolinones+as+EGFR+Inhibitors+to+Overcome+EGFR+Resistance+Obstacle&doi=10.1016%2Fj.bmc.2017.03.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle</span></div><div class="casAuthors">Patel, Harun M.; Pawara, Rahul; Ansari, Azim; Noolvi, Malleshappa; Surana, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2713-2723</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) T790M mutant is found in about 50% of clin. acquired resistance to gefitinib among patients with non-small cell lung cancer (NSCLC).  New derivs. of 4(3H)-quinazolinones were synthesized and evaluated for their inhibitory activity against NSCLC.  The results of the study demonstrated that compd. 79, 7-chloro-3-(5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylquinazolin-4(3H)-one was found to be the most potent compds. of the series with IC50 value of 0.031 μM against mutant T790M/L858R EGFR.  Compds. 15, 51, 73, 75, 78, 79 and 96 were less potent against A549 (WT EGFR and k-Ras mutation) and HT-29 (non-special gene type) cells, showing a high safety index.  The obtained results showed that compds. 15, 51, 73, 75, 78, 79 and 96 could be the promising template to overcome drug resistance mediated by the EGFR T790 Mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0aFIxV-do07Vg90H21EOLACvtfcHk0lgBi7WHWNSh1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVCjurk%253D&md5=33605a4dfa008b4e61ab4bb42b523a42</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.03.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.03.039%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BM.%26aulast%3DPawara%26aufirst%3DR.%26aulast%3DAnsari%26aufirst%3DA.%26aulast%3DNoolvi%26aufirst%3DM.%26aulast%3DSurana%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Quinazolinones%2520as%2520EGFR%2520Inhibitors%2520to%2520Overcome%2520EGFR%2520Resistance%2520Obstacle%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26issue%3D10%26spage%3D2713%26epage%3D2723%26doi%3D10.1016%2Fj.bmc.2017.03.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">EAI045: The Fourth-Generation EGFR Inhibitor Overcoming T790M and C797S resistance</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.canlet.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=27840244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2017&pages=51-54&author=S.+Wangauthor=Y.+Songauthor=D.+Liu&title=EAI045%3A+The+Fourth-Generation+EGFR+Inhibitor+Overcoming+T790M+and+C797S+resistance&doi=10.1016%2Fj.canlet.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</span></div><div class="casAuthors">Wang, Shuhang; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-54</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M pos. non-small cell lung cancer (NSCLC).  However, resistance develops rapidly.  EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors.  The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third-generation inhibitors.  This review summarizes the latest development on the discovery of a fourth-generation EGFR TKI, EAI045.3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2GMAIDfgfeLVg90H21EOLACvtfcHk0lgBi7WHWNSh1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVeqtL%252FM&md5=e429055412bec2ec2da28b2b959753ae</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DEAI045%253A%2520The%2520Fourth-Generation%2520EGFR%2520Inhibitor%2520Overcoming%2520T790M%2520and%2520C797S%2520resistance%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D385%26spage%3D51%26epage%3D54%26doi%3D10.1016%2Fj.canlet.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spellmon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span> <span> </span><span class="NLM_article-title">Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1756</span>– <span class="NLM_lpage">1758</span>, <span class="refDoi"> DOI: 10.21037/jtd.2017.06.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.21037%2Fjtd.2017.06.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28839955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhsFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1756-1758&issue=7&author=N.+Spellmonauthor=C.+Liauthor=Z.+Yang&title=Allosterically+Targeting+EGFR+Drug-Resistance+Gatekeeper+Mutations&doi=10.21037%2Fjtd.2017.06.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Allosterically targeting EGFR drug-resistance gatekeeper mutations</span></div><div class="casAuthors">Spellmon Nicholas; Yang Zhe; Li Chunying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1756-1758</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMer61q-2iHLZpSb_XWfMrfW6udTcc2ea-9CB-TZQRlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhsFCmsg%253D%253D&md5=32e7407f858050a7ddbb026c5477d183</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.21037%2Fjtd.2017.06.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Fjtd.2017.06.43%26sid%3Dliteratum%253Aachs%26aulast%3DSpellmon%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26atitle%3DAllosterically%2520Targeting%2520EGFR%2520Drug-Resistance%2520Gatekeeper%2520Mutations%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2017%26volume%3D9%26issue%3D7%26spage%3D1756%26epage%3D1758%26doi%3D10.21037%2Fjtd.2017.06.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatachalam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surana, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, C.</span></span> <span> </span><span class="NLM_article-title">Conformational Landscape of the Epidermal Growth Factor Receptor Kinase Reveals a Mutant Specific Allosteric Pocket</span>. <i>Chemical Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5212</span>– <span class="NLM_lpage">5222</span>, <span class="refDoi"> DOI: 10.1039/C8SC01262H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1039%2FC8SC01262H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29997876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFCntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=5212-5222&issue=23&author=S.+Kannanauthor=G.+Venkatachalamauthor=H.+H.+Limauthor=U.+Suranaauthor=C.+Verma&title=Conformational+Landscape+of+the+Epidermal+Growth+Factor+Receptor+Kinase+Reveals+a+Mutant+Specific+Allosteric+Pocket&doi=10.1039%2FC8SC01262H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket</span></div><div class="casAuthors">Kannan, Srinivasaraghavan; Venkatachalam, Gireedhar; Lim, Hong Hwa; Surana, Uttam; Verma, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5212-5222</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain give rise to several cancers including Non-Small Cell Lung Cancer (NSCLC).  Small mol. inhibitors targeted at these mutants have proven to be clin. successful drugs.  These mols. are ATP competitive and rapidly result in the emergence of resistance.  We present here a study combining extensive mol. dynamics simulations with binding assays to provide a structural basis underlying the mechanism of binding of this mol.  It appears that in mutants, conformational destabilization of the short helix (that carries Leu858 in the wildtype), is key to the exposure of the allosteric pocket which otherwise is occluded by a set of sidechains including L858.  We extend this hypothesis to show that a similar mechanism would enable the mol. to inhibit EGFRL861Q which is another oncogenic mutant and validate this with binding expts.  The screening of the human structural kinome revealed at least 12 other oncogenic kinases which carry at least one activating mutant in this disorder-prone region and hence would be amenable to allosteric inhibition by mols. such as EAI045.  Our study characterizes a druggable allosteric pocket which appears to be specific to certain oncogenic mutants of the EGFR and holds therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNJMPumMkZFbVg90H21EOLACvtfcHk0lgAQQAMMxLf3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFCntLo%253D&md5=57b221846f35482d03d19944ccc48919</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FC8SC01262H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC01262H%26sid%3Dliteratum%253Aachs%26aulast%3DKannan%26aufirst%3DS.%26aulast%3DVenkatachalam%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DH.%2BH.%26aulast%3DSurana%26aufirst%3DU.%26aulast%3DVerma%26aufirst%3DC.%26atitle%3DConformational%2520Landscape%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Kinase%2520Reveals%2520a%2520Mutant%2520Specific%2520Allosteric%2520Pocket%26jtitle%3DChemical%2520Science%26date%3D2018%26volume%3D9%26issue%3D23%26spage%3D5212%26epage%3D5222%26doi%3D10.1039%2FC8SC01262H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caporuscio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinivella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semrau, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storici, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Identification of Small-Molecule EGFR Allosteric Inhibitors by High-Throughput Docking</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1553</span>, <span class="refDoi"> DOI: 10.4155/fmc-2018-0063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.4155%2Ffmc-2018-0063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29766737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1545-1553&issue=13&author=F.+Caporuscioauthor=A.+Tinivellaauthor=V.+Restelliauthor=M.+S.+Semrauauthor=L.+Pinziauthor=P.+Storiciauthor=M.+Brogginiauthor=G.+Rastelli&title=Identification+of+Small-Molecule+EGFR+Allosteric+Inhibitors+by+High-Throughput+Docking&doi=10.4155%2Ffmc-2018-0063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking</span></div><div class="casAuthors">Caporuscio, Fabiana; Tinivella, Annachiara; Restelli, Valentina; Semrau, Marta S.; Pinzi, Luca; Storici, Paola; Broggini, Massimo; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1545-1553</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Aim: The EGFR inhibitors represent the first-line treatment of non-small-cell lung cancer.  However, the emergence of resistance urgently requires the development of new inhibitors targeting drug-resistant mutants.  Methodol.: A recently released structure of an EGFR kinase domain in complex with an allosteric inhibitor and a mutant protein model derived from it were used to set up a low-cost high-throughput docking protocol for the fast identification of EGFR allosteric inhibitors.  Conclusion: The virtual screening of com. available compds. led to the identification of interesting new hit compds.  The most promising hit was confirmed to be a new allosteric inhibitor of wild-type and T790M/L858R double mutant EGFR which was able to inhibit the growth of  non-small-cell lung cancer cell lines.  Graphical abstr. :.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy2wOxQCD3n7Vg90H21EOLACvtfcHk0lgAQQAMMxLf3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqurrJ&md5=4dc540ab8c42e50048b8f7f9f00a6a38</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0063%26sid%3Dliteratum%253Aachs%26aulast%3DCaporuscio%26aufirst%3DF.%26aulast%3DTinivella%26aufirst%3DA.%26aulast%3DRestelli%26aufirst%3DV.%26aulast%3DSemrau%26aufirst%3DM.%2BS.%26aulast%3DPinzi%26aufirst%3DL.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520Small-Molecule%2520EGFR%2520Allosteric%2520Inhibitors%2520by%2520High-Throughput%2520Docking%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26issue%3D13%26spage%3D1545%26epage%3D1553%26doi%3D10.4155%2Ffmc-2018-0063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of EGFR T790M/C797S/V948R in Complex with EAI045</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>502</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.05.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fj.bbrc.2018.05.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29802850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=502&publication_year=2018&pages=332-337&issue=3&author=P.+Zhaoauthor=M.+Y.+Yaoauthor=S.+J.+Zhuauthor=J.+Y.+Chenauthor=C.+H.+Yun&title=Crystal+Structure+of+EGFR+T790M%2FC797S%2FV948R+in+Complex+with+EAI045&doi=10.1016%2Fj.bbrc.2018.05.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045</span></div><div class="casAuthors">Zhao, Peng; Yao, Ming-Yu; Zhu, Su-Jie; Chen, Ji-Yun; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">502</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">332-337</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lung cancer is the leading cause of cancer deaths.  Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype of lung cancers.  Patients harboring most of these mutations respond well to the anti-EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib initially, but soon develop resistance to them in about half of the cases due to the emergence of the gatekeeper mutation T790M.  The third-generation TKIs such as AZD9291, HM61713, CO-1686 and WZ4002 can overcome T790M through covalent binding to the EGFR kinase through Cys 797, but ultimately lose their efficacy upon emergence of the C797S mutation that abolishes the covalent bonding.  Therefore to develop new TKIs to overcome EGFR drug-resistant mutants harboring T790M/C797S is urgently demanded.  EAI001 and EAI045 are a new type of EGFR TKIs that bind to EGFR reversibly and not relying on Cys 797.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR L858R/T790M and L858R/T790M/C797S.  Here we report the crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, and compare it to EGFR T790M/V948R in complex with EAI001.  The complex structure reveals why EAI045 binds tighter to EGFR than does EAI001, and why EAI001 and EAI045 prefer binding to EGFR T790M.  The knowledge may facilitate future drug development studies targeting this very important cancer target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouEvBqE0oB5LVg90H21EOLACvtfcHk0lgAQQAMMxLf3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKrtL7I&md5=b76b6a40ffef581fa2d5ca0a45bb8c14</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.05.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.05.154%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DM.%2BY.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DCrystal%2520Structure%2520of%2520EGFR%2520T790M%252FC797S%252FV948R%2520in%2520Complex%2520with%2520EAI045%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D502%26issue%3D3%26spage%3D332%26epage%3D337%26doi%3D10.1016%2Fj.bbrc.2018.05.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="note"><p class="first last">To determine the kinase selectivity for a given compound, the “SelectScreen Kinase Profiling Services” from ThermoFisher was used. The activity of a compound was determined in biochemical assays using single concentration measurements. The results were provided as percent inhibition values. A compound displaying a percent inhibition value of greater 70% was defined as hit. Three different kinase panels were used (30 kinases, 238 kinases, and 393 kinases), and the lists of kinases for these repective panels are provided in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf" class="ext-link">Tables S5–S7</a>. The EGFR<sup>L858R T790M C797S</sup> kinase assay was used as positive control.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traxler, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span> <span> </span><span class="NLM_article-title">Strategies Toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>82</i></span> (<span class="NLM_issue">2–3</span>),  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(98)00044-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&issue=2%E2%80%933&author=P.+Traxlerauthor=P.+Furet&title=Strategies+Toward+the+Design+of+Novel+and+Selective+Protein+Tyrosine+Kinase+Inhibitors&doi=10.1016%2FS0163-7258%2898%2900044-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0liCXcqHe0K1Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520Toward%2520the%2520Design%2520of%2520Novel%2520and%2520Selective%2520Protein%2520Tyrosine%2520Kinase%2520Inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26issue%3D2%25E2%2580%25933%26spage%3D195%26epage%3D206%26doi%3D10.1016%2FS0163-7258%2898%2900044-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chai, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head-Gordon, M.</span></span> <span> </span><span class="NLM_article-title">Long-range Corrected Hybrid Density Functionals With Damped Atom-Atom Dispersion Corrections</span>. <i>Phys. Chem. Chem. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">6615</span>– <span class="NLM_lpage">6620</span>, <span class="refDoi"> DOI: 10.1039/b810189b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1039%2Fb810189b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=18989472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCksbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=6615-6620&issue=44&author=J.-D.+Chaiauthor=M.+Head-Gordon&title=Long-range+Corrected+Hybrid+Density+Functionals+With+Damped+Atom-Atom+Dispersion+Corrections&doi=10.1039%2Fb810189b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Long-range corrected hybrid density functionals with damped atom-atom dispersion corrections</span></div><div class="casAuthors">Chai, Jeng-Da; Head-Gordon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Physical Chemistry Chemical Physics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">6615-6620</span>CODEN:
                <span class="NLM_cas:coden">PPCPFQ</span>;
        ISSN:<span class="NLM_cas:issn">1463-9076</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">We report re-optimization of a recently proposed long-range cor. (LC) hybrid d. functional [J.-D. Chai and M. Head-Gordon, J. Chem. Phys., 2008, 128, 084106] to include empirical atom-atom dispersion corrections.  The resulting functional, ωB97X-D yields satisfactory accuracy for thermochem., kinetics, and non-covalent interactions.  Tests show that for non-covalent systems, ωB97X-D shows slight improvement over other empirical dispersion-cor. d. functionals, while for covalent systems and kinetics it performs noticeably better.  Relative to our previous functionals, such as ωB97X, the new functional is significantly superior for non-bonded interactions, and very similar in performance for bonded interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRZ4m5IhMySbVg90H21EOLACvtfcHk0liCXcqHe0K1Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCksbfO&md5=c7848f8bf050e11972d438aaebd68fdf</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1039%2Fb810189b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb810189b%26sid%3Dliteratum%253Aachs%26aulast%3DChai%26aufirst%3DJ.-D.%26aulast%3DHead-Gordon%26aufirst%3DM.%26atitle%3DLong-range%2520Corrected%2520Hybrid%2520Density%2520Functionals%2520With%2520Damped%2520Atom-Atom%2520Dispersion%2520Corrections%26jtitle%3DPhys.%2520Chem.%2520Chem.%2520Phys.%26date%3D2008%26volume%3D10%26issue%3D44%26spage%3D6615%26epage%3D6620%26doi%3D10.1039%2Fb810189b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alihodžić, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bukvić, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenkov, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutinec, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koštrun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pešić, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomašković, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Žiher, D.</span></span> <span> </span><span class="NLM_article-title">Current Trends in Macrocyclic Drug Discovery and Beyond-Ro5</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1016/bs.pmch.2018.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1016%2Fbs.pmch.2018.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29680148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltFOgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=113-233&author=S.+Alihod%C5%BEi%C4%87author=M.+Bukvi%C4%87author=I.+J.+Elenkovauthor=A.+Hutinecauthor=S.+Ko%C5%A1trunauthor=D.+Pe%C5%A1i%C4%87author=G.+Saxtyauthor=L.+Toma%C5%A1kovi%C4%87author=D.+%C5%BDiher&title=Current+Trends+in+Macrocyclic+Drug+Discovery+and+Beyond-Ro5&doi=10.1016%2Fbs.pmch.2018.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Current Trends in Macrocyclic Drug Discovery and beyond-Ro5</span></div><div class="casAuthors">Alihodzic Sulejman; Bukvic Mirjana; Elenkov Ivaylo J; Hutinec Antun; Kostrun Sanja; Pesic Dijana; Saxty Gordon; Tomaskovic Linda; Ziher Dinko</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-233</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">This chapter will discuss the recent literature of macrocycles and drug-like property space moving beyond the rule of five (bRo5).  Trends in chemical classes that fall within this definition are discussed and the impact of the latest technologies in the field assessed.  The physicochemical properties, which have provided both successes and challenges, especially in scale-up, are discussed.  A recent patent literature is reviewed and the chapter concludes with a perspective on the future of macrocyclic drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ9pfcWWVZ5hWfpMXQLRstfW6udTcc2eYA8UIXui7Jgbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltFOgsA%253D%253D&md5=ac41d1a69cb0056d106d554b0b323e61</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2018.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DAlihod%25C5%25BEi%25C4%2587%26aufirst%3DS.%26aulast%3DBukvi%25C4%2587%26aufirst%3DM.%26aulast%3DElenkov%26aufirst%3DI.%2BJ.%26aulast%3DHutinec%26aufirst%3DA.%26aulast%3DKo%25C5%25A1trun%26aufirst%3DS.%26aulast%3DPe%25C5%25A1i%25C4%2587%26aufirst%3DD.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DToma%25C5%25A1kovi%25C4%2587%26aufirst%3DL.%26aulast%3D%25C5%25BDiher%26aufirst%3DD.%26atitle%3DCurrent%2520Trends%2520in%2520Macrocyclic%2520Drug%2520Discovery%2520and%2520Beyond-Ro5%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D57%26spage%3D113%26epage%3D233%26doi%3D10.1016%2Fbs.pmch.2018.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viarengo, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span> <span> </span><span class="NLM_article-title">Progress Towards the Broad Use of Non-Peptide Synthetic Macrocycles in Drug Discovery</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">7729</span>– <span class="NLM_lpage">7735</span>, <span class="refDoi"> DOI: 10.1039/C7OB00056A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1039%2FC7OB00056A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=28876025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKgsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=7729-7735&issue=37&author=A.+Whittyauthor=L.+A.+Viarengoauthor=M.+Zhong&title=Progress+Towards+the+Broad+Use+of+Non-Peptide+Synthetic+Macrocycles+in+Drug+Discovery&doi=10.1039%2FC7OB00056A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Progress towards the broad use of non-peptide synthetic macrocycles in drug discovery</span></div><div class="casAuthors">Whitty, Adrian; Viarengo, Lauren A.; Zhong, Mengqi</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">7729-7735</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The authors discuss progress towards addressing three key questions pertaining to the design of screening libraries of synthetic nonpeptidic macrocycles (MCs) for drug discovery: What structural and physicochem. properties of MCs maximize the likelihood of achieving strong and specific binding to protein targets.  What features render a protein target suitable for binding MCs, and can this information be used to identify suitable targets for inhibition by MCs.  What properties of synthetic MCs confer good pharmaceutical properties, and particularly good aq. soly. coupled with passive membrane permeability.  The authors addnl. discuss how the criteria that define a meaningful MC screening hit are linked to the size of the screening library and the synthetic methodol. employed in its prepn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeNdUQVdF6FrVg90H21EOLACvtfcHk0lgx252O0uNHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKgsLrO&md5=451ddddc4457d5a2ee84b384aa15508e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1039%2FC7OB00056A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7OB00056A%26sid%3Dliteratum%253Aachs%26aulast%3DWhitty%26aufirst%3DA.%26aulast%3DViarengo%26aufirst%3DL.%2BA.%26aulast%3DZhong%26aufirst%3DM.%26atitle%3DProgress%2520Towards%2520the%2520Broad%2520Use%2520of%2520Non-Peptide%2520Synthetic%2520Macrocycles%2520in%2520Drug%2520Discovery%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26issue%3D37%26spage%3D7729%26epage%3D7735%26doi%3D10.1039%2FC7OB00056A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ermert, P.</span></span> <span> </span><span class="NLM_article-title">Design, Properties and Recent Application of Macrocycles in Medicinal Chemistry</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.2533/chimia.2017.678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.2533%2Fchimia.2017.678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=29070413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=678-702&issue=10&author=P.+Ermert&title=Design%2C+Properties+and+Recent+Application+of+Macrocycles+in+Medicinal+Chemistry&doi=10.2533%2Fchimia.2017.678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Design, properties and recent application of macrocycles in medicinal chemistry</span></div><div class="casAuthors">Ermert, Philipp</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">678-702</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclic compds. have recently received increasing attention in drug discovery as these compds. offer the potential to modulate difficult targets and to access novel chemotypes.  Approaches towards libraries of macrocyclic compds. based on modular org. synthesis and applications of these technol. platforms to find and improve biol. active compds. are introduced in this minireview.  Alternatively, lead compds. may be obtained by truncation and modification of macrocyclic natural products.  Selected medicinal chem. programs are discussed, illustrating a macrocyclization approach toward ligands with improved properties.  The design of such ligands is often informed by X-ray crystal structures of protein-ligand complexes.  Efforts to understand cellular permeability and oral bioavailability of cyclic peptides and non-peptidic macrocycles are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo_L_ef2BYLrVg90H21EOLACvtfcHk0lgx252O0uNHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFeitbg%253D&md5=aca0ab87a30863de362d9002c3d9f6cc</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2017.678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2017.678%26sid%3Dliteratum%253Aachs%26aulast%3DErmert%26aufirst%3DP.%26atitle%3DDesign%252C%2520Properties%2520and%2520Recent%2520Application%2520of%2520Macrocycles%2520in%2520Medicinal%2520Chemistry%26jtitle%3DChimia%26date%3D2017%26volume%3D71%26issue%3D10%26spage%3D678%26epage%3D702%26doi%3D10.2533%2Fchimia.2017.678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Labute, P.</span></span> <span> </span><span class="NLM_article-title">LowModeMD - Implicit Low-Mode Velocity Filtering Applied to Conformational Search of Macrocycles and Protein Loops</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1021/ci900508k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900508k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=792-800&issue=5&author=P.+Labute&title=LowModeMD+-+Implicit+Low-Mode+Velocity+Filtering+Applied+to+Conformational+Search+of+Macrocycles+and+Protein+Loops&doi=10.1021%2Fci900508k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">LowModeMD - Implicit Low-Mode Velocity Filtering Applied to Conformational Search of Macrocycles and Protein Loops</span></div><div class="casAuthors">Labute, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">792-800</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present a method for conformational search of complex mol. systems such as macrocycles and protein loops.  The method is based on perturbing an existing conformation along a mol. dynamics trajectory using initial at. velocities with kinetic energy concd. on the low-frequency vibrational modes, followed by energy minimization.  A novel Chebyshev polynomial filter is used to heavily dampen the high-frequency components of a randomly generated Maxwell-Boltzmann velocity vector.  The method is very efficient, even for large systems; it is straightforward to implement and requires only std. force-field energy and gradient evaluations.  The results of several computational expts. suggest that the method is capable of efficiently sampling low-strain energy conformations of complex systems with nontrivial nonbonded interaction networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfWZjZhFqqUbVg90H21EOLACvtfcHk0lgx252O0uNHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSksrk%253D&md5=bb800eb2f9635a661578b978dae9da0a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fci900508k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900508k%26sid%3Dliteratum%253Aachs%26aulast%3DLabute%26aufirst%3DP.%26atitle%3DLowModeMD%2520-%2520Implicit%2520Low-Mode%2520Velocity%2520Filtering%2520Applied%2520to%2520Conformational%2520Search%2520of%2520Macrocycles%2520and%2520Protein%2520Loops%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26issue%3D5%26spage%3D792%26epage%3D800%26doi%3D10.1021%2Fci900508k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamenik, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liedl, K. R.</span></span> <span> </span><span class="NLM_article-title">Peptidic Macrocycles - Conformational Sampling and Thermodynamic Characterization</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">992</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00097</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00097" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFantrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=982-992&issue=5&author=A.+S.+Kamenikauthor=U.+Lesselauthor=J.+E.+Fuchsauthor=T.+Foxauthor=K.+R.+Liedl&title=Peptidic+Macrocycles+-+Conformational+Sampling+and+Thermodynamic+Characterization&doi=10.1021%2Facs.jcim.8b00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Peptidic Macrocycles - Conformational Sampling and Thermodynamic Characterization</span></div><div class="casAuthors">Kamenik, Anna S.; Lessel, Uta; Fuchs, Julian E.; Fox, Thomas; Liedl, Klaus R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">982-992</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocycles are of considerable interest as highly specific drug candidates, yet they challenge std. conformer generators with their large no. of rotatable bonds and conformational restrictions.  Here, we present a mol. dynamics-based routine that bypasses current limitations in conformational sampling and extensively profiles the free energy landscape of peptidic macrocycles in soln.  We perform accelerated mol. dynamics simulations to capture a diverse conformational ensemble.  By applying an energetic cutoff, followed by geometric clustering, we demonstrate the striking robustness and efficiency of the approach in identifying highly populated conformational states of cyclic peptides.  The resulting structural and thermodn. information is benchmarked against interproton distances from NMR expts. and conformational states identified by X-ray crystallog.  Using three different model systems of varying size and flexibility, we show that the method reliably reproduces exptl. detd. structural ensembles and is capable of identifying key conformational states that include the bioactive conformation.  Thus, the described approach is a robust method to generate conformations of peptidic macrocycles and holds promise for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFlE0cJ41tmrVg90H21EOLACvtfcHk0lgx252O0uNHhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFantrY%253D&md5=4c582a4036f17ac76c05d3e9e8718c02</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00097%26sid%3Dliteratum%253Aachs%26aulast%3DKamenik%26aufirst%3DA.%2BS.%26aulast%3DLessel%26aufirst%3DU.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DFox%26aufirst%3DT.%26aulast%3DLiedl%26aufirst%3DK.%2BR.%26atitle%3DPeptidic%2520Macrocycles%2520-%2520Conformational%2520Sampling%2520and%2520Thermodynamic%2520Characterization%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2018%26volume%3D58%26issue%3D5%26spage%3D982%26epage%3D992%26doi%3D10.1021%2Facs.jcim.8b00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span>, <span class="NLM_string-name">Mueller, G.</span>, <span class="NLM_string-name">Hamacher, M.</span></span>, Eds. <span> </span><span class="NLM_article-title">Protein Kinases as Drug Targets</span>.  <i>Methods and Principles in Medicinal Chemistry</i>; <span class="NLM_publisher-name">Wiley-VCH Verlag GmbH & Co. KGaA</span>: <span class="NLM_publisher-loc">Weinheim</span>, <span class="NLM_year">2011</span>; Vol.  <span class="NLM_volume">49</span>, 373 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=B.+Klebl&author=G.+Mueller&author=M.+Hamacher&title=Methods+and+Principles+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKlebl%26aufirst%3DB.%26atitle%3DProtein%2520Kinases%2520as%2520Drug%2520Targets%26btitle%3DMethods%2520and%2520Principles%2520in%2520Medicinal%2520Chemistry%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26date%3D2011%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span> <span> </span><span class="NLM_article-title">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1021/acschembio.7b00903</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.7b00903" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=36-44&issue=1&author=J.+B.+Baellauthor=J.+W.+M.+Nissink&title=Seven+Year+Itch%3A+Pan-Assay+Interference+Compounds+%28PAINS%29+in+2017-Utility+and+Limitations&doi=10.1021%2Facschembio.7b00903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017-Utility and Limitations</span></div><div class="casAuthors">Baell, Jonathan B.; Nissink, J. Willem M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on all necessary considerations for the appropriate use of PAINs filters formulated to process hundreds and thousands of compds. in seconds, and identify PAINS in order to exclude them from further anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocZ7E_j7zxfbVg90H21EOLACvtfcHk0li1uxcnZVoPwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFSlu7bK&md5=051115704137d6a91b8271702c619682</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facschembio.7b00903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.7b00903%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26atitle%3DSeven%2520Year%2520Itch%253A%2520Pan-Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520in%25202017-Utility%2520and%2520Limitations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D36%26epage%3D44%26doi%3D10.1021%2Facschembio.7b00903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&issue=7&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0li1uxcnZVoPwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D7%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dotson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lainchbury, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeap, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10176</span>– <span class="NLM_lpage">10191</span>, <span class="refDoi"> DOI: 10.1021/jm501578n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501578n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10176-10191&issue=23&author=E.+J.+Hananauthor=C.+Eigenbrotauthor=M.+C.+Bryanauthor=D.+J.+Burdickauthor=B.+K.+Chanauthor=Y.+Chenauthor=J.+Dotsonauthor=R.+A.+Healdauthor=P.+S.+Jacksonauthor=H.+Laauthor=M.+D.+Lainchburyauthor=S.+Malekauthor=H.+E.+Purkeyauthor=G.+Schaeferauthor=S.+Schmidtauthor=E.+M.+Sewardauthor=S.+Siderisauthor=C.+Tamauthor=S.+Wangauthor=S.+K.+Yeapauthor=I.+Yenauthor=J.+Yinauthor=C.+Yuauthor=I.+Zilberleybauthor=T.+P.+Heffron&title=Discovery+of+Selective+and+Noncovalent+Diaminopyrimidine-Based+Inhibitors+of+Epidermal+Growth+Factor+Receptor+Containing+the+T790M+Resistance+Mutation&doi=10.1021%2Fjm501578n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation</span></div><div class="casAuthors">Hanan, Emily J.; Eigenbrot, Charles; Bryan, Marian C.; Burdick, Daniel J.; Chan, Bryan K.; Chen, Yuan; Dotson, Jennafer; Heald, Robert A.; Jackson, Philip S.; La, Hank; Lainchbury, Michael D.; Malek, Shiva; Purkey, Hans E.; Schaefer, Gabriele; Schmidt, Stephen; Seward, Eileen M.; Sideris, Steve; Tam, Christine; Wang, Shumei; Yeap, Siew Kuen; Yen, Ivana; Yin, Jianping; Yu, Christine; Zilberleyb, Inna; Heffron, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10176-10191</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activating mutations within the epidermal growth factor receptor (EGFR) kinase domain, commonly L858R or deletions within exon 19, increase EGFR-driven cell proliferation and survival and are correlated with impressive responses to the EGFR inhibitors erlotinib and gefitinib in nonsmall cell lung cancer patients.  Approx. 60% of acquired resistance to these agents is driven by a single secondary mutation within the EGFR kinase domain, specifically substitution of the gatekeeper residue threonine-790 with methionine (T790M).  Due to dose-limiting toxicities assocd. with inhibition of wild-type EGFR (wtEGFR), we sought inhibitors of T790M-contg. EGFR mutants with selectivity over wtEGFR.  We describe the evolution of HTS hits derived from Jak2/Tyk2 inhibitors into selective EGFR inhibitors.  X-ray crystal structures revealed two distinct binding modes and enabled the design of a selective series of novel diaminopyrimidine-based inhibitors with good potency against T790M-contg. mutants of EGFR, high selectivity over wtEGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHIAeWoyjC2LVg90H21EOLACvtfcHk0li1uxcnZVoPwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrur3O&md5=b17adf4b49cebb2f2cea77015e1f6e4b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm501578n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501578n%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DBurdick%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DHeald%26aufirst%3DR.%2BA.%26aulast%3DJackson%26aufirst%3DP.%2BS.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DLainchbury%26aufirst%3DM.%2BD.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DYeap%26aufirst%3DS.%2BK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26atitle%3DDiscovery%2520of%2520Selective%2520and%2520Noncovalent%2520Diaminopyrimidine-Based%2520Inhibitors%2520of%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Containing%2520the%2520T790M%2520Resistance%2520Mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10176%26epage%3D10191%26doi%3D10.1021%2Fjm501578n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span> (<span class="NLM_issue">Pt 2</span>),  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&issue=Pt+2&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0ljM1YqjGOKZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26issue%3DPt%25202%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 Suite and Current Developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&issue=4&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+Suite+and+Current+Developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0ljM1YqjGOKZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520Suite%2520and%2520Current%2520Developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26issue%3D4%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">REFMAC5 Dictionary: Organization of Prior Chemical Knowledge and Guidelines for its Use</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>D60</i></span> (<span class="NLM_issue">12, Pt. 1</span>),  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2195</span>, <span class="refDoi"> DOI: 10.1107/S0907444904023510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1107%2FS0907444904023510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D60&publication_year=2004&pages=2184-2195&issue=12%2C+Pt.+1&author=A.+A.+Vaginauthor=R.+A.+Steinerauthor=A.+A.+Lebedevauthor=L.+Pottertonauthor=S.+McNicholasauthor=F.+Longauthor=G.+N.+Murshudov&title=REFMAC5+Dictionary%3A+Organization+of+Prior+Chemical+Knowledge+and+Guidelines+for+its+Use&doi=10.1107%2FS0907444904023510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span></div><div class="casAuthors">Vagin, Alexei A.; Steiner, Roberto A.; Lebedev, Andrey A.; Potterton, Liz; McNicholas, Stuart; Long, Fei; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2184-2195</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">One of the most important aspects of macromol. structure refinement is the use of prior chem. knowledge.  Bond lengths, bond angles and other chem. properties are used in restrained refinement as subsidiary conditions.  This contribution describes the organization and some aspects of the use of the flexible and human/machine-readable dictionary of prior chem. knowledge used by the max.-likelihood macromol.-refinement program REFMAC5.  The dictionary stores information about monomers which represent the constitutive building blocks of biol. macromols. (amino acids, nucleic acids and saccharides) and about numerous org./inorg. compds. commonly found in macromol. crystallog.  It also describes the modifications the building blocks undergo as a result of chem. reactions and the links required for polymer formation.  More than 2000 monomer entries, 100 modification entries and 200 link entries are currently available.  Algorithms and tools for updating and adding new entries to the dictionary have also been developed and are presented here.  In many cases, the REFMAC5 dictionary allows entirely automatic generation of restraints within REFMAC5 refinement runs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjDd-k3YHGrVg90H21EOLACvtfcHk0ljM1YqjGOKZyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F&md5=005910422c5fb72fe2434c39b5321bf4</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1107%2FS0907444904023510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904023510%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPotterton%26aufirst%3DL.%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DREFMAC5%2520Dictionary%253A%2520Organization%2520of%2520Prior%2520Chemical%2520Knowledge%2520and%2520Guidelines%2520for%2520its%2520Use%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3DD60%26issue%3D12%252C%2520Pt.%25201%26spage%3D2184%26epage%3D2195%26doi%3D10.1107%2FS0907444904023510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luippold, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnhold, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerg, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suessmuth, R. D.</span></span> <span> </span><span class="NLM_article-title">Application of a Rapid and Integrated Analysis System (RIAS) as a High-Throughput Processing Tool For In Vitro ADME Samples by Liquid Chromatography/tandem Mass Spectrometry</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1177/1087057110397358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=10.1177%2F1087057110397358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=21335598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktl2ltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=370-377&issue=3&author=A.+H.+Luippoldauthor=T.+Arnholdauthor=W.+Joergauthor=B.+Kruegerauthor=R.+D.+Suessmuth&title=Application+of+a+Rapid+and+Integrated+Analysis+System+%28RIAS%29+as+a+High-Throughput+Processing+Tool+For+In+Vitro+ADME+Samples+by+Liquid+Chromatography%2Ftandem+Mass+Spectrometry&doi=10.1177%2F1087057110397358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a Rapid and Integrated Analysis System (RIAS) as a high-throughput processing tool for in vitro ADME samples by liquid chromatography/tandem mass spectrometry</span></div><div class="casAuthors">Luippold, Andreas H.; Arnhold, Thomas; Joerg, Wolfgang; Krueger, Beate; Suessmuth, Roderich D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">370-377</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Over the past decade, drug discovery programs have started to address the optimization of key ADME properties already at an early stage of the process.  Hence, anal. chemists have been confronted with tremendously rising sample nos. and have had to develop methodologies accelerating quant. liq. chromatog./tandem mass spectrometry (LC/MS/MS).  This article focuses on the application of a generic and fully automated LC/MS/MS, named Rapid and Integrated Anal. System (RIAS), as a high-throughput platform for the rapid quantification of drug-like compds. in various in vitro ADME assays.  Previous efforts were dedicated to the setup and feasibility study of a workflow-integrated platform combining a modified high-throughput liq. handling LC/MS/MS system controlled by a customized software interface and a customized data-processing and reporting tool.  Herein the authors present an extension of this previously developed basic application to a broad set of ADME screening campaigns, covering CYP inhibition, Caco-2, and PAMPA assays.  The platform is capable of switching automatically between various ADME assays, performs MS compd. optimization if required, and provides a speed of 8 s from sample to sample, independently of the type of ADME assay.  Quantification and peak review are adopted to the high-throughput environment and tested against a std. HPLC-ESI technol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbv6ToQVM4JLVg90H21EOLACvtfcHk0liyfyw5oGlDyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktl2ltrk%253D&md5=1ba4e5b3957219231afa698a0695e6f5</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1177%2F1087057110397358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057110397358%26sid%3Dliteratum%253Aachs%26aulast%3DLuippold%26aufirst%3DA.%2BH.%26aulast%3DArnhold%26aufirst%3DT.%26aulast%3DJoerg%26aufirst%3DW.%26aulast%3DKrueger%26aufirst%3DB.%26aulast%3DSuessmuth%26aufirst%3DR.%2BD.%26atitle%3DApplication%2520of%2520a%2520Rapid%2520and%2520Integrated%2520Analysis%2520System%2520%2528RIAS%2529%2520as%2520a%2520High-Throughput%2520Processing%2520Tool%2520For%2520In%2520Vitro%2520ADME%2520Samples%2520by%2520Liquid%2520Chromatography%252Ftandem%2520Mass%2520Spectrometry%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2011%26volume%3D16%26issue%3D3%26spage%3D370%26epage%3D377%26doi%3D10.1177%2F1087057110397358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B','PDB','6S9B'); return false;">PDB: 6S9B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9C" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9C','PDB','6S9C'); return false;">PDB: 6S9C</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D','PDB','6S9D'); return false;">PDB: 6S9D</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01169">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_04010"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01169">10.1021/acs.jmedchem.9b01169</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Details for the QM-calculation for <a id="rightTab-" class=" internalNav" href="#fig4">Figure <a id="rightTab-" class=" internalNav" href="#fig4">4</a></a>; description of the analytic and preparative HPLC methods as well as synthesis and analytic data (RT, MS, HRMS, and <sup>1</sup>H NMR) of compounds <b>13a</b>, <b>13e</b>, <b>16b</b>, <b>16c</b>, <b>20a</b>, <b>20b</b>, <b>22b</b>, <b>22c</b>, <b>24</b>, <b>25a</b>, <b>25</b>, <b>26</b>, <b>34</b>, <b>35</b>, <b>35a</b>, <b>36</b>, <b>37</b>, <b>39</b>, <b>40</b>, <b>43</b>, and <b>44</b>; X-ray data collection and refinement statistics for compounds <b>1</b>, <b>5</b>, <b>6</b>, and <b>9Br</b>; HPLC-traces for compounds <b>1</b>, <b>2</b>, <b>3</b>, <b>3a</b>, <b>4</b>, <b>5</b>, <b>6</b>, <b>7</b>, <b>8</b>, <b>9</b>, <b>9Br</b>, and <b>BI-4020</b>; list of kinases of the kinase selectivity panels; and biochemical data for <b>6–BI-4020</b> and PK graphs of <b>BI-4020</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_001.pdf">jm9b01169_si_001.pdf (1.28 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01169/suppl_file/jm9b01169_si_002.csv">jm9b01169_si_002.csv (0.88 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates and structure factors have been deposited at the PDB/CCDC with PDB/CCDC codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9B">6S9B</a> (compound <b>1</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9C">6S9C</a> (compound <b>5</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6S9D">6S9D</a> (compound <b>6</b>), and 1941612 (compound <b>9Br</b>). We will release coordinates and experimental data upon publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01169%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01169" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a60b7fa1e3d76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
